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Abstract

Recent research has revealed a role of NF-B in the resolution of inflammation.  Using Cre-lox mediated gene targeting, IKK was selectively deleted in macrophages (IKKβ∆Mye). From in vitro studies, LPS stimulated IKKMye macrophages increased STAT1 phosphorylation, iNOS, MHC II and IL-12 production, suggesting negative cross talk between NF-B and STAT1 signalling pathways.  Since IKK is required for TNF gene expression and TNF signalling, I investigated the hypothesis that TNF inhibits ‘classical’ macrophage activation through IKK activation. Macrophages from p55-/- and mice treated with anti-TNF antibody show increased STAT1 activation and IL-12 expression after LPS and IFN stimulation. BMDM infected with adenovirus expressing IKKβ dominant negative rescued the inhibitory effect of TNFα on IL-12p40 production, indicating TNFα inhibits IL-12p40 via IKKβ activation.  Macrophages are antigen presenting cells while IL-12 and MHC II are critical factors for TH1 cell development. I thus investigate the inhibitory effects of IKKβ∆Mye macrophages in TH1 responses.  FACS analysis showed higher MHC II, costimulatory molecules expression on IKKβ∆Mye macrophages after LPS stimulation.  In a DTH model, recall assay has shown increased antigen-specific IFN production from IKKMye splenocytes compared to IKKβF/F splenocytes. Furthermore, IFN production was greatly enhanced by CD4+ OTII T cells co-cultured with IKKMye macrophages.  Further analysis of CD4+ OTII T cells with qRT-PCR showed increased TH1 genes including IRF1, IFN, IL-12R1 and IL-12R2 and reduced TH2 marker IL-4. In addition to the enhanced antigen-specific T cell responses, IKKMye macrophages also increased anti-tumour immunity. Injection of H-Y positive MB49 tumour cells into IKKF/F and IKKMye female mice has shown tumour rejection, but no tumours were rejected after CD8+ T cells depletion, suggesting tumour rejection is associated with enhanced CTL activity. Taken together, these studies demonstrated the negative regulatory roles of IKK in macrophage activation and their impact to the innate and adaptive immunity.
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1. Introduction
1.1 Macrophages and their roles in innate and adaptive immunity
Macrophages have pleiotropic functions in the immune system (Gordon 2003; Gordon and Taylor 2005); they are classified as professional phagocytes responsible for microbe recognition and phagocytosis, macrophages also produce reactive oxygen intermediates and lysosomal enzymes to destroy microorganisms.  Furthermore, macrophage activation results in the release of proinflammatory cytokines interleukin (IL) -1, IL-6 and tumour necrotic factor (TNF) , these proinflammatory cytokines are important in host defence and the development of adaptive immune responses. In addition to the production of proinflammatory cytokines, macrophages can also act as antigen presenting cells by providing costimulatory molecules and major histocompatibility complex (MHC) II-antigen complex for T cell activation (Janeway 2001; Goldsby R 2003).  Apart from recognising ‘non-self’, macrophages can also recognise ‘altered self’ such as necrotic and apoptotic cells.  This is important in the immune system to maintain homeostasis and prevent prolonged inflammation  ADDIN EN.CITE (Fadok, Bratton et al. 1998).

1.2 Macrophage heterogeneity 
Different macrophage population represents the diverse functions of macrophages.  Circulating monocytes migrate into different tissues and differentiate into resident macrophages.  Under the influence of the microenvironment, macrophages acquire specific phenotype and distinct effector functions (Gordon and Taylor 2005; Mosser and Edwards 2008). During microbial infection, macrophages activated by microbial products and/or proinflammatory cytokine such as interferon (IFN)  and become the ‘classically’ activated macrophages or M1 macrophages. These cells are proinflammatory cells of the immune system that are responsible in the killing intracellular pathogens and tumour cells.  In addition, they also secrete proinflammatory cytokines such as IL-12 and act as antigen presenting cells that promote the development of TH1 immune responses (Gordon and Taylor 2005).  In 1992, Stein et al. described another type of macrophage; "alternatively" activated macrophages or M2 macrophages that can be induced by TH2 cytokines, such as IL-4, IL-13 (Stein, Keshav et al. 1992). To date, the precise roles of M2 macrophages in the immune system are still not clear, but these cells have been associated with parasitic diseases (Wim Noël 2004), anti-inflammation (Goerdt S 1999; Gordon 2003) and wound healing (Song, Ouyang et al. 2000).

M1 and M2 macrophages have distinct characteristic phenotypes in terms of receptor expression, effector function and cytokine production. The cytokine profile of M1 macrophages includes predominantly proinflammatory cytokines; such as IL-12, IL-6 and TNF α, whereas M2 macrophages typically produce anti-inflammatory cytokines - IL-10, IL-1 receptor antagonist (IL-1ra), the type II IL-1 decoy receptor and transforming growth factor (TGF) β (Goerdt S 1999; Gordon 2003).  In terms of chemokine receptors and ligands, M1 macrophages predominantly express the IFN inducible chemokine IP-10 (CXCL10) and MIG (CXCL9), which preferentially attract TH1 cells.  On the other hand, IL-4 selectively induces TARC (CCL17) (Imai, Nagira et al. 1999), CCL18 (also known as AMAC1) and MDC (CCL22) (Imai, Nagira et al. 1999).   The up-regulation of these chemokines preferentially recruiting CCR4 positive T cells, thereby amplifying TH2 responses (Bonecchi, Sozzani et al. 1998). 

The inducible nitric oxide synthase (iNOS)-arginase balance has also been demonstrated as a marker to distinguish between M1 and M2 macrophages (Munder, Eichmann et al. 1998).   M1 macrophages produce elevated nitric oxide (NO) and L-citrulline by upregulating iNOS, which uses L-arginine as a substrate.  In M2 macrophages, arginase is up-regulated instead of iNOS (Hesse, Modolell et al. 2001), the induction of arginase hydrolyses L-arginine into L-ornithine and urea. L-ornithine is a necessary metabolite for the production of polyamines and prolines, polyamines are involved in the cell growth and division and proline is a key component of collagen.  Consistent with this observation, Song et al. 2000, have shown that M2 macrophages enhance fibrogenesis while M1 macrophages release anti-fibrotic and fibrolytic factors (Song, Ouyang et al. 2000). M2 macrophages also actively inhibit proliferation of peripheral blood lymphocytes and CD4+ T cells in vitro  ADDIN EN.CITE (Kodelja, Muller et al. 1997). Two transcription factors, FIZZ1 and YM1 have also been shown to be distinctly induced in M2 macrophages although their function is not clear (Raes, De Baetselier et al. 2002).

Tumour associated macrophages (TAM) or myeloid derived suppressor cells (MDSC) are another type of macrophage that is abundantly found within tumours.  The roles of TAM in tumour development including angiogenesis, metastasis and tumour growth are well demonstrated (L. Bingle 2002) and poor prognosis is often correlated to the increased TAM density (Lewis and Pollard 2006).  It has been suggested that tumour cells polarize infiltrating macrophages to a tumour promoting phenotype (Hagemann, Wilson et al. 2006) and because of the similar biological functions of TAMs and M2 macrophages, TAMs are also described as M2 macrophages (Mantovani, Sozzani et al. 2002). Like the phenotype of M2 macrophage, TAMs produce suppressive mediators and growth factors that facilitate tumour development and suppress anti-tumour immunity  ADDIN EN.CITE (Loercher, Nash et al. 1999; Sica, Saccani et al. 2000; Mantovani, Sozzani et al. 2002). Over-expression of arginase in macrophages have shown enhanced tumour cell proliferation and suppress NO mediated tumour cytotoxicity (Chang, Liao et al. 2001). Furthermore, arginase production by TAM impairs T cell receptor CD3 chain expression and antigen specific T cell proliferation (Rodriguez, Quiceno et al. 2004). TAMs are poor antigen presenting cells and they suppress T cell responses by producing IL-10 and TGF  ADDIN EN.CITE (Loercher, Nash et al. 1999; Sica, Saccani et al. 2000; Mantovani, Sozzani et al. 2002).  Furthermore, TAMs synthesis epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and fibroblast growth factor (FGF) to promote angiogenesis and tumour cell proliferation (Mantovani, Sozzani et al. 2002).

Macrophages are capable to switch their phenotype after differentiation (Stout and Suttles 2004); in response to lipopolysaccharide (LPS) and IFNγ, M2 macrophages generated in the TH2 environment of helminth infection were capable to switch to a more classical activated phenotype.  This was illustrated by the switch in the enzymatic pathway for arginine metabolism from arginase to iNOS and the reduced expression of YM-1 (Mylonas, Nair et al. 2009).  These studies clearly illustrated the plasticity of macrophages and their ability in phenotype switching to adapt the changing environments.

1.3 Pathogen recognition
Macrophages recognize pathogens by their cell surface receptors termed pattern recognition receptors (PRR), these receptors recognize pathogen associated molecular patterns (PAMPs) that are selectively conserved among microorganisms.  Examples of PAMPs include LPS  ADDIN EN.CITE (Hoshino, Takeuchi et al. 1999; Qureshi, Lariviere et al. 1999), peptidoglycan (PGN) (Schwandner, Dziarski et al. 1999) and flagellin (Hayashi, Smith et al. 2001). Macrophages are professional phagocytes that express a wide range of PRRs to recognise, bind and internalise invading pathogens in the innate immune response.  A number of different PRRs have been described, they can be divided into two main types; receptors that mediate antigen uptake, including phagocytic receptors, and receptors that lead to activation of proinflammatory signalling pathways such as Toll like receptors (TLRs).  

1.4 Non signalling pattern recognition receptors
Examples of phagocytic receptors include C-type lectins, scavenger receptors and opsonic receptors. C-type lectin receptors recognise a broad range of carbohydrate structures in a calcium dependent manner.  Interaction of these carbohydrate structures with different lectin receptors is dependent on carbohydrate branching, spacing and multivalency.  C-type lectins are either produced as transmembrane proteins (Type II receptors) or secreted as soluble proteins (collectins). Examples of membrane C-type lectins include selectins (Ley and Kansas 2004), the mannose receptor (MR) family (Isacke 2002) and the dendritic cell specific ICAM-3 grabbing non-integrin (DC-SIGN) (Yeunis B. H. Geijtenbeek 1 2000).  Membrane C-type lectins are designed to capture pathogens for intracellular destruction, degradation and antigen loading on MHC molecules.  In addition, C type lectins have been shown to act as adhesion receptors. DC-SIGN mediates the contact between dendritic cells and T cells, by binding to ICAM-3 (Yeunis B. H. Geijtenbeek 1 2000).  Soluble collectins, like mannose binding protein (MBP) (Bohlson, Fraser et al. 2007), lung surfactant protein A (SP-A) (Heinrich, Hartl et al. 2006) and SP-D (Hartl and Griese 2006) function by opsonising microorganisms.  

The scavenger receptors are a family of cell surface glycoproteins that are able to bind modified lipoproteins (mLDLs) such as oxidised and acetylated LDLs and polyanonic molecules like lipid A  ADDIN EN.CITE (Hampton, Golenbock et al. 1991; Maxeiner, Husemann et al. 1998). Some of these receptors are also implicated in the phagocytosis of apoptotic cells and bacteria (Platt, Suzuki et al. 1996; Thomas, Li et al. 2000), as well as in cell adhesion  ADDIN EN.CITE (Khoury, Hickman et al. 1996; van Velzen, Suzuki et al. 1999).  These transmembrane receptors vary markedly in structure, for example, they can be cysteine rich, collagenous, C type lectins (S 2001).  The high diversity of receptor allows them to bind a wider range of modified host molecules and microorganisms.  In addition to PRR, opsonic phagocyte receptors are another type of non-signalling receptor expressed on the cell surface of macrophages, examples of these are Fc and complement receptors (CR) that recognise antibody and complement coated pathogens or apoptotic cells and contribute to their enhanced uptake and destruction (Cairns, Crockard et al. 2003; Hart SP 2004).

1.5 Phagocytosis 
Once antigen is bound, the phagocytes extend their pseudopodia around the antigen and create a membrane-bound structure called phagosome.  Cytosolic vesicles called lysozomes containing hydrolytic enzymes and defensins then fuse with the phagosomes to become phagolysosomes where the antigen is digested (Janeway 2001; Goldsby R 2003).  In addition to hydrolytic enzymes, phagocytes can also eliminate microorganisms by the respiratory burst generating reactive oxygen intermediates (ROIs) and reactive nitrogen intermediates (RNI) (Table 1) (Janeway 2001; Goldsby R 2003).  

Table 1. ROI, RNI
Reactive oxygen intermediates 	Reactive nitrogen intermediates	Others
O2- (superoxide anion)	NO (nitric oxide)	NH2Cl (monocloramine)
OH (hydroxyl radicals)	NO2 (nitrogen dioxide)	
H2O2 (hydrogen peroxide)	HNO2 (nitrous acid)	
ClO- (hypochlorite anion)		

1.6 Toll like receptors signalling
Toll was originally discovered in Drosophila melanogaster and described as a protein involved in embryonic development and only later, an additional role in innate immunity was defined (Bruno Lemaitre 1996; Keshishian 1998).  Currently, 10 human TLRs and 12 mouse TLRs are described (TLRs 1-9 and 11-13) (Takeda and Akira 2005).   TLRs are differentially distributed within cells; most of them are present on the cell surface, whereas others like TLR3, TLR7, TLR8 and TLR9 are expressed in intracellular compartments, such as endosomes  ADDIN EN.CITE (Kaisho and Akira 2006)  (Figure 1.6.1).   






Figure 1.6 1 Location of TLRs

TLRs play a critical role in spotting ‘non-self’ by recognising the unique molecular patterns associated with different classes of pathogens, and a series of genetic studies have revealed their ligands (Table 2) (Takeda and Akira 2005).  For examples, TLR2 is required for the response to microbial lipoproteins (Takeuchi, Kaufmann et al. 2000) and yeast cell wall (Underhill, Ozinsky et al. 1999). TLR3 binds double stranded RNA that is produced from viruses during replication (Alexopoulou, Holt et al. 2001).  TLR4 binds the exogenous ligands LPS (Gram-negative bacteria) (Qureshi, Lariviere et al. 1999) and fusion protein of respiratory syncytial virus (RSV) (Kurt-Jones, Popova et al. 2000) as well as the endogenous ligands such as hsp60, hsp70, hsp96  ADDIN EN.CITE (Vabulas, Ahmad-Nejad et al. 2001; Vabulas, Ahmad-Nejad et al. 2002; Vabulas, Braedel et al. 2002), fibronectin (Okamura, Watari et al. 2001), polysaccharides of hyaluronic acid (Termeer, Benedix et al. 2002) and fibrinogen (Smiley, King et al. 2001).  TLR5 binds to the flagella element flagellin (Hayashi, Smith et al. 2001).  TLR7 and TLR8 bind to ssRNA from viruses (Lund, Alexopoulou et al. 2004) as well as small nuclear RNAs, TLR9 binds unmethylated CpG DNA from bacteria (Hemmi, Takeuchi et al. 2000) and TLR11 for the response to unknown components of uropathogenic bacteria (Zhang D 2004) and a profiling-like molecule of the protozoan parasite Toxoplasma gondii (Yarovinsky F 2005).  In addition to function individually, TLRs can also cooperate and recognise different components of pathogens  ADDIN EN.CITE (Ozinsky, Underhill et al. 2000; Wyllie, Kiss-Toth et al. 2000).  In the combination with TLR6, TLR2 recognises peptidoglycan (Ozinsky, Underhill et al. 2000) and furthermore, TLR2 can also pair with TLR1 to recognise soluble factors released by Neisseria meningitis (Wyllie, Kiss-Toth et al. 2000). 






























Table 2. Exogenous and endogenous TLR ligands
TLR 	Exogenous ligands	Endogenous ligands
TLR1/2 and TLR2/6	Lipoproteins/lipopeptides	Hsp60 
	Peptidoglycan	Hsp70 
	Lipteichoic acid	Gp96 
	Lipoarabinomannan 	
	Glycosylphosphatidylinositol anchors 	
	Porins 	
	Zymonsan 	
		
TLR3	Double stranded RNA	mRNA 
TLR4	Lipopolysaccharide 	Hsp60 
	Taxol 	Hsp70 
	Respiratory syncytial virus (RSV) 	Gp96 
	Envelop proteins (MMTV)	Fibronectin 
	Hsp60 (Chlamydia pneumoniae 	Oligosaccharides of hyaluronic acid 
		Heparan sulphate 
		Fibrinogen 
		Saturated fatty acid 
TLR5	Flagellin 	
TLR7	ssRNA 	Small nuclear RNAs 
TLR8	ssRNA 	Small nuclear RNAs 
TLR9	Unmethylated CpG DNA 	Chromatin-Ig complexes 




















TLR signalling can lead to activation of several transcription factors, including nuclear factor kappa B (NF-κB), activating protein (AP) 1 and IFN responsive factors (IRFs)  ADDIN EN.CITE (Kaisho and Akira 2006).  These transcription factors subsequently activate a wide variety of genes that results in the induction of inflammatory cytokines, chemokines and costimulatory molecules expression. All TLRs use similar signal transduction mechanisms and TLRs interact with different combinations of adaptor proteins to activate various signalling cascade.  To date, five adaptor molecules have been characterised (O'Neill and Bowie 2007); myeloid differentiation primary response gene 88 (MyD88), TIR-associated protein (TIRAP)/MyD88-adaptor-like (MAL), TIR-domain-containing adaptor protein-inducing IFN-β (TRIF)/TIR-domain containing molecule 1(TICAM1), and TRIF-related adaptor molecule (TRAM)/TIR-domain containing molecule 2 (TICAM2).  A fifth TIR domain containing adaptor molecule SARM (sterile α and HEAT-Armadillo motifs) was shown to be a TRIF-specific inhibitory protein (O'Neill and Bowie 2007).  MyD88 is utilised by all TLRs except TLR3 and is unique by the presence of a death domain (DD) at its N-terminus.  For TLR2 and TLR4 signalling, an additional adaptor molecule - MAL is required that acts as a bridge for recruiting MyD88 to the receptor (Kagan and Medzhitov 2006).  The adaptor molecule TRIF is recruited to TLR3 and TLR4 (MyD88 independent pathway) while TRAM binds to the TIR domain of TLR4 and serves as a bridge between the receptor and TRIF (Figure 1.6.1).




TLRs are characterised structurally by the cytoplasmic Toll/IL-1 receptor (TIR) domain and extracellular leucine rich repeats.  The presence of a TIR domain in the cytoplasmic region of the IL-1R suggests that both receptors share a common molecular framework for signalling (Figure 1.6.2).  Upon ligand binding, TLR and IL-1R recruit the adaptor protein MyD88 through homotypic interactions (Wesche H 1997), MyD88 in turn recruits the interleukin receptor associated kinase (IRAK) 1 and IRAK-2 by its death domain.  After binding, IRAK-1 and IRAK-2 become activated, phosphorylated and subsequently associate with TNFR-associated factor 6 (TRAF6).  TRAF6 activates the kinases TGF-activated protein kinase (TAK1) and TAK1 binding protein 1 (TAB1) (Wang, Deng et al. 2001).  TAK1 then phosphorylates the IB kinase (IKK) complex that leads to nuclear factor kappa B (NF-кB) activation.  At the same time, TAK1 can also phosphorylates mitogen activated protein (MAP) kinase kinase (MKK)3 and MMK6, which in turn activate c-Jun NH2 terminal kinase (JNK) and p38 MAP kinase (Daun and Fenton 2000; Akira and Takeda 2004).  In addition to the MyD88 dependent pathway, MyD88 independent pathway has also been described and is associated with type I IFN response to LPS  (Kawai, Takeuchi et al. 2001). Upon LPS stimulation, Toll/IL-1 receptor domain containing adaptor inducing IFN (TRIF) activates TRAF family member associated NF-B activator (TANK) binding kinase 1 (TBK1) via TRAF3  ADDIN EN.CITE (Hacker, Redecke et al. 2006; Oganesyan, Saha et al. 2006).  TBK1 together with inducible IB kinase (IKK/IKKi) activate IRF3 and IRF7 (Fitzgerald, McWhirter et al. 2003) that subsequently translocate into the nucleus, and bind to the interferon stimulated response element (ISRE), resulting in the expression of IFN that can initiate type I IFN responses (Doyle S 2002; Toshchakov, Jones et al. 2002). 


Figure 1.6 2 TNF/IL-1/TLR signalling
















1.7 TNF signalling pathway
TNF is a pro-inflammatory cytokine that can be expressed as a 26kDa transmembrane protein and as a soluble form by metalloprotease TNF converting enzyme (TACE)  ADDIN EN.CITE (Black, Rauch et al. 1997; Moss, Jin et al. 1997). TNF induces cellular responses upon binding to specific cell surface receptors; TNF receptor type -1 (TNFR-1; p55) and TNFR-2 (p75) (Vandenabeele, Declercq et al. 1995).  These receptors share 28% homology in their extracellular domains and are characterised by the presence of cysteine repeats (MacEwan 2002).  However, p55 and p75 are structurally different in the intracellular region, suggesting distinct biological functions between the two receptors.  TNF is pleiotropic cytokine that regulates various aspects of immune and inflammatory reactions by activate multiple signalling pathways including Fas associated death domain (FADD), JNK and NF-B pathways.  Engagement of TNF to TNFR1 results in receptor trimerization and the recruitment of TNF receptor associated death domain (TRADD).  In turn, TRADD interacts with TRAF2 and receptor interacting protein (RIP), which subsequently activates the IKK complex and initiate the NF-B signalling event (Hailing Hsu 1996). Alternatively, TRAF2 can also induce the activation of MAPK cascade that results in the activation of JNK, a kinase that phosphorylates AP-1 and increases its transcriptional activity (Chen and Goeddel 2002).  These signalling pathways are important for the gene expression involved in inflammation and cell survival.  On the other hand, TRADD can also interact with FADD. This adaptor protein which in turn recruit caspase 8 and initiates a protease cascade that leads to apoptosis (Hailing Hsu 1996).  In contrast to TNFR1, the expression of TNFR2 is more restricted and its expression are only found on hematopoietic and endothelial cells (Aggarwal 2003). Occupancy of TNFR2 results in direct recruitment of TRAF2 (Rothe M 1994) in which subsequently activate transcription factors AP1, p38 and NF-B (Aggarwal 2003).

1.8 NF-кB signalling pathway
NF-кB transcription factors regulate expression of a wide range of genes involved in the control of immune responses, inflammation, cellular proliferation and survival (Caamano and Hunter 2002). NF-кB consists of homo- and hetero-dimeric complexes of Rel proteins; Rel-A (p65), c-Rel, Rel-B, p105/p50 (NF-кB1) and p100/p52 (NF-кB2). NF-кB1 and NF-кB2 are expressed as precursor proteins p105 and p100 that are post-transcriptionally cleaved to generate DNA-binding subunits p50, and p52.  All NF-кB proteins carry a Rel-homology domain (RHD) that contains a nuclear localization sequence (NLS) that is involved in dimerisation, sequence-specific DNA binding and interaction with the inhibitory IкB proteins (Li and Verma 2002).  However, only Rel-A, c-Rel and Rel-B posses transcription domains that regulate transcription.

Activation of the NF-кB pathway is dependent on the IKK complex that consists of 2 catalytic subunits; IKKβ, IKKα, and a regulatory subunit IKKγ (NEMO).  In unstimulated cells, NF-κB dimers are retained in the cytoplasm as a consequence of the interaction between the RHD and ankyrin repeats of IκB (inhibitor of κB) α protein.  Two distinct NF-κB pathways have been described; the canonical and the alternative pathways.  Activation of canonical pathway is dependent on IKKβ, this pathway can be triggered by PAMP and pro-inflammatory cytokines such as TNFα and IL-1 and leads to activation of RelA/p50 dimers.  Upon activation, IKK phosphorylates IκBα at amino terminal serine residues Ser32 and Ser36, the phosphorylated IκBα is then ubiquitylated at Lys21 and Lys22 which targets it for degradation by the 26s proteasome (Karin and Ben-Neriah 2000), the released NF-κB dimers translocate to the nucleus and activate gene transcription (Ghosh and Karin 2002).

TNF-related cytokines lymphotoxin (LT) β (Dejardin, Droin et al. 2002), CD40 ligand (CD40L)(O'Sullivan and Thomas 2002) and receptor activator of NF-B ligand (RANKL) (Novack, Yin et al. 2003), but not TNFα  ADDIN EN.CITE (Matsushima, Kaisho et al. 2001) have been shown to be “inflammatory triggers” of the alternative NF-κB signalling pathway.  In contrast to the canonical pathway, the alternative pathway is dependent on IKKα, and not IKKβ or NEMO.  Stimulation of this pathway leads to activation of NF-κB inducing kinase (NIK), this in turn phosphorylates and activates IKKα.  IKKα then selectively phosphorylates p100 resulting in the release of active p52/RelB and its translocation to the nucleus.  Accumulating evidence suggests the IKKβ-dependent canonical pathway is important for innate immunity  ADDIN EN.CITE (Alcamo, Mizgerd et al. 2001; Senftleben, Li et al. 2001) whereas the IKKα-dependent alternative NF-κB pathway is essential in development of lymphoid organs and adaptive immunity  ADDIN EN.CITE (Senftleben, Cao et al. 2001).  





1.9 IFN signalling pathway 
IFNs are widely expressed cytokines that play an important role in viral infection (Stark, Kerr et al. 1998).  The IFN family includes two main classes termed type I and II interferons; type I interferons includes of the IFN-α family (IFNαI, IFNαII, or IFNω and IFN-τ) and IFNβ.  The type II interferon (IFNγ) is structurally unrelated to IFNα/β, and the mechanisms that regulate its production are also different.  Type I IFN is secreted by virus infected cells, whereas type II IFN is secreted by activated T cells and NK cells.  

Both type I and II IFN receptors are composed of two subunits. Type I interferon (IFNα/β) transmits signals through its homologous receptor complex IFNAR1 and IFNAR2, whereas the type II IFN signals through a different receptor complex IFNGR1 and IFNGR2.  Each of these receptor subunits interact with a member of the Janus activated kinase (JAK) family.  For the type I IFN receptor, IFNAR1 and IFNAR2 associate with tyrosine kinase 2 (TYK2) and JAK2 (Darnell, Kerr et al. 1994).  In the case of the type II IFN receptor, IFNGR1 and IFNGR2 associate with JAK1 and JAK2 respectively (Bach, Aguet et al. 1997). 








Upon ligand binding to the type I IFN receptor, a signalling complex consisting IFNAR1, IFNAR2, TYK2 and JAK1 is formed.  This complex formation leads to TYK2 and JAK1 auto-phosphorylation and activation that results in the subsequent tyrosine phosphorylation of signal transducer and activator of transcription (STAT) 1 and STAT2.  Following downstream of the signalling cascade, phosphorylated STAT1 and STAT2 then create a heterotrimeric transcriptional complex, termed IFN stimulated gene factor 3 (ISGF3) together with IRF-9 (p48/ISGF3γ) (Bluyssen, Durbin et al. 1996), which can then translocate to the nucleus and bind IFN-stimulated response elements (ISREs- AGTTTCNNTTTCNC/T) to initiate gene transcription.  TThe transcription of type II IFN (IFN-γ) dependent genes is regulated by gamma interferon activation site (GAS) elements, and STAT1 is the most important IFN- γ activated transcription factor for the regulation of these transcriptional responses.  After engagement of the type II IFN receptor by IFN-γ, JAK1 and JAK2 are activated and regulate downstream phosphorylation of STAT1 on the tyrosine residue at position 701 (Tyr 701).  Such phosphorylation results in rapid dissociation of the receptor:STAT complex and leads to the formation of STAT homodimers.  These dimers translocate to the nucleus and bind to gamma activated site - GAS elements (TTNCNNNAA) to initiate transcription (Platanias 2005).  Examples of STAT1 regulated genes include iNOS, IRF1, IL-12 and MHCII indirectly through CTIIA.  IRF1 itself is also a transcription factor that recognises ISRE, and acts like STAT1 to induce IFN gene expression  ADDIN EN.CITE (Kamijo, Harada et al. 1994; Briken, Ruffner et al. 1995), and thus further amplify the response. 

1.10 Resolution of Inflammation
During inflammation, leukocytes accumulate and amplify the response, however, excessive or prolonged inflammation can be damaging to the host.  In normal circumstances, the immune system has several mechanisms to resolve the inflammatory responses (Lawrence and Gilroy 2007).  The resolution of inflammation requires the termination of pro-inflammatory signalling pathways and clearance of inflammatory cells, allowing the restoration of normal tissue function, a failure of these mechanisms may lead to chronic inflammation and disease. 

1.11 Negative regulation of signalling
The inflammatory response is a complex process involving many different signalling pathways.  Most of our knowledge of signalling is gained from studying members of TNFR, IL1R, and TLRs.  Although these signalling pathways are well characterised, most of these studies are limited to a single pathway, which is unlikely to represent the complexity of the inflammatory responses. There are many examples of synergistic effects of mediators and signalling pathways. The production of TNFα and IFNβ by LPS can activate other signalling pathways in an autocrine loop through receptors on the cell surface and amplify immune responses.  Cooperation between cytokines is another way to enhance the immune response.  IFNγ and TNFα have been shown to synergize in the induction pro-inflammatory genes (Ohmori, Schreiber et al. 1997), such as RANTES (Lee AH 2000).  This cooperation is dependent on the presence of binding sites for STAT1 and NF-кB on the gene promoter  ADDIN EN.CITE (Ohmori and Hamilton 1995; Ohmori, Schreiber et al. 1997). These synergistic effects permit a more efficient clearance of infection.  However, excessive and prolonged expression of pro-inflammatory mediators could be harmful to the host.  Therefore, a variety of negative regulatory mechanisms have evolved to prevent prolonged inflammation.  Inducible suppressors of cytokine signalling (SOCS), characterised by a central Src homology domain (SH) 2 domain and a SOCS box, function as a ubiquitin ligases to induce proteasomal degradation or a competitor for the activation loop of JAK, are responsible for negative feedback control of JAK-STAT signalling (Alexander and Hilton 2004).  A20, a direct target gene for NF-кB signalling can also function as a deubiquitinating enzyme to negative regulates TLR and TNFR signalling via interacting with TRAF6  ADDIN EN.CITE (Heyninck and Beyaert 1999; Boone, Turer et al. 2004).  MyD88s, an alternative spliced form of MyD88 that blocks recruitment of IRAK4 has also been shown to act as a negative regulator of Toll and IL-1 signalling  ADDIN EN.CITE (Janssens, Burns et al. 2002; Janssens, Burns et al. 2003).  Protein–tyrosine phosphatases  (PTPs) are another type of inhibitor, these include src-homology 2 domain phosphatase (SHP-1), SHP-2, CD45, plasma membrane intrinsic protein (PIP) 1B, T cell protein tyrosine phosphatase (TC-PTP) and PTP-BL).  PTPs bind to the tyrosine phosphorylated residues in the cytoplasmic domain of receptors, and catalyses their dephosphorylation (Jiao, Berrada et al. 1996), thereby blocking downstream signalling.

1.12 Apoptosis
Programme cell death or apoptosis, is critical in the resolution of inflammation (Savill, Dransfield et al. 2002), this non-phlogistic mechanism of cell death is required to clear inflammatory cells and furthermore the phagocytosis of apoptotic cells is an important mechanism to switch off macrophage activation  ADDIN EN.CITE (Fadok, Bratton et al. 1998).  During apoptosis, the plasma membrane of apoptotic cells undergoes dramatic rearrangement and expresses specific markers for phagocyte recognition (Savill and Fadok 2000; Savill, Dransfield et al. 2002).   One of the key markers of apoptotic cells is the exposure of phospholipids, the intracellular portion of the membrane of viable cells.  Externalization of membrane phospholipids triggers recognition of phosphatidyserine (PS) by macrophages and facilitates phagocytosis (Fadok, de Cathelineau et al. 2001). Increasing evidences suggest defective clearance of apoptotic cells could lead to chronic inflammatory diseases.  For example, systemic lupus erythematous (SLE) patients express autoantibodies that are able to opsonise apoptotic cells and facilitate the binding of macrophage Fc receptors  ADDIN EN.CITE (Reefman Esther 2007).  Anti-phospholipid autoantibodies were reported as one of the autoantibodies.  They recognise and bind PS exposed on apoptotic cells and facilitate the production of TNF-α by macrophages (Angelo A. Manfredi 1998). In addition to the removal of inflammatory cells by phagocytosis, the phagocytic clearance of apoptotic cells by macrophages can also promote the release of anti-inflammatory cytokine TGF-1 to suppress the pro-inflammatory activity and promote wound healing (Huynh ML 2002; Reidy and Wright 2003). 

1.13 NF-ĸB and the resolution of inflammation
NF-B transcription factors regulate genes involved in many aspects the inflammatory response (Bonizzi and Karin 2004). In response to a diverse array of pro-inflammatory stimuli; cytokines, PAMPs and stress (oxidative stress or UV radiation), NF-ĸB transcription factors induce the pro-inflammatory genes; including cytokines, chemokines and adhesion molecules which are essential for both the innate and adaptive immune response (Ghosh and Karin 2002). NF-ĸB activation is also widely implicated in inflammatory diseases and much attention has focused on the development of anti-inflammatory drugs targeting NF-ĸB (Karin, Yamamoto et al. 2004).  However, recent research has revealed another side of NF-ĸB and a role in the resolution of inflammation  ADDIN EN.CITE (Lawrence, Gilroy et al. 2001; Greten, Arkan et al. 2007; Fong, Bebien et al. 2008). The NF-ĸB family composes of 5 members NFB1 (p50), NFB2 (p52), Rel-A, Rel-B and c-Rel. Different combinations of NF-ĸB subunits generate different homodimers and heterodimers with distinct roles in the immune response.  Homodimers of the p50 subunit of NF-ĸB, which lack transactivation domains have been shown to repress expression of NF-ĸB target genes. A homodimeric complex of p50 was found in resting T cells and reduced p50 expression was observed after T cell activation, furthermore, over-expression of p50 was shown to repress IL-2 expression in T cells (Kang SM 1992). Increased p50 expression was reported to suppress TNF production in LPS tolerance (Kastenbauer and Ziegler-Heitbrock 1999). However, Gadjeva et al. have shown that p50-/-p65+/- mice were extremely sensitive to LPS induced shock (Gadjeva, Tomczak et al. 2004). These studies suggest anti-inflammatory roles of p50 homodimer and p50p65 heterodimers in septic shock.   Apart from sepsis, an anti-inflammatory role of NF-ĸB was also reported in inflammatory bowel disease; p50-/-p65+/- mice were more susceptible to Helicobacter hepaticus induced colitis (Erdman, Fox et al. 2001).  Later studies have shown that colitis was associated with increased IL-12p40 expression in the colon (Tomczak, Erdman et al. 2003), and a further study has shown administration of IL-10 Ig fusion protein inhibited IL-12p40 production and H. hepaticus induced colitis, which was dependent on p50/p105 expression in macrophages (Tomczak, Erdman et al. 2006).  These studies suggest NF-B can have anti-inflammatory roles by directly inhibiting expression of pro-inflammatory genes and by manipulating the expression or activity of anti-inflammatory cytokines such as IL-10.

1.14 NF-ĸB and apoptosis
As described above, apoptosis is an essential mechanism to prevent prolonged inflammation; neutrophil apoptosis during acute inflammation and activation induced cell death (AICD) of antigen-specific T cells are important mechanisms to limit inflammatory and immune responses.  Studies from Teixeiro et al. and Kasibhatla et al. have shown that inhibition of NF-ĸB activation decreases Fas (CD95) ligand expression on T cells that is required for AICD  ADDIN EN.CITE (Ju, Panka et al. 1995; Emma Teixeiro 1999; Kasibhatla, Genestier et al. 1999).  Over-expression of the endogenous NF-B inhibitor, IB in T cells also suggests a pro-apoptotic role for NF-B in double positive thymocytes (Hettmann, DiDonato et al. 1999). These studies contradict the anti-apoptotic role of NF-ĸB in inducing expression Bcl-xL, TRAF1, TRAF2, c-IAP1 and cIAP2 (Martin SJ 1995; Wang, Mayo et al. 1998).  Studies from Lin et al 1999 have shown the involvement of NF-ĸB in both pro- and anti-apoptotic function in T cells. Inhibiting NF-ĸB reduces phorbol myristate acetate (PMA)/ionomycin mediated induction of FasL and apoptosis while inhibition of NF-ĸB increase the glucocorticoid mediated apoptosis.  Glucocorticoids are produced in the thymus and function to induce thymocyte apoptosis during positive selection. However, Fas and FasL interaction is important in AICD and peripheral T cell deletion. These data suggest NF-ĸB inhibits glucocorticoid-mediated apoptosis and survival during positive selection.  On the other hand, NF-ĸB has the opposite role in mature peripheral T cells, promoting apoptosis by increasing FasL expression (Lin B 1999). These studies suggest NF-ĸB activation can have distinct roles in different cell lineages, physiological contexts or even throughout cell differentiation. 

In 2001, Lawrence and colleagues showed the involvement of NF-ĸB in both the onset and resolution of acute inflammation. These studies confirmed the expected role of NF-ĸB in pro-inflammatory gene induction during the onset of inflammation, but also demonstrated a role for NF-ĸB in expression of anti-inflammatory genes and induction of leukocyte apoptosis during the resolution of inflammation.  Inhibition of NF-ĸB during the resolution of inflammation prolonged inflammatory response and inhibited apoptosis (Lawrence, Gilroy et al. 2001). In 2007, Greten et al. have also shown an anti-inflammatory role for IKK, an essential activator of NF-B, in sepsis.  Conditional deletion of IKK in myeloid cells increased sensitivity of mice to endotoxin-induced shock associated with elevated plasma IL-1 as a result of increased pro-IL-1 processing in macrophages and neutrophils (Greten, Arkan et al. 2007).  In addition, Greten et al. confirmed a pro-apoptotic role for NF-B in neutrophils, which may also contribute to the anti-inflammatory role of NF-B as previously described by Lawrence et al.  



1.15 NF-B and macrophage activation
Although many macrophage sub-types and their specific effector roles have been described (Gordon 2003; Gordon and Taylor 2005), the signalling pathways that regulate their activation is limited.  Recent studies published by our group have shown the tissue specific role of IKK during infection and a role for IKK in inhibition of M1 macrophages (Fong, Bebien et al. 2008).  Using Cre-lox gene targeting, IKK was deleted in either macrophages or lung epithelial cells, in a model of Streptococcal pneumonia, neutrophil recruitment and bacterial clearance was inhibited in mice lacking IKK in lung epithelial cells (IKKEpi) but were enhanced in mice with IKK deletion in macrophages (IKKMye). In addition, IKKMye macrophages showed increased MHC II, iNOS and IL-12 expression, which are hallmarks of M1 macrophage activation. Furthermore, CD124 (IL-4 receptor) was absent on IKKMye macrophages suggesting these cells have less ability to respond to IL-4 and develop a M2 phenotype. Arginase 1 (Arg-1) expression was also decreased in IKKMye macrophages, the balance of iNOS and Arg-1 expression has also been demonstrated as a marker to discriminate M1 macrophages from M2 macrophages, M2 macrophages up-regulate Arg-1 while M1 macrophages express high levels of iNOS.  Arg-1 activity contributes to the immunosuppressive activity of M2 macrophages and suppresses iNOS expression (Kropf, Fuentes et al. 2005). Taken together, these data suggest that IKK is involved in the suppression of the pro-inflammatory M1 phenotype, and favours the development of anti-inflammatory M2 macrophages.  M2 macrophages are also thought to be important in promoting cancer, Hagemann et al. 2008 have shown in a parallel study that inhibiting IKK in TAM switched the phenotype from M2 to M1, characterized by increased IL-12, iNOS and MHC II, but decreased IL-10 and Arg-1. Furthermore, adoptive transfer of IKK targeted macrophages inhibited tumour growth in a mouse model of ovarian cancer.  These studies suggest another anti-inflammatory role for NF-B to promote the immunosuppressive phenotype of macrophages that limits their tumoricidal and bactericidal function.

1.16 Macrophages bridge innate and adaptive immunity
The development of adaptive immunity is initiated by the interaction between antigen presenting cells and naïve T cells.  Optimal T cell activation requires two signals; the engagement of T cell receptors with MHC II-peptide complex (signal 1) and signal from the accessory costimulatory molecules (signal 2).  In the absence of signal 2, T cell undergoes anergy or apoptosis (Jenkins, Chen et al. 1990).  Resting macrophages have low or no costimulatory molecules and MHC class II molecules express on their surface (Janeway 2001).  The expression of these molecules is induced by the ingestion of microorganism and recognition of PAMPs.  Macrophages, like dendritic cells (DCs) express a wide range of receptors including mannose receptor, scavenger receptor, complement receptor and TLRs.  Uptake of microorganisms via any of these receptors lead to the degradation in the endosomes and lysosomes, generating peptides that can be presented by MHC class II molecules.  At the same time, the receptors recognising these microorganisms transmit a signal that leads to expression of MHC II and costimulatory molecules and subsequently present the antigen to T cells. Activated T cells differentiate into TH1 cells and migrate to infected sites and secrete a variety of cytokines and chemokines to amplify the immune response (Janeway 2001).  IFNγ, one of the proinflammatory cytokines secreted by TH1 cells, drive ‘classical’ macrophage activation in which increased levels of phagocytosis and their ability to kill microorganisms through various cytotoxic mediators.

1.17 The effector functions of T cells
Differentiation of naïve T cells into effector T helper cells plays a crucial part in the development of the adaptive immunity. The most well studied T helper cells are TH1 and TH2 cells.  Different T cell lineage secretes specific cytokines that contribute to their characteristic effector functions.  IFN is the principal TH1 effector cytokine and is important in the cellular mediated immunity against intracellular pathogens and tumours.  For example, IFNγ activates macrophages and enhance their microbicidal activity, upregulate the level of MHC II expression and IL-12 production.  IFNγ is also important in antibody class switching to IgG classes, which is important in facilitating opsonisation and phagocytosis.  Furthermore, IFNγ and IL-2 produced by TH1 cells can also induce cytotoxicity indirectly by promoting CD8+ T cells differentiation into active cytotoxic cells (Abbas, Murphy et al. 1996; O'Garra 1998).  TH2 cells secrete IL-4, IL-5 and IL-13 and are responsible for immunity against extracellular parasites (Sher and Coffman 1992).  IL-4 is the major inducer of on antibody class switching from IgM to IgE and therefore important in inducing IgE B cell dependent reactions mediated by mast cells (Galli 1993).  IL-5 is an eosinophil-activating cytokine  ADDIN EN.CITE (Rothenberg and Hogan 2006).  Mice knockout for IL-5 receptor or treated with neutralising antibody for IL-5 showed marked defects in eosinophil responses to helminths (Yoshida, Ikuta et al. 1996). 
1.18 T cell polarisation
When antigen presenting cells (APC) interact with the naïve T cells, the surrounding cytokine microenvironment has a great impact on determining TH1 or TH2 cell development (Seder and Paul 1994).  IL-12 and IFNγ are the well-known cytokines for driving TH1 polarisation.  Mice deficient in IL-12 or STAT4 have markedly reduced TH1 responses  ADDIN EN.CITE (Kaplan, Sun et al. 1996; Magram, Connaughton et al. 1996; Thierfelder, van Deursen et al. 1996). In response to intracellular bacteria, DCs or macrophages produce IL-12, which provide the primary source of IL-12 for driving TH1 cell differentiation. IFNγ is another important cytokine for TH1 development.  Both activated NK cells or TH1 cells are the producers of IFN in the immune system (Abbas, Murphy et al. 1996; He XS 2004).   IL-4 is an important differentiation factor for TH2 cells (Swain, Weinberg et al. 1990) and its critical role in TH2 cell polarisation is illustrated from the impairment of  TH2 cell development in IL-4 knockout mice (Kopf, Gros et al. 1993).  Other evidence comes from the reduced TH2 responses in mice deficient for STAT6, a factor required for IL-4 receptor signalling  ADDIN EN.CITE (Kaplan, Schindler et al. 1996; Shimoda, van Deursent et al. 1996; Takeda, Tanaka et al. 1996). The initial source of IL-4 has been controversial. TH2 cells are the key cell population in the immune system for IL-4 production. However, IL-4 is only produced after TH2 differentiation, so the initial source of IL-4 has always been an open question.  Basophils and mast cells have been also suggested as the source of IL-4 production (Seder RA 1991) (Plaut, Pierce et al. 1989).  However, later study by Schmitz et al. has shown TH2 differentiation does not depend on IL-4 produced by non-T cells (Schmitz J 1994), suggesting signals other than IL-4 might contribute to TH2 differentiation. The existence of IL-4 independent signals is suggested by the observation that strong TH2 responses occur in STAT6-/- mice infected with parasites (Jankovic, Kullberg et al. 2000).  Similarly, dendritic cells incubated with parasite products, cholera toxin, or Prostaglandin E2 (PGE2) induce IL-4 independent TH2 responses  ADDIN EN.CITE (Maria Cristina Gagliardi 2000; de Jong, Vieira et al. 2002). 

Notch pathway has increasingly been recognised as another factor that contributes to T cell polarisation (Amsen, Blander et al. 2004). Different Notch ligands were shown to be express on DCs under different conditions.  Upon stimulation with LPS, a typical stimulus for TH1 promotion, Delta was induced whereas Jagged was induced when stimulated with PGE2 and cholera toxin, conditions that have previously been shown to induce TH2 responses (Amsen, Blander et al. 2004).  The direct influence of the Notch ligands on T cell differentiation was further demonstrated by APC cell line engineered to express either Delta or Jagged.  APC expressing Delta strongly promoted the generation of TH1 cells as demonstrated by the enhanced IFNγ, reduced IL-4 and IL-5 production.  Opposite results were observed with APC expressing Jagged (Amsen, Blander et al. 2004). RBPJĸ was reported as the key mediator in Notch signalling. These papers demonstrate that Jagged and Delta play as an instructive signal for T cell differentiation. 

Much effort has been made in identifying the transcription factors that control the transition of naïve T cells into effector T cells.  In 2000, Szabo et al. discovered a novel TH1 specific T box transcription factor T-bet and have shown its role in directing TH1 lineage development (Szabo, Kim et al. 2000). For example, T-bet induces IFNγ production by directly activating IFNγ reporter activity, inducing IL-12Rβ2 expression and stabilising its own expression  ADDIN EN.CITE (Mullen, High et al. 2001; Mullen, Hutchins et al. 2002). Furthermore, T-bet suppresses TH2 responses by repressing IL-4 and IL-5 production (Szabo, Kim et al. 2000). IRF1, another transcription factor that has been shown to be involved in TH1 cell development  ADDIN EN.CITE (Lohoff, Ferrick et al. 1997; Kano, Sato et al. 2008) (Taki, Sato et al. 1997).  CD4+ T cells from IRF-/- DO11.10 TCR transgenic mice fail to differentiate into IFNγ producing TH1 cells when stimulated with ovalbumin (OVA) in the present of wild type (WT) APC.  It was also shown that in response to IFNγ, IRF1 directly regulates the gene expression of IL-12Rβ1, which consequently defect IL-12-STAT4 signalling.

As TH1 cells, numerous transcriptional factors have been reported and used as the markers of TH2 cells. GATA3 is a transcription factor that can be induced by IL-4  ADDIN EN.CITE (Zhang, Cohn et al. 1997; Ouyang, Ranganath et al. 1998).  In addition to its selective expression in TH2 cells, GATA3 has also been shown regulating TH2 cytokines.  Zhang et al. has shown that GATA3 is important in transactivation of the IL-5 promoter in which mutation in GATA3 site abolished IL-5 promoter activation (Zhang, Cohn et al. 1997).  Later study by Zhu et al. has further confirmed the role of GATA3 in IL-5 expression and illustrated its regulatory role on other TH2 cytokine, IL-13 (Zhu, Min et al. 2004). Furthermore, ectopic expression of GATA3 in STAT6-/- T cells induces TH2 cell specific cytokines (Ouyang, Ranganath et al. 1998; Ouyang, Lˆhning et al. 2000). GATA3 also plays negative regulatory role in TH1 development. Ouyang et al. has shown an IL-4 independent inhibitory role of GATA3 (Ouyang, Ranganath et al. 1998).  Retroviral expression of GATA3 in TH1 cells inhibited IL-12R2 expression and IL-12 induced IFN production was also suppressed. GATA3 has also been shown in participating in cell population expansion.  Deletion of GATA3 caused a substantial reduction in the expansion of the TH2 cell population while no effect was observed when GATA 3 was deleted in TH1 cells (Zhu, Min et al. 2004). C-Maf is another TH2 specific transcription factor that was identified in 1996 by Ho et al. c-Maf belongs to the b-ZIP protein family and was shown to regulate the expression of IL-4 by direct interaction with the IL-4 promoter at the MARE element (Ho, Hodge et al. 1996). Transgenic mice over-expressing c-Maf increased skewing towards TH2 responses as demonstrated by the increased TH2 cytokines and Ig isotype - IgG1 and IgE (Ho, Lo et al. 1998).  In addition to the factors mentioned above, many other factors have also been reported to have an influence in the balance between TH1 and TH2 subsets.  For example, antigen dose, the form of the antigen, costimulatory molecules, the affinity of the peptide antigen-TCR interaction  ADDIN EN.CITE (Constant and Bottomly 1997).  Taken together, these studies illustrate that polarisation of TH cells from a naïve T cell is a complex process that is not dependent on single mechanism but the balance from many factors occur at the moment of T cell-APC interaction.

1.19 NF-B, inflammation and carcinogenesis
The idea on linking inflammation and cancer was first proposed by Virchow in 1863 (Balkwill and Mantovani 2001).  This assumption was based on the observations of the frequent occurrence of malignant neoplasm at the sites of inflammation.  Since then, mounting evidences have arisen to support this hypothesis.  From epidemiological studies, approximately 20% of total cancer death is related to infection and inflammatory responses (H. Kuper 2000; Mantovani, Allavena et al. 2008) (Schottenfeld and Beebe-Dimmer 2006). Helicobacter pylori is a microbial agent that have been reported in association with stomach cancer.  Other examples included Herpes viruses in cervical cancer (Castellsague, Bosch et al. 2002) and Schistosomes in bladder cancer (Rosin, Anwar et al. 1994; Mostafa, Sheweita et al. 1999). Autoimmune disease such as ulcerative colitis has been reported as an increased risk on the development of colorectal cancer (Kornfeld, Ekbom et al. 1997). 

Tumours have also been described as ‘wounds that do not heal’ (Dvorak 1986).  Throughout the process of wound healing, leukocytes infiltrate to the injured site and secrete a variety of cytokines, chemokines and growth factors to support the growth of connective tissues.  This process is similar to the tumour microenvironment that tumour cells and infiltrating leukocytes provide the necessary factors to facilitate the proliferation and invasion of the neoplastic cells.  NF-B signalling pathway is well known as the regulator of proinflammatory and anti-apoptotic gene, hence it is proposed as the molecular player in inflammatory associated tumour development. Study of inflammation-associated colon cancer with conditional knockout mice supports this hypothesis.  Deletion of IKKβ in enterocytes decreased colitis associated tumour incidence by enhanced epithelial apoptosis.  On the other hand, reduction of tumour size was observed when IKKβ is deleted in myeloid cells and the reduction of tumour size was suggested to be the consequence of reduced inflammatory mediators produced by the myeloid cells (Greten, Eckmann et al. 2004). In addition to tumour progression, IkappaB kinase has also been related to metastasis.  In 2007, Luo et al. has demonstrated the role of IKKα in metastasis.  IKKαAA/AA TRAMP mice developed fewer secondary site metastases compared to WT/TRAMP mice.  Subsequent analysis has shown that IKKα regulates the expression of maspin at the transcriptional level.    These data provide a new insight for the promotion of metastasis in which tumour infiltrating macrophages expressing RANKL activate IKKα in prostatic epithelial tumour cells that subsequently repress maspin and induce metastasis (Luo, Tan et al. 2007).  Within solid tumours, non-malignant cells including immune cells, fibroblasts, adipocytes, and blood vessel cells are often found and reported to be participating in tumour development (Balkwill and Mantovani 2001). TAM is one of the key cell populations found in solid tumour. Much evidence has demonstrated the roles of TAM in angiogenesis, metastasis, and tumour growth, however the molecular mechanism behind TAM in tumour biology is still not clear. A recent study by Hagemann et al. 2008 has reported a role of IKK in maintaining the immunosuppressive phenotype of TAM (Hagemann, Lawrence et al. 2008).  Conditional knockout of IKKβ in TAM switches its phenotype from immunosuppressive (IL-10 high, arginase high, IL-12 low) to cytotoxic as the classical activated macrophages (IL-12 high, IL-10 Low, MHC II high)(Hagemann, Lawrence et al. 2008).  Other member of NF-B pathway, p50 has also been reported in maintaining the phenotype of TAM.  TAM isolated from p50-/- mice shows production of M1 cytokines, and it was associated with reduced tumour growth (Saccani, Schioppa et al. 2006). Taken together, these studies illustrate different roles of NF-B pathway in tumour development.  One of its ways is to prevent cell death and second, by production of pro-inflammatory cytokines in inflammatory cells in the tumour mass and thirdly by promoting metastasis.
1.20 Aim of the thesis
1. Determine the effect of IKKβ deletion on macrophage activation in vitro
2. Investigate cross talk between TNF signalling and STAT1 activation
3. Investigate the inhibitory roles of IKKβ in the adaptive immunity
4. Investigate the effect of IKKβ deletion in anti-tumour immunity


















2. Methods and Materials
2.1 Mice
All mice were housed in negative pressure isolation at the Cancer Research UK containment facility.  p55 (TNFR1) and p75 (TNFR2) knockout mice and age match WT on a C57BL/6 background were provided by Jackson labs.  8-10 week old mice were used for all experiments.

2.2 Cell lines and primary cells
All glassware, used for cell culture, was baked at 220oC for 12 h to remove contaminating endotoxin.  All media was prepared at Claire Hall using endotoxin free water and glassware.

2.2.1 Cell lines 
Murine bladder (MB) 49 tumour cells (a kind gift from Dr Jian-Guo Chai, Imperial College, London, UK) and JH293 cells (a kind gift from Iain McNeish) were grown in RPMI supplemented with L-glutamine (2mM), penicillin (10,000U/ml)/streptomycin (10,000µg/ml), 20mM HEPES, 10% heat-inactivated fetal bovine serum (FBS) at 37oC, 5% carbon dioxide (CO2).  The adherent cells were passaged when reaching 80% confluent in a T175 flask.  Cells were trypsinised and 3x106 cells were seeded in a fresh T175 flask in 25ml RPMI.  Cells were routinely checked for the presence of mycoplasma.



2.2.2 Macrophage Colony-Stimulating Factor derived bone marrow derived macrophages 
8-10 week old mice were killed; tibias and femurs were removed from both legs.  The remaining muscle was removed and the top and bottom of the bones were cut with scissors.  A 26g needle was attached to a 10ml syringe filled with complete DMEM and the needle inserted into the bone marrow cavity.  The bone marrow was flushed into a 50ml falcon and collected cells were centrifuged at 453xg for 5 min at 4oC.  The cells were resuspended in 1-2ml of red blood cell lysis buffer (Sigma) and centrifuged at 453xg, 4oC, 5 min.  Supernatant was discarded, cells were resuspended in 20ml of complete medium and centrifuged again at 453xg, 4oC, 5 min. Bone marrow cells were cultured at a density of 1x106 cells/ml in DMEM supplemented with L-glutamine (2mM), penicillin/streptomycin, 20mM HEPES, 10% heat inactivated FBS and 10ng/ml recombinant macrophage colony stimulating factor (MCSF) (Peprotech) at 37oC, 5% CO2. After 7 days, adherent cells were removed by adding cell dissociation buffer (Invitrogen) and left at 37oC for 5-10 min. Cell viability was measured using the ViCell XR Counter (Beckman Coulter), and was typically >90%.













2.2.3 Thioglycolate elicited macrophages
Thioglycolate (tg) (BD Pharmingen) induced peritoneal macrophages were collected via peritoneal lavage on day 3 after 1.5ml injection of 3% tg.  3x106 tg elicited peritoneal macrophage were cultured in 6 well tissue culture plates at 37oC and 5% CO2 in RPMI supplemented with 10% heat-inactivated FBS, penicillin/streptomycin, and 2mM glutamine. For different experiments, cells were treated as indicated in Table 3.

Table 3 Stimulus used in experiments
Treatment	Final concentration	Company
LPS (E.coli)	100ng/ml	Sigma
Recombinant murine IFNγ	100U/ml	Preprotec
Recombinant murine TNFα	20ng/ml	Preprotec
Recombinant murine IL-1	10ng/ml	Preprotec
Recombinant murine M-CSF	10ng/ml	Preprotec













2.3 Delayed-type hypersensitivity
2.3.1 Immunisation 
Fresh reagents were prepared for each experiment; mBSA/ complete Freund’s adjuvant (CFA) solution was prepared by mixing solutions A and B.  Solution A; 50mg of mBSA (Sigma) was dissolved in 5ml of distilled water and 45mg of sodium chloride (Sigma) was added.  Solution B; 5ml of incomplete Freund’s adjuvant (IFA) (Sigma) was added dropwise to 20mg Mycobacterium Butyricum (Difco) and mixed by passing in and out with 21g needle attached to a 10 ml syringe.  Solution B was placed on ice and sonicated for 1 min, then solution A was added.   The mixture was again sonicated until an emulsion was obtained.  For primary immunisation, 0.1ml of mBSA/CFA was injected intradermally.  After 14 days, a subsequent boost with mBSA/IFA was given.













2.3.2 CD4+ T cell isolation 
CD4+ T cells were purified by negative selection using CD4+ T cell isolation kit (Miltenyi Biotech) following the manufacturer’s instructions.  8-10 week old C57BL/6 mice were killed and lymph nodes (superficial cervical nodes, brachial nodes, mesenteric nodes, inguinal nodes) collected.  Lymph nodes were mashed through a 70μm cell strainer to obtain single cell suspension.  Cells were centrifuged at 453xg, 10 min, 4oC and supernatant was aspirated.  Cell pellet was resuspended in 40μl MACS buffer (phosphate buffered saline (PBS), 0.5% bovine serum albumin (BSA), 2mM ethylenediaminetetraacetic acid (EDTA)) per 107 cells and incubated with 10μl of biotin-antibody cocktail per 107 cells at 4oC.  After 10 min, 30μl of MACS buffer and 20μl of anti-biotin microbeads were added per 107 cells.  Cells were incubated at 4oC.  After 15 min, 40ml of MACS buffer was added and cells were centrifuged at 453xg for 10 min at 4oC.  Cell pellets were resuspended in 500μl of MACS buffer per 108 cells.  LS columns (Miltenyi Biotech) were placed on a magnetic MACS separator and prepared by adding 3ml of MACS buffer.  For each column, 500μl of cell suspension was applied and columns were washed three times with 3ml of MACS buffer.  Unbound CD4+ T cells were obtained from the washout and centrifuged at 453xg, 5 min, 4oC.  CD4+ T cells were resuspended in 15ml of PBS, cell number and viability were measured using ViCell XR Counter and viability was typically >90%.




2.3.3 CFSE labelling
Carboxyfluorescein succinimidyl ester (CFSE) solution was prepared in pre-warmed PBS to give a final concentration of 2μM.  CD4+ T cells were purified from lymph nodes as described in section 2.3.2.  After purification, T cells were washed with 15ml of PBS by centrifugation at 453xg, 5 min, 4oC.  After 2 washes, cells were stained by adding 1ml of CFSE solution per 107 cells and placed in a 37oC water bath for 4 min.  After incubation, 10ml of cold PBS was added and cells were centrifuged at 453xg, 4oC, 5 min.  Supernatant was aspirated and cells were resuspended in 15ml cold PBS and centrifuged at 453xg, 4oC, 5 min.  The cell pellet was resuspended in pre-warmed RPMI medium supplemented with 10% heat-inactivated FBS, penicillin/streptomycin, and 2mM glutamine medium.

2.3.4 Allogenic mixed lymphocyte reaction
8-10 week old Balb/c mice were killed and lymph nodes (superficial cervical nodes, brachial nodes, mesenteric nodes, inguinal nodes) collected.  CD4+ T cells were isolated and stained with CFSE as described in section 2.3.3.  To determine the optimum ratio of T cells and macrophages, 3x105 T cells were cultured with 2x104, 4x104 and 6x104 allogenic tg elicited macrophages from C57BL/6 mice.  At indicated timepoints, non-adherent CD4+ T cells were collected and washed with 200μl FACS buffer by centrifugation at 453xg, 4oC, 5 min. After two washes, T cells were resuspended in 150μl FACS buffer and 10μl 40g/ml 7-amino-actinomycin D (AAD) (Sigma) was added.  CFSE dilution was measured by FACS as a measure of T cell proliferation.  

2.3.5 Characterisation of OTII specific CD4+ T cells
1.6x106 macrophages were treated with 100ng/ml LPS with or without 20nM OVA323-339.  After 24 h, 8x106 CD4+ T cells isolated from OTII mice were added.  At indicated timepoints, non-adherent CD4+ T cells were collected and washed with 200μl of PBS by centrifugation at 453xg, 4oC, 5 min. After two washes, total RNA was isolated and analysed by quantitative real time polymerase chain reaction (qRT-PCR).  Culture supernatant was collected and IFN production was measured by enzyme-linked immunosorbent assay (ELISA). 

2.3.6 Characterisation of CD4+ T cells isolated from mBSA immunised mice
IKKF/F, IKKMye or WT mice were immunised with mBSA as described in section 2.3.1.  After 21 days, CD4+ T cells were isolated from the lymph nodes of immunised mice and stained with CFSE (section 2.3.3). 6x104 WT BMDM or IKKF/F, IKKMye tg elicited macrophages were treated with 100ng/ml LPS and pre-loaded with or without 20g/ml mBSA.  After 24 h, 3x105 CFSE labelled CD4+ T cells were added.  At indicate timepoint, tissue culture supernatant was collected and IFN production was measured by ELISA. 

2.3.7 mBSA recall assay
mBSA immunised mice were killed 21 days post-immunisation (Section 2.3.1).  Spleens were collected and single cell suspensions prepared by mashing the spleens through a 70μm cell strainer.  Splenocytes were centrifuged at 453xg for 10 min at 4oC and 2-3ml of red blood cell lysis buffer (Sigma) was added per spleen.  Splenocytes were incubated at room temperature for 5 min, an equal volume (2-3ml per spleen) of complete RPMI medium was added and the cells were centrifuged at 453xg, 4oC, 10 min.  Splenocytes were resuspended in complete RPMI medium and counted with ViCell XR Counter.  3x106 splenocytes were plated in a 24 well plate in 2ml of complete RPMI medium with or without 0.1, 10, 50, and 100μg/ml mBSA.  Cells were incubated at 37oC, 5% CO2, culture supernatant was collected on day 4, IFNγ and IL-10 were measured by ELISA.

2.4 MB49 tumour model
2.4.1 Preparation of MB49 tumour cells for injection
MB49 tumour cells at 80% confluence were used for all experiments.  Cells were trypsinised and centrifuged at 453xg for 5 min, then resuspended in RPMI without FBS and penicillin/streptomycin.  Single cell suspensions were prepared by passing cells through a 21g needle and 0.5x106 cells in 0.1ml were injected subcutaneously in the right flank of each mouse.  Tumour size was measured every other day with electronic callipers. 

2.4.2 Tumour digestion
Tumours were collected on day 7 under sterile conditions, placed in small glass bottles and cut into pieces with scissor.  2ml of digestion buffer (RPMI, 5% FBS, 2.5mg/ml collagenase II (Invitrogen), 2.5mg/ml collagenase IV (Invitrogen) and 0.5mg/ml deoxribonuclease (Sigma)) was added and tumours were placed at 37oC on a magnetic stirrer for 10-15 min. After digestion, tumour cells were collected and passed through a 70μm cell strainer.  Cell strainers were flushed with complete RPMI and tumour cells collected by centrifugation at 453xg, 5 min, 4oC and then resuspended in complete RPMI.  Cell number and viability were measured using ViCell XR Counter and viability was typically >80%.  RNA was extracted with Tri-reagent as described in section 2.5.2 and analysed by qRT-PCR (section 2.5.4).

2.4.3 H-Y recall assay
IKKβF/F and IKKβ∆Mye female mice were injected subcutaneously in the right flank with 0.5x106 MB49 tumour cells.  After two weeks, mice were sacrificed and spleens were collected. Single cell suspensions were obtained by mashing spleens through a 70μm cell strainer.  Splenocytes were centrifuged at 453xg for 10 min at 4oC and 2-3ml of red blood cell lysis buffer was added per spleen and incubated at room temperature.  After 5 min, an equal volume (2-3ml per spleen) of complete RPMI medium was added and centrifuged at 453xg, 4oC, 10 min.  Cells were resuspended in complete RPMI medium and counted with ViCell XR Counter.  7x106 splenocytes from tumour bearing mice were co-cultured with 3x106 syngenic female or male splenocytes in triplicate wells of 24 well plates in a final volume of 2ml complete RPMI.  Cells were cultured at 37oC, 5% CO2.  Culture supernatant was collected after 24 h and IFNγ production was measured by ELISA.





2.5 RNA 
2.5.1 RNA extraction with QIAamp RNA blood mini kit
All ribonucleic acid (RNA) was extracted with QIAamp RNA blood mini kit unless stated.  Procedures were followed according to the instructions of the manufacturer.  3x106 cells were washed twice with PBS and lysed with 350μl of buffer RLT supplemented with 10μl -mercaptoethanol per 1ml.  Lysate was pipetted repeatedly until the sample became homogenous and transferred to QIAshredder spin column and centrifuged at 7826xg, 2 min, room temperature. After centrifugation, 350μl of 70% ethanol was added to the lysate and mixed by pipetting, then transferred to QIAamp spin column, followed by centrifugation at 7826xg, 15 sec, room temperature.  The flow through was discarded and 350μl of RW1 buffer was added to the column.  The tube was centrifuged at 7826xg for 15 sec, 80μl of DNase reaction mix (10μl DNase, 70μl RDD buffer) was added to the membrane of the column and left at room temperature.  After 15 min, 350μl RW1 was added and centrifuged at 7826xg for 15 sec.  After spinning, the QIAamp spin column was placed into a new 2ml collection tube and 500μl of buffer RPE buffer was added to the column, followed by centrifugation at 7826xg for 15 sec.  The flow through was discarded and another 500μl of RPE buffer was added.  The tube was centrifuged at 13226xg for 3 min.  The flow through was discarded and the centrifugation was repeated to remove the remaining buffer.  After spinning, the QIAamp spin column was placed into a fresh 1.5ml collection tube and 35μl of diethylpyrocarbonate (DEPC)-treated water was added directly to the membrane, after 1 min, the tube was centrifuged at 7826xg for 1 min.  

2.5.2 RNA extraction with Tri-reagent
MB49 tumour cells were prepared as described in section 2.4.2.  Tumour cells were washed 3 times with PBS by centrifugation at 453xg, 4oC, 5 min.  After the last wash, PBS was aspirated and cell pellet was resuspended with 1ml of Tri-Reagent (Sigma) per 1x107 cells.   Cells were left at room temperature to allow complete nucleoprotein complex dissociation.  After 5 min, 200μl of chloroform (Sigma) was added and samples were immediately shaken for 15 sec.  The RNA mixture was left at room temperature for 5 min and centrifuged at 13226xg, 15 min, room temperature.  The upper aqueous phase was transferred to fresh tube and 500μl of isopropanol (Sigma) was added, followed by vortexing for 15 sec.  The RNA mixture was incubated at room temperature for 30 min, followed by centrifugation at 13226xg, 15 min, room temperature.  The supernatant was removed and the pellet was washed by vortexing with 0.5ml 75% ethanol (Merck/BDH made with DEPC-treated water).  The tube was centrifuged at 13226xg for 5 min at 4oC.  The supernatant was removed and the pellet was air-dried and resuspended in an appropriate volume of DEPC water.

2.5.3 DNase treatment of RNA 
Total RNA was DNase-treated to remove contaminating genomic DNA. 1l RNasin ribonuclease inhibitor (Promega), 10l transcription optimised 5x buffer (Promega), 10g RNA, 2l DNaseI (Amersham), DEPC-treated water to a final volume of 50l.  The reagent mixture was incubated at 37oC for 1 h.  



The RNA mixture was phenol: chloroform extracted as follows: 50l of DEPC-treated water was added to the RNA mixture, followed by 100l of citrate-buffered phenol:chloroform (5:1 ratio Sigma).  The contents were vortexed for 15 sec, then centrifuged at 13226xg for 5 min at 4oC.  The upper aqueous phase was transferred to fresh tube and 100l of chloroform: isoamyl alcohol (24:1 ratio, Merck/BDH) was added, followed by vortexing for 15 sec and centrifugation at 13226xg for 5 min at 4oC.  The upper aqueous phase was transferred to a fresh tube.  1l glycogen (Roche), 1/5 volume (20l) of 5M ammonium acetate (Sigma) and 2.5 volumes (250l) of absolute alcohol (Merck/BDH) were added.  The tube was placed on dry ice for 30 min and centrifuged at 13226xg for 15 min at 4oC.  The supernatant was removed and the pellet was washed by vortexing with 0.5ml 75% ethanol (Merck/BDH made with DEPC-treated water).  The tube was centrifuged at 13226xg for 5 min at 4oC and the supernatant was removed, the pellet was air-dried and resuspended in an appropriate volume of DEPC water.

2.5.4 Quantitative real-time polymerase chain reaction 
Total RNA was extracted with QIAamp RNA Blood Mini Kit (Qiagen) or Tri-reagent as described in sections 2.5.1-2.5.3 and the concentration of RNA was quantified by Nanodrop 1000 UV-vis spectrophotometer (Thermo Scientific).  cDNA was syntheized from 0.5g of DNase treated total RNA using Moloney murine leukaemia virus (M-MLV) reverse transcriptase kit (Promega) according to the manufacturer’s instruction.  The following reagents were added to a ribonuclease-free 1.5ml eppendoff tube, followed by incubation at 75oC for 5 min: 2l of random hexamer primers, 0.5g DNase treated RNA, DEPC-treated water to a final volume 12l.  The tube was cooled on ice for 5 min and the following reagents (5l deoxyribonucleotide triphosphate (dNTP), 5l M-MLV RT 5 x reaction buffer, 1l M-MLV RT enzyme), followed by incubation at room temperature for 10 min and then 40oC for 50 min.  The cDNA was made up to the volume of 200µl with DEPC-treated water.

Ten micro-litres of cDNA was used as a template for qRT-PCR.  Sequence specific primers were used to analyse expression of specific mRNA (Table 4).  Cycle conditions were as follows:  50oC for 2 min, 10 min at 95oC, 15 sec at 95oC and 1 min at 60oC repeated 50x.  Experiments were performed in triplicate for each sample.  Gene expression was normalized to the level of cyclophillin RNA.













Table 4 Primer sequences for qRT-PCR
Gene		Primer sequences	
Cyclophillin	For	ATG GTC AAC CCC ACC GTG	
 	Rev	TTC TTG CTG TCT TTG GAA CTT TGT C
TNF	For	ACA GAA AGC ATG ATC CGC G
	Rev	GCC CCC CAT CTT TTG GG
iNOS	For	CCC TCC TGA TCT TGT GTT GGA
	Rev	CCA CCC GAG CTC CTG GAA C
IFN	For	ACT AGA GGA AAA GCA AGA GGA
	Rev	CTG GTA AGT CTT CGA ATG ATG
IFN	For	ACT GGC AAA AGG ATG GTG AC
	Rev	TGA GCT CAT TGA GAA TGC TTG G
T-bet	For	CCT CTT CTA TCC AAC CAG TAT C
	Rev	GTC CAC CAA ACT TCC ACC GA
IRF1	For	CAG AGG AAA GAG AGA AAG TCC
	Rev	CAC ACG GTG ACA GTG CTG G
IL-12R1	For	GGG AGG CAA CAT GAC ATC
	Rev	TTG GCA GGA TCT TCT TCT TC
IL-12R2	For	GGC ATT TAC TCT CCT GTC
	Rev	GAG ATT ATC CGT AGG TAG C
IP10	For	GGA GTG AAG CCA CGC ACA C
	Rev	ATG GAG AGA GGC TCT CTG CTG T
GATA	For	CGA GAT GGT ACC GGG CAC TA
	Rev	GAC AGT TCG CGC AGG ATG T
IL-4	For	ACA GGA GAA GGG ACG CCAT
	Rev	GAA GCC CTA CAG ACG AGC TCA
Arginase-1	For	CAG AAG AAT GGA AGA GTC AG
	Rev	CAG ATA TGC AGG GAG TCA CC
CD206	For	ATG CCA AGT GGG AAA ATC TG
	Rev	TGT AGC AGT GGC CTG CAT AG


2.5.5 Ribonuclease protection assay
0.5g of RNA was dried in MV-100 vacuum evaporator (Tomy Tech) by centrifugation for 20 min.  RNA was reconstituted with 8l of hybridization buffer (BD Biosciences).  Following reconstitution, RNA was hybridized with RNA probes.  

RNA probes were synthesized using RiboquantTM Multiprobe RPA system (BD Biosciences) according to the manufacturer’s instructions. A reaction mix containing 1l RNasin, 1l GACU pool, 1l DTT, 4l 5x transcription buffer, 1l multi-probe template set, 10l [-32P], 1l T7 RNA polymerase was prepared and incubated at 37oC for 1 h.  1l of DNase was added and RNA probe was incubated at 37oC for 15 min.  In order to remove the enzymes from the RNA probe, the reaction mix was passed through MicroSpin G-25 column (Amersham).  79l of DEPC-treated water was added to make up the final volume of 100l and ratio of 1:1 volume of phenol:chloroform (Sigma) was added.  RNA probe was vortexed and centrifuged with 15,700xg at room temperature for 5 min.  After centrifugation, the aqueous phase was collected and transferred to the column.  RNA probe was centrifuged at 0.8rcf for 1 min, and 1l of purified RNA probe was diluted in 2ml of scintillant for cpm reading (Scintillation Counter LS6500, Beckman Coulter).
 




2l of 40,000cpm probe was added to each RNA sample and mixed by pipetting.  A drop of mineral oil was added to each tube.  The mixture was heated at 90oC and temperature was allowed to decrease to 56oC gradually incubated for 12-16 h.  Samples were placed at room temperature for 15 min to allow the temperature equilibrate slowly. After hybridization, non-protected fragments of RNA were treated with RNase, RNase cocktail for 20 samples was prepared: 2.5ml RNase buffer and 6l RNase A/T1, 100l of RNase cocktail was added to each sample.  RNA samples were centrifuged for 10 sec and incubated at 37oC for 30 min.  During the digestion, Proteinase K cocktail containing 390l Proteinase K buffer, 20l Proteinase K, 30l yeast tRNA was prepared (for 20 samples) and 18l was aliquot into new eppendorf tubes.  After digestion, RNase digests underneath the oil were transferred to the tube containing the Proteinase K solution, samples were vortexed, centrifuged and incubated for 15 min at 37oC.  100l of phenol:chloroform was added to each sample and vortexed into emulsion.  Samples were again centrifuged at 15,700xg for 5 min at room temperature.  After centrifugation, the upper aqueous phase (approx. 100l) was collected and transferred to a new tube, 100l of 4M ammonium acetate and 500l ice cold 100% ethanol were added, samples were mixed by inverting and incubated at -20oC for 1 h.  Samples were centrifuged at 15,700xg for 15 min at 4oC, the supernatant was carefully removed from the RNA pellet and 100l of ice cold 90% ethanol was added.  Samples were centrifuged again for 15 min at 4oC, the supernatant was removed and the pellet was air dried for 5 min.  10l of 1x loading buffer was added, and each sample was vortexed for 2-3 min, centrifudged and heated at 90oC for 3 min, then immediately placed on ice.  In parallel, 50,000cpm unprotected labelled probe was prepared with the samples.  Samples were run on a 6% denaturing polyacrylamide gel at 0.2 A until the leading edge of the bromophenol blue disappeared from the gel (approx. 2-3 h), the gel was placed on a filter paper and dried in a gel drier (Bio-Rad Model 583) under vacuum for 2 h at 80oC.  

2.5.6 Polyacryamide gel preparation
A set of gel plates (>40cm in length) was cleaned thoroughly with water followed by ethanol.  Plates were assembled together with a 0.5mm spacer and a gel comb.  Acrylamide solution was prepared and poured into the plate cassette and allowed to polymerize at room temperature for 1 h.  After polymerization, gel was pre-run with 0.5% tris-borate-EDTA (TBE) buffer at 0.2 A for 45 min.  Before sample loading, wells were flushed with 0.5% TBE buffer to remove the excessive urea.  










2.6 Genotyping for IKKβF/F and IKKβΔMye mice
2.6.1 Polymerase chain reaction
Ear biopsies were collected from IKKβF/F and IKKβΔMye mice and digested with digestion buffer (100mM Tris, pH8, 500mM KCl, 0.1mg/ml gelatin, 0.45% NP-40, 0.4% Tween 20) containing 500g/ml proteinase K (Ambion) at 55oC for 5 h.  Samples were then heat-inactivated at 95oC for 10 min.

A master mix was prepared with reagents shown in Tables 5 and 6.  Master mix was added to 1l genomic DNA, and the final volume was adjusted to 25l with DEPC-treated water.  PCR was performed using a GeneAmp PCR System 9700 thermal cycler (PerkinElmer).  The following cycle conditions were used for IKKβF/F: 94oC (5 min); 35 cycles 94oC (1 min), 56oC (1 min), 72oC (1 min); 72oC (10 min). LysMCre: 94oC (3 min); 35 cycles 94oC (30 sec), 63.oC (1 min), 72oC (1 min); 72oC (2 min).

After PCR, products were analysed by electrophoresis, 3l loading buffer (10mM TrisHCl pH 7.5, 60mM EDTA, 0.03% [w/v] bromophenol blue, 60% [v/v] glycerol) was added to the PCR reaction sample and electrophoresed through a 1.5% agarose gel containing 0.5g/ml ethidium bromide (Sigma).  Bands were visualised by UV transillumination and analysed with Kodak digital science 1D software (Eastman Kodak Company).





Table 5 PCR primer sequences
Primers	Sequences
IKKβF/F                     For                           Rev	CCT TGT CCT ATA GAA GCA CAA CGTC ATT TCC ACA GCC CTG TGA
LysMCre            For                           Rev	CCC AGA AAT GCC AGA TTA CGCCT GGG CTG CCA GAA TTT CTC

Table 6 Master mix of PCR reagents
	IKKβlox-P	LysMCre
PCR reagents	Volume
10x PCR buffer	2.5l	2.4l
25mM MgCl2	2.5l	1.9l
10mM dNTPs	2.5l	0.5l
5U/l Taq DNA polymerase	0.25l	0.2l
Primer forwardPrimer reverse	1l1l	1l1l









2.7 Adenovirus production
2.7.1 Initial adenoviral amplification
30l of virus stock was diluted into 30ml of DMEM media containing 2% FBS and used to infect a 90% confluent T175cm2 flask of AD-293 cells.  At full cytopathic effect (CPE), the crude lysate from the T175 cm2 flask was collected and stored at -80oC until required.

2.7.2 Cell factory -10TM preparation and infection
Four T175 cm2 flasks of >80% confluent AD-293 cells were required to seed a single cell factory (CF)-10TM (Fisher Scientific).  Five millilitres of trysin was added to each T175 cm2 flasks of AD-293 cells and left at 37oC for 1-3 min.  Once the cells detached, 5ml of DMEM 10% FBS was added to each flask and cells were centrifuged for 5 min at 453xg, room temperature.  Supernatant was discarded and collected cells were resuspended in 40ml of DMEM 10% FBS.  From the 40ml cell suspension, 1ml was transferred to a fresh T175 flask containing 30ml of DMEM 10% FBS and the remaining cells were transferred to 400ml of fresh DMEM 10% FBS.  Using a funnel, the 439ml of cell suspension was slowly added to CF-10TM via a sterile tube.  Once all the cell suspension had passed into the unit, 600ml of fresh DMEM 10% FBS was added to flush any remaining cells from the tubing into the CF-10TM.  The unit was allowed to stand for a few minutes to ensure even distribution of the medium.  A filter (VWR international) was inserted into the CF-10TM and cells were incubated at 37oC, 5% CO2 for 48-72 h.  The confluency of cells in CF-10TM was determined by the parallel culture of the T175cm2 flask.  

Infection was performed once the cells reached >80% confluence; crude lysate from -80oC was defrosted at 37oC, and the freeze and thaw cycle was repeated twice.  7ml of crude lysate was added to 400ml of infection medium (DMEM, 2% FBS). Medium from the CF-10TM was discarded and 407ml of virus suspension was slowly transferred to CF-10TM through a sterile tube.  600ml of fresh DMEM 2% FBS was added to flush any remaining virus from the tubing into the CF-10TM.  Once all medium has transferred, the unit was allowed to stand for a few minutes to ensure even distribution of the medium.  Cells were left at 37oC, 5% CO2 until cells detached (Approx. 48-72 h).

Once the cells detached (approx. 48-72 h), cells were harvested and centrifuged at 805xg for 10 min at 4oC.  Supernatant was aspirated and cell pellets were resuspended in 15ml of cold PBS.  Cell suspensions were transferred to 50ml falcon and centrifuged at 200xg for 10 min at 4oC, supernatant was aspirated and cell pellets were resuspended in 12ml cold 10mM Tris.HCl (pH8).   Cell suspension was then transferred to a single 50ml falcon and stored at -80oC until ready for Cesium Chloride (CsCl) purification.











2.7.3 Cesium Chloride purification
Virus concentrate was defrosted at 37oC and the freeze and thaw cycle was repeated twice.  After defrosting, virus suspension was centrifuged for 10 min at 6000rpm at room temperature, and virus solution was collected.  Cesium Chloride gradient was prepared by placing 11.4ml of a 1.25g/ml CsCl solution into a 1x3.5in ultra centrifuge tube (Beckman Coulter) followed by underlay 7.6ml of 1.4g/ml CsCl solution.  Once the CsCl gradient was generated, virus solution was slowly loaded and this was then centrifuged at 25,000rpm for 2 h at 15oC using Beckman SW28 swing out rotor in an Optima LE-80K centrifuge.  Following ultracentrifugation, the tube was fixed in a clamp and pierced using a 19G needle fitted to a 10ml syringe.  The virus bands were collected and pooled in a 15ml tube.  Once all bands were collected, the virus concentrate was layered onto 3-4ml of 1.35g/ml CsCl solution in 0.5 x 2in centrifuge tubes (Beckman Coulter).  Tubes were then centrifuged at 40,000rpm at 15oC for 15 h using Beckman SW50.1 swing out rotor in an Optima LE-80K ultracentrifuge.  Virus bands were collected using 19G needle as described above and transferred to a 15ml tube.  The volume was made up to 12ml with TSG buffer (96mM NaCl, 0.5mM NaHPO4, 2.8mM KCl, 0.3mM MgCl2, 0.5mM CaCl2, 30% glycerol [v/v]).  Virus solution was injected into a dialysis cassette (Perbio) using the 18G needle and the dialysis cassette was placed on a float in a 5L beaker containing 2L of dialysis solution (10mM Tris HCl (pH7.4), 1mM MgCl2, 150mM NaCl, 10% glycerol [v/v]).  The beaker was placed on a magnetic stirrer in a cold room and the virus was left to dialyze for 24 h.  After dialysis, the virus solution was collected using a syringe and the solution transferred to a 15ml tube.  A small aliquot was removed for particle count and the remaining virus solution was aliquoted and stored at -80oC.	 

2.7.4 Determination of particle counts
Table 7 Determination of particle counts
Tube	Virus stock (l)	Dialysis buffer (l)	Lysis buffer (l)
1	100	100	200
2	200	/	200
3	/	200	200

Three tubes were prepared and labelled as shown in Table 7.  All tubes were vortexed and heated at 56oC.  After 10 min of incubation, tubes were removed, vortexed and allowed to cool at room temperature for 5-10 min.    600l of sterile water was added to all tubes to make to the final volume of 1ml, vortexed, and samples were read in a spectrophotometer at 260nm twice.  Particle count per ml was calculated with the equation shown below –

Particle count/ml = average reading x dilution factor x 1.12E12 (extinction coefficient).













2.7.5 The tissue culture infectious dose 50 Assay
In order to titre how many viral particles (per ml of the stock) are able to infect cells, tissue culture infectious dose (TCID) 50 Assay was performed.  A single T175cm2 flask of JH293 cells was prepared.  Once cells reached 80% confluence, cells were trypsinized and plated at 10,000 cells/well in 200l of DMEM 10% FBS in four 96 well plates.  From the defrosted virus stock, a range of dilutions was prepared in eppendoff tubes as shown in Table 8.  From the 10-5 dilution, 22l of virus was added to cells along row A and mixed, using a multi-channel pipette, 22l of diluted virus from row A was added to row B, mixed and so on until virus dilution reached 10-11.  Cells were left at 37oC, 5% CO2 for 10 days, and plates were scored under light microscope by counting wells with full CPE.

Table 8 TCID 50 Assay
Dilutions	Volume of virus stock	TrisHCl (pH8)  (l)
10-1	10l of virus stock	90
10-2	10l from 10-1	90
10-3	10l from 10-2	90
10-4	30l from 10-3	270
10-5	200l from 10-4	1800







Final virus dilution along each row of 96 well plates

22l of virus of 10-5 	            Row A final = 10-6
22l of 10-6 from A		Row B final = 10-7
22l of 10-7 from B		Row C final = 10-8
22l of 10-8 from C		Row D final = 10-9
22l of 10-9 from D		Row E final = 10-10
22l of 10-10 from E		Row F final = 10-11

2.7.6 Infecting bone marrow derived macrophages with adenovirus 
Bone marrow cells were infected with adenovirus expressing IKK dominant negative (Ad-IKKdn) or green fluorescence protein (Ad-GFP) with multiplicity of infection (M.O.I) 200:1 on day 3 of macrophage differentiation for 24 h in the presence of 10ng/ml recombinant M-CSF (Preprotec).   After 24 h of infection, cells were washed and fresh complete DMEM with 10ng/ml recombinant mouse MCSF was added. 





2.8 Immunoblotting
2.8.1 Preparation and quantification of whole cell protein lysates
3x106 macrophages were washed in 1ml ice cold PBS and lysed for 20 min on ice in 80l of lysis buffer (50mM Hepes, pH 7.9, 250mM NaCl, 3mM EDTA, pH8, 3mM EGTA, 1% Triton X100 and 10% Glycerol) containing proteases and phosphatase inhibitors (Table 9).  Lysates were cleared of cell debris by centrifugation at 4oC for 15 min at 14,263xg, lysates were collected and stored at -80oC until further use.  Protein concentration was quantified by Bradford assay (Bio-Rad), 1µl of protein extract was diluted in 99µl of PBS, 900µl of Bradford reagent was added and the absorbance was measured at 595nm on a spectrophotometer.  Protein concentration was determined against a standard curve using BSA.













Table 9 Supplement per ml of whole cell lysis buffer
Reagent	Volume 	Final Concentration	Company
1M DTT	2μl	2μl	Sigma
100mM PMSF 	10μl	1mM	Sigma
100mM NaVO4	1μl	0.1mM	Sigma
1M p-Nitrophenyl Phosphate (PNPP)	2μl	2μl	Sigma
1M β-glycerophosphate	10μl	10μM	Sigma
Protease inhibitor cocktail -	10μl		Sigma
AEBSF (104mM) Aprotinin (80μM)Leupeptin (2mM)Bestatin (4mM)Pepstatin A (1.5mM)E-64 (1.4mM)		1.04mM0.8μM0.02mM0.04mM15μM14μM	



















2.8.2 Sodium dodecyl suphate-polyacrylamide gel electrophoresis
Protein samples were denatured prior electrophoresis by addition of laemmli buffer (50 mM Tris-HCl; pH 6.8, 2% SDS, 10% Glycerol, 1% b-Mercaptoethanol, 12.5 mM EDTA, 0.02 % Bromophenol Blue) followed by boiling at 95oC for 5 min.  10μg of lysate was fractionated on 10% sodium dodecyl suphate-polyacrylamide gel electrophoresis (SDS-PAGE) gels (Invitrogen) and electro-transferred to polyvinylidene difluoride (PVDF) membrane (Perkin Elmer Life Science inc) with transfer buffer (25mM Tris base, 192mM Glycine, 20% [v/v] methanol) at 0.5 A for 2 h.  Membranes were blocked in 5% [w/v] dried milk powder in Tris Buffered Saline (TBS)-0.05%Tween20 for 1 h at room temperature and incubated with the primary antibodies (Table 10) at 4oC overnight.  

To visualize proteins, the membrane was incubated with appropriate secondary HRP-conjugated antibody (Table 10) for 1 h at room temperature.  Proteins were detected using the chemiluminecence substrate solution ECL (Amersham Biosciences) and visualized on Super RX-Fujifilm (Fujifilm).  Films were developed by automatic film processor IGP Compact 2 Developer.  In most cases, the membranes were stripped with stripping buffer (Chemicon International) and re-probed with different antibodies; 3 ml of 1X stripping buffer was added on the membranes at room temperature for 15 min.  Membranes were washed with TBS-0.05% Tween20 twice for 15 min and blocked again with 5% [w/v] milk in TBS-0.05% tween20 for 1 h at room temperature before incubated with primary antibodies at 4oC overnight as described above.
Table 10 Antibodies for Western Blotting
Antibodies	Dilution	Company
Rabbit anti-mouse IRF1 (M-20)	1:1000	Santa Cruz Biotechnology
Mouse anti-beta actin	1:1000	abcam
Mouse anti-mouse IKKβ	1:1000	Cell signaling
Rabbit anti-mouse NOS2 (M-19)	1:2000	Santa Cruz Biotechnology
Rabbit anti-mouse STAT1, CT 	1:1000	Upstate
Rabbit anti- mouse phospho-STAT1 (Tyr701)	1:1000	Upstate
		
Anti-goat IgG F (ab)2 HRP conjugate	1:5000	Amersham Biosciences
Anti-mouse IgG F(ab)2 HRP conjugate	1:5000	Amersham Biosciences
Anti-rabbit IgG F(ab)2 HRP conjugate	1:5000	Amersham Biosciences
		

















2.9 ELISA
Nunc MaxiSorp 96 well plates were coated with 100µl of capture antibody (Table 11) diluted in PBS at 4oC overnight. Wells were washed three times with washing buffer (PBS, 0.05% Tween-20) and blocked in 250µl dilution buffer (PBS, 10% FBS [v/v]) for 1 h at room temperature.  Following another 3 washes, 100µl of samples and serial dilution of recombinant protein (standard) were added to the plates and incubated for 2 h at room temperature or overnight at 4oC.  The plates were washed three times and incubated with 100µl of biotin conjugated secondary antibody for 1 h at room temperature.  Plates were washed three times and 100µl of streptavidin-HRP conjugate was added to each well.  After 1 h incubation, plates were washed three times, TMB peroxidase substrate (TMB (3,3’,5,5’-tetramethylbenzidine) (KPL Inc) was added and the reaction was stopped with 2N H2SO4 between 5-15 min. Absorbance 490nm was read on a spectrophotometer plate reader and analysed using Acent 2.4.2 labsystems software program.










Table 11 Antibodies for ELISA
Primary antibodies	Final Concentration	Company
Goat anti-mouse TNF-α	1μg/ml	R & D systems
Rat anti-mouse IL-10	4μg/ml	BD Bioscience


Secondary antibodies	Final Concentration	Company
Biotinylated anti-mouse TNF-α	250ng/ml	R & D systems
Biotinylated rat anti-mouse IL-10	1:2000	BD Bioscience

ELISA kit	Company
Anti-mouse IL-12p40	BD Bioscience
Anti-mouse IL-12p70	BD Bioscience
Anti-mouse IL-6	BD Bioscience
Anti-mouse IFN	BD Bioscience



















2.10 Fluorescence activated cell sorting analysis
2.10.1 Cell surface staining 
2.5x105 cells were washed twice with 2ml ice-cold (fluorescence activated cell sorting) FACS buffer (PBS, 1% BSA [w/v], 0.01% sodium azide [v/v]) and centrifuged at 453xg for 5 min at 4oC.  Fc receptors were blocked with anti-CD16.2/32.2 for 10 min on ice.  Cells were incubated with 0.1-0.5μg/ml of primary antibody as listed in Table 12 for 30 min on ice.  The cells were washed three times with FACS buffer and fixed by 0.1% formaldehyde. Cells were analysed by flow cytometry using FACScalibur and CellQuest software (Becton Dickinson).

2.10.2 Intracellular staining
1x106 cells were washed twice with 2ml ice-cold FACS buffer and centrifuged at 453xg for 5 min at 4oC.  Cells were fixed by incubation in 100l of fixing buffer (6% formaldehyde, PBS) for 15 min at room temperature, followed by 3 washes with FACS buffer.  Non-specific binding was blocked by adding 100l of blocking buffer (0.5% saponin [w/v], 10% FBS [v/v], PBS) and cells were left at room temperature.  After 20 min, cells were washed 3 times with permeabilisation buffer (0.5% saponin [w/v], PBS).  After washing, 1.25μg/ml of rat anti-mouse IFN-PE and hamster anti-mouse CD3-FITC (1:100) diluted in permeabilisation buffer were added and cells were incubated at room temperature for 20 min. The cells were washed three times with permeabilise buffer and resuspended in FACS buffer after the final wash, cells were analysed by flow cytometry using FACScalibur and CellQuest software (Becton Dickinson).
Table 12 Antibodies used for FACS analysis
Antibodies	Dilution	Company
Rat anti-mouse CD16.2/32.2	1:100	eBioscience
Rat anti-mouse CD11b : APC	1:200	eBioscience
Rat anti mouse CD11b - PE	1:300	eBioscience
Rat anti mouse MHC II -PE	1:300	eBioscience
Rat anti-mouse MHC - FITC	1:100	eBioscience
Rat anti-mouse CD86 - PE	1:100	eBioscience
Rat anti-mouse CD86 - APC	1:100	eBioscience
Rat anti-mouse CD80 - PE	1:100	eBioscience
Rat anti-mouse IL-4R - PE	1:100	eBioscience
Rat anti-mouse B220 - FITC	1:100	eBioscience
Rat anti-mouse CD4 - FITC	1:100	eBioscience
Rat anti-mouse CD8 - PE	1:100	eBioscience
Hamster anti-mouse CD11c - PE	1:100	BD Pharmingen
Rat anti-mouse IFN - PE	1:150	BD Pharmingen
Hamster anti-mouse CD3 - FITC 	1:100	eBioscience
		
Rat IgG1 - PE	1:100	BD Pharmingen
Rat IgG2a - FITC	1:100	eBioscience
Rat IgG2b - FITC	1:100	eBioscience
Rat-IgG2a - PE	1:100	eBioscience
Rat IgG2b - PE	1:100	eBioscience
Rat IgG2a - APC	1:100	eBioscience
Rat IgG2b - APC	1:100	eBioscience
Hamster IgG - FITC	1:100	eBioscience
Hamster IgG - PE	1:100	eBioscience
2.11 Statistical analysis 
Standard error mean (SEM), student’s T test, one way ANOVA, two way ANOVA and post-hoc Bonferroni tests, Log-rank test were calculated using GraphPad Prism version 4 (GraphPad Software. Inc)







































2.12 Full company name and location
Company name	Location
Abcam	Cambridge, UK
Amersham International plc.	Buckinghamshire, UK
Applied Biosystems	Cheshire, UK
BD Pharmingen	Oxford, UK
Beckman Coulter	High Wycombe, UK
BioRad Laboratories Ltd	Hertfordshire, UK
Cell Signalling Technology	Hertfordshire, UK
Fisher Scientific	Leicestershire, UK
Fujifilm	Bedfordshire, UK
Invitrogen	Paisley, UK
KPL Inc.	Maryland, USA
Merck/BDH	West Sussex, UK
Millipore	Watford, UK
Miltenyl Biotec	Bergisch Gladbach, Germany
PeproTech Inc.	Rocky Hill, UK
PerkinElmer	Beaconsfield, UK
Promega	Hampshire, UK
Qiagen	West Sussex, UK
Roche	Hertfordshire, UK
Santa Cruz Biotechnology	Heidelberg, Germany
Sigma-Aldrich	Dorset, UK
Thermo Scientific	Wilmington, USA
Tomy Tech	California, USA
VWR International	West Sussex, UK
	
	
	
	


3. Results
3.1 Negative regulatory role of IKK in macrophage activation
It has long been known that NF-B transcription factors are important in the onset of inflammation. However, recent research also suggests a role for NF-B in the resolution of inflammation. Earlier studies by our group have revealed a tissue specific role for IKK in inflammation in vivo (Fong, Bebien et al. 2008).  Deletion of IKK in airway epithelial cells reduce neutrophil recruitment during lung infection, however, inflammation was increased when IKKβ was deleted in myeloid cells. These data illustrate a tissue specific role for IKK in inflammation and suggest IKKβ activity in macrophages inhibits the inflammatory response during infection.  In this chapter, I extended these studies and investigated the possible mechanisms of the inhibitory effect of IKKβ in macrophage activation.











3.1.1 Genotyping of IKKF/F and IKKMye mice
IKK knock out (Ikbkb-/-) mice die in utero due to TNF induced apoptosis of liver progenitors  ADDIN EN.CITE (Li, Antwerp et al. 1999; Tanaka, Fuentes et al. 1999).  To characterise the possible roles of IKKβ in inflammatory resolution, a Cre-lox recombinase system (Sauer 1998; Clausen, Burkhardt et al. 1999) was used to generate tissue specific IKK knockout mice.  To specifically knock out IKK in macrophages, mice expressing a floxed Ikbkb allele (IkkF/F) were generated and bred with LysMCre mice that utilise the lysozome M promoter to express Cre recombinase in myeloid cells (Figure 3.1.1.1). Tissue specific targeting of IKKβ in these mice has been previously established  ADDIN EN.CITE (Greten, Eckmann et al. 2004; Broide, Lawrence et al. 2005; Greten, Arkan et al. 2007). Ear biopsies were collected from mice and genomic DNA was prepared and analysed for the IkkF/F allele and Cre transgene expression by PCR (Figure 3.1.1.2). 



























Figure 3.1.1 1 Selective deletion of IKK in macrophages using Cre-lox recombinase
(1-3) A targeting vector with three loxP sites and a positive selective marker, neomycin (neo) was used to insert loxP sites into the flanking region of exon 3 (IKK) through homologous recombination.  (4) Cre recombinase was transiently expressed in embryonic stem (ES) cells resulting in the combination of loxP sites, two loxP sites remain flanking exon 3 in the target gene (IKKloxP). (5) IKKloxP mice were bred with mice expressing Cre recombinase in the lysosome M promoter to generate myeloid cell specific IKK knockout mice.
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Figure 3.1.1 2 PCR analysis of Ikbkb and Cre transgenic mice
Genomic DNA was prepared from ear biopsies and analysed for the floxed Ikk allele and Cre transgene expression by PCR.  (A) The 310bp band represents the Ikk allele with the presence of the loxP sites.  The 220bp band represents the Ikk allele without the loxP sites.  (B) The 700bp band represents the presence of Cre transgenic gene.


The level of IKK deletion in the IKKF/F and IKK∆Mye macrophages was determined by western blot.  An example of the IKKβ level in IKKβF/F and IKKβ∆Mye thioglycolate elicited peritoneal macrophages is shown in Figure 3.1.1.3.










Figure 3.1.1 3 Level of IKK expression in IKKβF/F and IKKβ∆Mye peritoneal macrophages
1.5ml of 3% tg was injected into peritoneum of two IKKβF/F and IKKβ∆Mye mice labelled as 1 and 2.  Thioglycolate elicited peritoneal macrophages were harvested 3 days after injection.  Whole cell lysates were prepared and IKK expression was analysed by western blot. Alpha actin was used as a loading control.
3.1.2 IKK inhibits STAT1 activation

Previous studies from our group have shown that knocking out IKKβ in macrophages increased resistance to Group B Streptococcus (GBS) infection and this was associated with increased iNOS expression in alveolar macrophages (Fong, Bebien et al. 2008). STAT1 activation is important for innate immunity and anti-microbial activity of macrophages, which are severely impaired in STAT1 knockout mice (Matsukawa 2007).  Multiple transcription factor binding sites including; GAS, ISRE and B were identified in the promoter of iNOS  ADDIN EN.CITE (Gao, Morrison et al. 1997).  STAT1 is the transcription factor that binds GAS and increases iNOS gene expression  ADDIN EN.CITE (Gao, Filla et al. 1998; Ganster, Taylor et al. 2001), I first investigated the inhibitory roles of IKKβ on STAT1 signalling.  IKKβF/F and IKKβΔMye thioglycolate elicited peritoneal macrophages were stimulated with LPS, the cell wall component of gram-negative bacteria, that activates NF-B signalling via TLR4  ADDIN EN.CITE (Takeda and Akira 2004), or in combination of recombinant IFN in vitro, STAT1 phosphorylation was analysed by immunoblotting.  As shown in Figure 3.1.2.1A, the expression of total STAT1 and STAT1 phosphorylation were increased in IKKβΔMye macrophages when compared to IKKβF/F macrophages.  STAT1 phosphorylation was induced after 8 hours of LPS stimulation in IKKβF/F macrophages.  In contrast, the basal level of STAT1 phosphorylation was high even in unstimulated IKKβΔMye macrophages and phosphorylation was increased further after 2 h of LPS treatment. iNOS expression was markedly increased in LPS stimulated IKKβΔMye macrophages at 8 h.  In response to the combination of LPS and IFN treatment, STAT1 phosphorylation was detected at 30 min and remained present at 2 h in IKKβF/F macrophages (Figure 3.1.2.1B).   In comparison, higher levels of STAT1 phosphorylation were detected from IKKβΔMye macrophages at both 30 min and 2 h. Furthermore, iNOS expression was detected only after 8 h of LPS/IFN stimulation in IKKβF/F macrophages but iNOS expression was detected at 4 h and further increased at 8 h in IKKβΔMye macrophages. These data suggest negative cross talk between IKK and STAT1 signalling pathways.



























Figure 3.1.2 1 IKK inhibits STAT1 activation and iNOS expression
3x106 tg elicited macrophages/well were cultured in 6 well plates and stimulated with (A) 100ng/ml LPS or (B) in combination with 100U/ml IFN in vitro. Whole cell lysates were collected at the indicated time points and the expression of total STAT1, pSTAT1 and iNOS were analysed by immunoblotting.  Alpha-actin was used as a loading control.  Experiments were repeated at least 3 times and representative data are shown.







3.1.3 IKKβ suppresses expression of iNOS and IRF1 mRNA 
Total RNA from LPS stimulated tg elicited peritoneal macrophages was isolated at indicated timepoints and analysed by qRT-PCR. TNF is a typical NF-κB dependent gene that does not contain STAT1 binding sites, I first tested if knocking out IKK decreased the mRNA levels of TNF.  After 4 h of LPS stimulation, the mRNA level of TNF was 40% lower in IKKβΔMye macrophages as compared to IKKF/F macrophages (Figure 3.1.3.1A). IFN, another NF-κB regulated gene (Honda, Yanai et al. 2005) was also analysed.   IFN mRNA level was reduced by 50% from IKKΔMye macrophages after 4 h of LPS stimulation (Figure 3.1.3.1B).  However, the mRNA level of iNOS was 2 fold higher in IKKβΔMye macrophages when compared to IKKF/F macrophages after 8 h of LPS stimulation (Figure 3.1.3.1C) in keeping with iNOS protein expression (Figure 3.1.2.1). Another STAT1 dependent gene, IRF1 (Durbin, Hackenmiller et al. 1996; Meraz MA 1996) was increased by 3 fold at 8 h in LPS stimulated IKKβΔMye macrophages (Figure 3.1.3.1D).























	










Figure 3.1.3 1 IKK inhibits STAT-dependent gene expression
3x106 tg elicited macrophages/well were plated in 6 well plates and stimulated with 100ng/ml LPS in vitro. Total RNA was isolated at the indicated time points for qRT-PCR analysis of TNF, IFN, iNOS and IRF1 mRNA. Experiments were repeated 3 times and representative data are shown.  


















Increased iNOS expression is characteristic of M1 macrophage activation, MHC II is also a marker of M1 macrophage (Gordon and Taylor 2005). IFN mediated JAK/STAT signalling has been shown to regulate MHC II expression CIITA (Chang CH 1994; Steimle, Siegrist et al. 1994).  To test if deleting IKK had a negative influence on MHC II expression, tg elicited macrophages from IKKF/F and IKKβΔMye mice were stimulated with IFNγ in vitro for 24 h and the expression levels of MHC II were measured by FACS.  Figure 3.1.3.2 shows that IKKβΔMye macrophages have 2.5 fold higher MHC II expression (mean fluorescence intensity (MFI); IKKβΔMye 1829 vs IKKF/F 720) when compared to IKKβF/F macrophages upon IFNγ stimulation.








Figure 3.1.3 2 IKKβ inhibits MHC II expression
3x106 tg elicited macrophages/well were plated in a 6 well plate and stimulated with 100U/ml IFN for 24 h. MHC II level was measured by FACS and the expression of MHC II was gated on CD11b positive cells. Black – isotype control. Red - IKKF/F. Blue -IKKMye Experiment was repeated at least 3 times and representative data are shown.  








3.1.4 IKK inhibits IL-12 production
IL-12 is a typical proinflammatory cytokine produced by M1 macrophages and its expression is regulated by IFN/STAT1 signalling  ADDIN EN.CITE (Scharton-Kersten, Wynn et al. 1996; Gautier, Humbert et al. 2005), I therefore tested if the inhibitory effect of IKK also applied to IL-12 production. After 8 h of LPS and IFN stimulation, IL-12p40 production was 2 fold higher from IKKMye macrophages (Figure 3.1.4.1A). IL-12p70, the active form of IL-12 (Watford, Moriguchi et al. 2003) was also measured. Consisting to IL-12p40, 7.5 fold increase in IL-12p70 levels detected in macrophages isolated from IKKMye macrophages when compared to IKKF/F macrophages after 8 h of LPS and IFN stimulation (Figure 3.1.4.1B). 







Figure 3.1.4 1 IKK inhibits IL-12 production
0.5x106 tg elicited macrophages/well were plated in a 24 well plate and stimulated with 100ng/ml LPS and 100U/ml IFN.  Culture supernatant was collected at indicated timepoints and cytokine production was analysed by ELISA. Data represents mean+sem of triplicates. Two way ANOVA and post-hoc Bonferroni tests were used for statistical analysis; *** P<0.001
3.1.5 TNFα inhibits STAT1 activation in macrophages in vivo

It is known that IKKβ is required for TNFα expression (Figure 3.1.3.1A) and TNFα signalling  ADDIN EN.CITE (Collart, Baeuerle et al. 1990; Beg, Finco et al. 1993; Caamano and Hunter 2002), I therefore explored the hypothesis that TNFα modulates cross talk with IFN signalling through IKKβ activation.  To test the role of TNFα in vivo, anti-TNFα neutralising antibody or rabbit IgG was injected together with Tg into C57BL/6 mice. Anti-TNFα treatment resulted in increased total STAT1, pSTAT1 and iNOS expression upon stimulation of tg elicited macrophages with LPS in vitro (Figure 3.1.5.1).  STAT1 phosphorylation was induced from 2 h and increased further at 8 h in macrophages of IgG treated mice.  As observed in tg elicited macrophages of IKKMye mice, the basal level of pSTAT was higher in peritoneal macrophages from anti-TNFα treated mice and the level of pSTAT was further increased upon LPS stimulation.  Similar to data from IKKMye macrophages, the level of iNOS expression was detected from 4 h and further increased at 8 h in macrophages from mice treated with anti-TNF neutralizing antibody while iNOS expression was only detected at 8 h from macrophages of control mice.











Figure 3.1.5 1 Blocking TNF in vivo increased STAT1 phosphorylation and iNOS expression
1.5ml of 3% tg was injected i.p with 750g of neutralizing anti-TNF antibody or rabbit IgG into C57BL/6 mice and peritoneal macrophages were harvested after 3 day. 3x106 Tg elicited macrophages/well were plated in 6 well plates and stimulated with 100ng/ml LPS. At indicated time points, protein lysates were prepared and total STAT1, pSTAT1 and iNOS expression were analysed by immunoblotting. Alpha-actin was used as loading control. 
























I next tested if the inhibitory effect of TNF also applied to IL-12 production. After 8 h of LPS stimulation, IL-12p40 production was 2.5 fold higher from macrophages of anti-TNFα treated C57BL/6 mice (Figure 3.1.5.2A). Correlating to IL-12p40, IL-12p70, the active form of IL-12 (Watford, Moriguchi et al. 2003) was 3 fold higher after 8 h LPS stimulation from macrophages isolated from anti-TNFα treated C57BL/6 mice (Figure 3.1.5.2B). To test if the inhibitory effect of TNFα was selective to IL-12, I measured IL-6, a proinflammatory cytokine that is regulated independently of STAT1 but induced by TNF  ADDIN EN.CITE (Kishimoto, Akira et al. 1995; Vanden Berghe W 2000; Yu, Kennedy et al. 2003). Figure 3.1.5.2C shows a more than 80% reduction in the levels of IL-6 from the macrophages of anti-TNFα treated mice compared to non-treated macrophages.  This data shows the inhibitory effect of TNFα is selective to IL-12.

















 





Figure 3.1.5 2 TNF selectively inhibits IL-12 production
C57BL/6 mice were injected with 1.5ml 3% tg i.p with 750g of neutralizing anti-TNF antibodies or rabbit IgG. Peritoneal macrophages were harvested after 3 days.  0.5x106 tg elicited macrophages/well were plated in a 24 well plate and stimulated with 100ng/ml LPS.  Culture supernatant was collected at indicated timepoints and cytokine production was analysed by ELISA. Data represents mean+sem of triplicates. Two way ANOVA and post-hoc Bonferroni tests were used for statistical analysis; ** P<0.01, *** P<0.001






3.1.6 TNF inhibits STAT1 activation in macrophages in vitro

The experiments described in sections 3.1.5.1 and 3.1.5.2 showed that neutralizing TNF in vivo increased STAT1 activation, iNOS and IL-12 production in LPS stimulated macrophages.  To further confirm the inhibitory effect of TNFα, I pre-treated BMDM with recombinant TNFα prior to stimulation with LPS alone or in combination with IFNγ.  Upon LPS stimulation, STAT1 phosphorylation was detected at 4-8 h from both BMDM with and without TNF treatment, but the level of pSTAT1 was reduced in TNF pre-treated BMDM (Figure 3.1.6.1A).    For BMDM stimulated with LPS and IFN, pSTAT1 expression was detected from 30 min and the expression level was reduced at 4 h in TNF pre-treated BMDM.  However, the reduction was modest at 30 min and 8 h when compared to untreated BMDM (Figure 3.1.6.1B). To determine if these inhibitory effects were selective to TNF, BMDM were pre-treated with IL-1β, a cytokine that can also activate the IKKβ dependent canonical NF-κB pathway.  Figures 3.1.6.1A & B shows that pre-treatment of BMDM with IL-1β has no inhibitory effect on pSTAT1 upon LPS or LPS/IFN stimulation in fact IL-1β treatment increased pSTAT1 activation.  Taken together, these results illustrate that TNFα specifically inhibits STAT1 activation in macrophages.















Figure 3.1.6 1 Inhibition of STAT1 phosphorylation in BMDM pre-treated with TNF 
Bone marrow cells were cultured with 10ng/ml MCSF, on day 4, 20ng/ml TNF or 10ng/ml IL-1 was added to the culture as indicated.  On day 7, 3x106 BMDM/well were plated in 6 well plates and stimulated with 100ng/ml LPS alone or in combination with 100U/ml IFN.  Protein lysates were collected at indicated time points and the expression of pSTAT1 was analysed by immunoblotting. Alpha-actin was used as loading control. Experiments were repeated 3 times and representative data are shown.






In parallel, tissue culture supernatant was collected for cytokine analysis.  Figure 3.1.6.2A shows TNF pre-treated BMDM produced 73% less IL-12p40 after 4 h LPS/IFN stimulation while 29% reduction was obtained at 8 h compared to the untreated group.  Consistent with the IL-12p40 production, pre-treatment of BMDM with TNFα dramatically reduced IL-12p70 production by more than 90% (Figure 3.1.6.2B) at 8 h.  The inhibitory effect was not seen with IL-1β treatment. 







Figure 3.1.6 2 Reduction of IL-12 production by TNF pre-treated MCSF-BMDM 
Bone marrow cells were cultured with 10ng/ml MCSF, with or without TNF or IL-1 as described.  On day 7, 0.5x106 BMDM/well were plated in 24 well plates and stimulated with 100ng/ml LPS and 100U/ml IFN.  Tissue culture supernatant was collected at 4 and 8 h. The levels of IL-12p40 and IL-12p70 were measured by ELISA. Data represents mean+sem of triplicates. Experiments were repeated 3 times and representative data are shown.  Two way ANOVA and post-hoc Bonferroni tests were used for statistic analysis; *P<0.05, ** P<0.01, *** P<0.001





To test if pre-treatment of TNF has an inhibitory effect at the transcriptional level of IL-12, ribonuclease protection assay (RPA) was performed to measure mRNA levels.  In BMDM stimulated with LPS/IFN, IL-12p40 mRNA expression was detected from 4 h and increased further at 8 h, comparable levels of IL-12p40 were obtained from BMDM pre-treated with IL-1 (Figure 3.1.6.3A & B). In response to TNF pre-treatment, there was an 85% reduction of IL-12p40 mRNA expression after 4 h of LPS/IFN stimulation. IP10 (CXCL10), another IFNγ regulated gene, was reduced by 80% in BMDM pre-treated with TNF (Fig 3.1.6.3A & C).   Again, the inhibitory effect was not seen with BMDM pre-treated with IL-1.































Figure 3.1.6 3 Reduced mRNA level of IL-12p40 and IP10 by TNF pre-treated MCSF-BMDM
Bone marrow cells were cultured with 10ng/ml MCSF, with or without TNF or IL-1 as described.  On day 7, 3x106 BMDM/well were plated in a 6 well plate and stimulated with 100ng/ml LPS and 100U/ml IFN. Total RNA was isolated at the time points indicated and analysed by ribonuclease protection assay using Pharmingen’s multiprobe template.  Protected RNA fragments were resolved on a 6% polyacrylamide gel (A).  The gel was dried and exposed to a PhosphoImager screen for quantification indicated as specific activity (B & C). 


3.1.7 TNF inhibits STAT1 through p55

To study which TNF receptor was responsible for the inhibitory effect of TNF in macrophages, TNF receptor 1 (TNFR1; p55) and TNF receptor 2 (TNFR2; p75) deficient mice were injected with 1.5ml of 3% tg as described and peritoneal macrophages were stimulated with LPS and IFNγ in vitro.  In control mice, STAT1 phosphorylation was detected at 30 min and was almost undetectable from 4-8 h (Figure 3.1.7.1).  In comparison, pSTAT1 expression in p55-/- macrophages was greatly increased at all time points tested, although the basal level of pSTAT1 was also increased in p55-/- macrophages.  In p75-/- macrophages, pSTAT1 levels were not increased compared to WT BMDM. Immunoblotting also showed iNOS expression was significantly higher in p55-/- macrophages at 4 h compared to both WT and p75-/- macrophages.
























Figure 3.1.7 1 The inhibitory effect of TNF on STAT1 was mediated by p55
WT, p55-/- and p75-/- mice were injected with 1.5ml 3% tg i.p and peritoneal macrophages were harvested after 3 days.  3x106 tg elicited macrophages/well were plated in 6 well plates.  Macrophages were stimulated with 100ng/ml LPS and 100U/ml IFN.  At indicated time points, protein lysates were prepared and the level of pSTAT1 and the iNOS expression were analysed by immunoblotting.  Alpha-actin was used as loading control. Experiments were repeated 3 times and representative data are shown.
























To test if the inhibitory effect of TNF on IL-12 production is also mediated by p55, tissue culture supernatant was collected and the levels of IL-12 were measured by ELISA. As shown in Figures 3.1.7.2A and B, p55-/- macrophages showed 50% increase in IL-12p40 and 40% increase in IL-12p70 production after 24 h of LPS/IFN stimulation when compared to WT macrophages. To test if the inhibitory effect was specific for IL-12, IL-6 was measured in parallel, and no significant difference was detected between WT and p55-/- macrophages (Figure 3.1.7.2C).































Figure 3.1.7 2 Increased IL-12 production from p55-/- peritoneal macrophages
0.5x106 tg elicited macrophages/well were plated in 24 well plates and stimulated with 100ng/ml LPS and 100U/ml IFN.  At indicated time points, culture supernatant was collected and analysed for IL-12p70, IL-12p40 and IL-6 production by ELISA. Data represents mean+sem of triplicates. Experiments were repeated 3 times and representative data are shown.  Two way ANOVA and post-hoc Bonferroni tests were used for statistical analysis; *P<0.05, ** P<0.01







3.1.8 Inhibition of IKK activity in vitro with adenovirus expressing IKK dominant negative inhibitor

To confirm the inhibitory role of IKK in IFN signalling seen in IKKMye macrophages, BMDM were infected with recombinant adenovirus expressing IKKβ dominant negative inhibitor (Ad-IKKβdn) or control adenovirus expressing green fluorescent protein (Ad-GFP).  Infection efficiency was determined by the percentage of the cells with GFP expression. An example of BMDM infected with Ad-GFP is shown in Figure 3.1.8.1A & B, the efficiency of virus infection was approximately 60%.







Figure 3.1.8 1 Efficiency of adenovirus infection
Bone marrow cells were cultured with 10ng/ml MCSF and infected with Ad-GFP with M.O.I of 200:1 on day 3. Virus was removed after 24 h and fresh complete DMEM+MCSF was replaced. Infection efficiency was determined on day 7 by the percentages of GFP positive cells.  A) Phase contrast image B) GFP fluorescence image.





3.1.9 Ad-IKKdn infected BMDM increased STAT1 phosphorylation and iNOS expression
To test if BMDM infected with Ad-IKKβdn also increase STAT1 activation as IKKMye macrophages, BMDM infected with Ad-GFP or Ad-IKKβdn were stimulated with LPS and STAT1 phosphorylation was measured by immunoblotting.  Consistent to the results from IKKMye macrophages, STAT1 phosphorylation and iNOS expression were both increased from BMDM infected with Ad-IKKβdn (Figure 3.1.9.1).  Upon LPS stimulation, pSTAT1 was detected from 8 h in Ad-GFP infected BMDM while it was detected at 4 h from Ad-IKKβdn infected BMDM and the expression level remained high up to 24 h compared to Ad-GFP infected cells.  Increased STAT1 activation correlated with elevated expression of iNOS from 4 to 24 h.


















Figure 3.1.9 1 Ad-IKKdn infected BMDM increased STAT1 phosphorylation
Bone marrow cells were cultured with 10ng/ml MCSF and infected as described in Figure 3.1.8.1.  On Day 7, 3x106 BMDM/well were plated in 6 well plates and stimulated with 100ng/ml LPS.  Whole cell lysates were collected at indicate time points.  Expression of iNOS and STAT1 phosphorylation were analysed by immunoblot.  Alpha-actin was used as loading control.  Experiments were repeated at least 3 times and representative data are shown.















I next measured IL-12p40 production from BMDM infected with Ad-GFP or Ad-IKKβdn after stimulation with LPS and IFN by ELISA.  As shown in Figure 3.1.9.2, IL-12p40 production was 7.5 fold higher from macrophages infected with Ad-IKKβdn compared to macrophages infected with control virus.













Figure 3.1.9 2 IKKdn infected BMDM increased IL-12p40 production 
Bone marrow cells were cultured with 10ng/ml MCSF and infected as described. On Day 7, 0.5x106 BMDM/well were plated in 24 well plates and stimulated with 100ng/ml LPS and 100U/ml IFN.  Culture supernatant was collected at indicated time points and IL-12p40 production was analysed by ELISA. Data represents mean+sem of triplicates. Experiments were repeated 3 times and representative data are shown.  Two way ANOVA and post-hoc Bonferroni tests were used for statistical analysis; *** P<0.001







3.1.10 TNFα inhibits IL-12p40 production through activation of IKKβ 
To investigate if the inhibitory effect of TNFα on IL-12 production is mediated by IKKβ, BMDM were infected with Ad-IKKβGFP or Ad-IKKβdn before treating cells with TNFα.  Tissue culture supernatant was collected and IL-12p40 was measured by ELISA (Figure 3.1.10.1). Compared to the untreated group, TNFα-treated BMDM produced 30% less IL-12p40 at 8 h. On the other hand, infection of TNFα treated-BMDM with Ad-IKKβdn prevented the inhibition of IL-12 production and in fact further increased IL-12p40 level by 2.5 fold. 












Figure 3.1.10 1 IKKβ inhibition rescued TNFα mediated suppression of IL-12p40 production
Bone marrow cells were cultured with 10ng/ml MCSF and infected as described. Virus was removed after 24 h and fresh complete DMEM+MCSF with or without 20ng/ml TNFα was added.  On day 7, 0.5x106 BMDM/well were plated in 24 well plates and stimulated with 100ng/ml LPS and 100U/ml IFNγ.  Cell culture supernatant was collected at 4 and 8 h and IL-12p40 was measured by ELISA. Data represents mean+sem of triplicates. Experiments were repeated 3 times and representative data are shown.  Two way ANOVA and post-hoc Bonferroni tests were used for statistical analysis; ** P<0.01, *** P<0.001

IL-10 is a well known inhibitor of IL-12 production (Aste-Amezaga, Ma et al. 1998).  I tested whether TNFα mediated inhibition of IL-12 production was due to increased IL-10 expression.  Figure 3.1.10.2 shows TNFα pre-treatment inhibited IL-10 production by 50% and the inhibition was blocked by adenovirus expressing IKKβ dominant negative inhibitor.












Figure 3.1.10 2 TNF and IKK inhibits IL-10 production
Bone marrow cells were cultured with 10ng/ml MCSF and infected as described.  On day 7, 0.5x106 BMDM/well were plated in 24 well plates and stimulated with 100ng/ml LPS and 100U/ml IFNγ.  Cell culture supernatant was collected at 4 and 8 h and IL-10 was measured by ELISA. Data represents mean+sem of triplicates. Experiments were repeated 3 times and representative data are shown.  Two way ANOVA and post-hoc Bonferroni tests were used for statistical analysis; *P<0.05, ** P<0.01, *** P<0.001






3.1.11 Summary 
Earlier studies from our group have shown that knocking out IKK in macrophages increased iNOS expression in alveolar macrophages, with increased bacterial clearance in a lung infection model (Fong, Bebien et al. 2008).  To further investigate the inhibitory role of IKK in macrophage activation, Cre-lox mediated gene targeting was used to specifically delete IKK expression in macrophages (IKKMye) and macrophage activation was investigated in vitro.  Upon LPS stimulation, IKKβ∆Mye macrophages show increased iNOS, IL-12 and MHC II expression.  Immunoblotting showed enhanced STAT1 phosphorylation in IKK knockout macrophages, further experiments with adenovirus expressing IKK dominant negative inhibitor also showed increased STAT1 phosphorylation, iNOS and IL-12 expression.  These data confirm the results obtained from IKKβ∆Mye macrophages and suggest that negative cross talk between IKK and STAT1 signalling might be a mechanism for inhibition of ‘classical’ macrophage activation.  Because IKK is required for TNF gene expression and TNF signalling, I investigated the hypothesis that TNF inhibits ‘classical’ macrophage activation through activation of IKK.  I used macrophages from TNF receptor I knockout (p55-/-) mice and blocked TNF in vivo with neutralising antibody. p55-/- macrophages and macrophages from mice treated with anti-TNF antibody show increased STAT1 activation and IL-12 expression when stimulated in vitro with LPS and IFN.  In addition, pre-treatment of macrophages with recombinant TNF prior to LPS and IFN stimulation inhibited both STAT1 activation and IL-12 expression.  Furthermore, bone marrow derived macrophages infected with recombinant adenovirus expressing IKKβ dominant negative inhibitor blocked the inhibitory effect of TNFα on IL-12 production, suggesting TNF mediated IKKβ activation is required for inhibition of IL-12.

3.1.12 Discussion
3.1.12.1 Mechanisms of IKK inhibition of classical macrophage activation
My studies show increased expression of MHC II, IL-12, iNOS and IRF1 when IKK is deleted in macrophages.  This was also associated with increased activation of STAT1. IFN is a NF-B regulated gene in response to LPS stimulation (Honda, Yanai et al. 2005).  It has been shown that autocrine/paracrine IFN production is required for LPS mediated iNOS expression through activation of STAT1 (Gao, Filla et al. 1998),  neutralising IFN with anti-IFN antibody abolished STAT1 phosphorylation and the subsequent iNOS expression (Gao, Filla et al. 1998). My studies show a reduction of IFN mRNA expression from LPS stimulated IKKMye macrophages (Figure 3.1.3.1B), suggesting the elevated iNOS expression was not related to the increased IFN production and suggests IKK inhibits STAT1 signalling. Earlier studies from our group used luciferase reporter assays to confirm the role of IKK in the suppression of STAT1 transcription activity (Fong, Bebien et al. 2008); transient over-expression of IKK in RAW 264.7 macrophages suppressed GAS reporter activity, whereas transfection of endogenous NF-B inhibitor IB increased GAS reporter activation (Fong, Bebien et al. 2008), these studies illustrate an inhibitory role of IKK in STAT1 transcription activity and suggest increased expression of M1-associated genes in IKKMye macrophages is, at least in part, associated with the elevated GAS activity. 
3.1.12.2 TNF and inhibition of classical macrophage activation 
TNF is a proto-typical proinflammatory cytokine thought to be a key mediator of chronic inflammation.  Because IKK is required for TNF gene expression and TNF signalling  ADDIN EN.CITE (Collart, Baeuerle et al. 1990; Beg, Finco et al. 1993; Caamano and Hunter 2002), I tested the hypothesis TNF inhibits ‘classical’ macrophage activation through IKK. First, I tested if TNF can suppress STAT1 signalling in macrophages. Macrophages from mice administered with anti-TNF neutralising antibody show increased STAT1 activation when stimulated in vitro (Figure 3.1.5.1).  Furthermore, IL-12 production was also increased from these macrophages (Figure 3.1.5.2).   These data illustrate the inhibitory effect of endogenous TNF in STAT1 activation. The effect of TNFα can be mediated via two receptors; TNF receptors p55 and p75 (Vandenabeele, Declercq et al. 1995). In order to determine which receptor was involved, macrophages were isolated from p55 and p75 knockout mice and stimulated with LPS and IFN in vitro.   These experiments showed the inhibitory effect of TNFα was mediated by p55 and not p75 (Figures 3.1.7.1 & 3.1.7.2).  Moreover, the inhibitory effect of TNF on STAT1 signalling was further tested with exogenous TNF treatment. Pre-treatment of macrophages with recombinant TNF prior to LPS and IFN stimulation inhibits both STAT1 activation and IL-12 expression while suppression was not seen with IL-1 pre-treatment. Since IKK can be activated by both TNF and IL-1, these data indicate the effect of IKK on STAT1 is dependent on other elements that are not involved in IL-1 signalling. TNF is a well known inducer of cell apoptosis, so it is possible that reduced IL-12 production was associated with reduced cell viability.  However, no changes in cell viability were observed microscopically in the experiments performed, hence cell death is unlikely the explanation for the reduced IL-12.  Consistent with current study, the negative regulatory effect of TNF on IL-12 has been reported elsewhere (Marino, Dunn et al. 1997)  ADDIN EN.CITE (Hodge-Dufour, Marino et al. 1998; Zakharova and Ziegler 2005). Marino et al. 1997 suggested a role for TNF in limiting the inflammatory response to heat killed C.parvum in mice.  From their studies, WT mice developed prompt granulomatous response followed by resolution of the granuloma whereas TNF-/- mice showed little or no initial response, but later developed a vigorous inflammatory responses leading to death (Marino, Dunn et al. 1997). Later, Hodge-Dufour et al. showed increased serum levels of IL-12 in TNF-/- mice (Hodge-Dufour, Marino et al. 1998). Furthermore, administration of anti-IL-12 neutralising antibody led to the resolution of granulomatous responses to C.parvum in the livers and spleens of TNF-/- mice (Hodge-Dufour, Marino et al. 1998). These studies together with the current study clearly demonstrate the inhibitory effect of TNF on IL-12 production and a role in resolving inflammation. IFN/STAT1 signalling is a key pathway involved in IL-12 production.  Similar to the current study, an inhibitory effect of TNF on IFN/STAT1 signalling has been reported by other studies (Wang, Contursi et al. 2000).  Elevated TNF is found in viral hepatitis patients and was suggested to be associated with resistance to IFN therapy (Larrea, Garcia et al. 1996; Hong, Nguyen et al. 2001). In 2001, Hong et al. have shown TNF inhibits STAT1 Tyr 701 phosphorylation in the liver and further analysis indicated the inhibitory effect was associated with SOCS3 and SHP2 induction (Hong, Nguyen et al. 2001).   Taken together, the inhibitory effect of TNF on IL-12 expression could be mediated by direct STAT1 inhibition, or alternatively through the production of suppressing proteins such as SOCS3 and SHP2.  From the later section of this chapter, BMDM infected with recombinant adenovirus expressing IKKβ dominant negative inhibitor blocked the inhibitory effect of TNFα on IL-12 production (Figure 3.1.10.1), demonstrating TNF inhibits IL-12 production through IKK activation.  However, the increase in IL-12 p40 production by Ad-IKKdn infected BMDM was greater than the level of inhibition with TNF.  This suggests other mechanisms regulated by IKK/NF-B inhibits IL-12 expression in the context of viral infection. 

3.1.12.3 Experimental limitations
3.1.12.3.1 Targeting IKK in macrophages
Knockout of the Ikbkb gene is lethal, IKK-/- embryos die at E13 due to hepatocyte apoptosis  ADDIN EN.CITE (Li, Antwerp et al. 1999; Li, Chu et al. 1999; Tanaka, Fuentes et al. 1999), this phenotype is also seen in RelA-/- mice (Beg, Sha et al. 1995).  Cell death was attributed to TNF signalling as double knockout mice (RelA-/-TNFR1-/-, RelA-/-TNF-/-) were rescued from embryonic lethality  ADDIN EN.CITE (Doi, Marino et al. 1999; Alcamo, Mizgerd et al. 2001). The Cre-lox recombinase system was utilised to generate mice with tissue specific IKK deficiency.  LysMCre transgenic mice utilise the lysosyme M promoter to express Cre recombinase in myeloid cells, thus crossing LysMCre mice with IKK floxed (F/F) mice selectively targeted the IKK gene in the myeloid cell lineage. This method allows investigation of IKK function selectively in macrophages. Although the Cre-lox recombinase system is a powerful tool to create conditional knock out in specific tissues, there are several limitations of the LysMCre mouse to study gene function selectively in macrophages; the LysM-promoter drives Cre expression in both granulocytes and macrophages and higher deletion efficiency is obtained in the granulocyte lineage (Clausen, Burkhardt et al. 1999). In fact, due to the cell heterogeneity, there is still lack of specific gene markers for macrophages and M1/M2 sub-types and this is an area that needs focus for the field to move forward. Another potential limitation of the Cre-lox recombination system is the variation of deletion efficiency between mice.  This problem was overcome by increasing repetition of experiments.  Furthermore, deletion efficiency is not 100% using the Cre-lox system, typically between 80-95% deletion of IKKMye mice, however this may offer some advantages including less compensation through increased expression of other genes, and a more comparable effect expected with pharmacological targeting of IKK.

According to earlier studies from our group, tg elicited peritoneal macrophages exhibit the most efficient IKK deletion in IKKMye mice.  The peritoneal cavity provides an easily accessible site to harvest a large numbers of macrophages. Upon tg injection, tg elicited an inflammatory response, neutrophils are the predominant cell population recruited initially followed by monocytes that differentiate into macrophages. A disadvantage of this system is tg is an inflammatory irritant, so tg elicited macrophages are exposed to proinflammatory cytokines before harvesting.  As observed in IKKMye and p55-/- mice, a high basal level of STAT1 phosphorylation was detected suggesting macrophages were activated in vivo before harvesting (Figures 3.1.2.1 & 3.1.7.1).   To further confirm the data obtained from IKKMye tg elicited peritoneal macrophages, different experiment approach was used to block IKK activation, MCSF derived BMDM were infected with recombinant adenovirus expressing IKK dominant negative.  In the absent of IKK activity, similar results were obtained compared to experiments with IKKMye tg elicited macrophages, thus further confirm the inhibitory role of IKK on STAT1 signalling.  Despite the consistent data obtained from the current studies, other studies have reported opposing results using different approaches to target IKK.  Shultz et al. 2007 has shown that IKK is required for the activation of IFN regulated genes (Shultz, Fuller et al. 2007), knocking down IKK by recombinant retrovirus in mouse embryonic fibroblast (MEF) showed impairment of IP10 induction after IFN stimulation. Similar observations were obtained from siRNA mediated targeting of IKK in RAW 264.7 cells, a mouse macrophage cell line (Shultz, Fuller et al. 2007). Furthermore, STAT1 activation was not affected by IKK inhibition as illustrated by equivalent STAT1 tyrosine and serine phosphorylation between scrambled siRNA and siRNA targeting IKK in RAW 264.7 cells. Different approaches to target IKK might be responsible for the inconsistent data, siRNA is a common in vitro system to induce specific gene silencing, however there are limitations of this technique. Off-target effects are often an issue with siRNA technology and different mechanisms were reported.  For example, high concentration of siRNA has reported to induce global up/down regulation of genes (Persengiev SP 2004), partial sequence complementation could lead to unspecific mRNA degradation (Saxena S 2003). Furthermore, it has also been reported that transfection of siRNA results in IFN mediated activation of JAK/STAT pathway and global upregulation of IFN genes (Sledz, Holko et al. 2003), suggesting siRNA technology might not be the ideal method when studying JAK/STAT1 signalling. Lastly, the use of RAW 264.7 macrophage cell line may not reflected studies in primary cells due to changes in cell signalling pathways during transformation.




































3.2 Inhibitory roles of IKK in adaptive immunity
Classically activated, or M1 macrophages are important in T cell activation and the development of the adaptive immune responses (Gordon 2003).  From earlier data, I have shown an inhibitory effect of IKK on MHC II expression and IL-12 production by macrophages. MHC II is required for antigen presentation to CD4+ T cells while IL-12 is important in TH1 cell development.  Based on these results, it is plausible to suggest knocking out IKK in macrophages will increase T cell activation and subsequently promote TH1 responses. The aim of this section was to investigate the inhibitory roles of IKK in the adaptive immunity and T cell activation. 














3.2.1 IKKMye macrophages express higher levels of CD80, CD86, MHCII and low CD124/IL-4 receptor  

Knocking out IKKβ in macrophages enhanced MHC II expression upon IFNγ stimulation in vitro (Figure 3.1.3.2).  In addition to antigen presentation by MHC II, CD80 and CD86 are costimulatory molecules that are important for successful T cell activation, I thus measured CD80 and CD86 on tg elicited peritoneal macrophages from IKKF/F and IKKΔMye mice by FACS.  As shown in Figures 3.2.1.1A, unstimulated tg elicited peritoneal macrophages from IKKΔMye mice expressed higher basal level of CD80 when compared IKKF/F macrophages.  Upon LPS stimulation, approximately 1.5 fold increased of CD80 was detected on both IKKF/F and IKKΔMye macrophages.    Compare to CD80, the induction of CD86 expression was more profound on IKKΔMye macrophages after LPS stimulation (MFI; IKKF/F 343 vs IKKΔMye 734) (Figure 3.2.1.1B), there was approximately 4 fold increased in CD86 expression on IKKΔMye macrophages while there was only 2.5 fold induction on IKKF/F macrophages.  MHC II expression was also measured, and as expected MHC II levels were higher on IKKΔMye macrophages with or without LPS stimulation (Figure 3.2.1.1C). The basal level of MHC II of tg elicited macrophages from IKKΔMye mice was very high compared to IKKF/F macrophages (MFI; IKKF/F 742 vs IKKΔMye 2245) and because of the high basal, there was no significant increase in MHC II expression after LPS stimulation (MFI; IKKF/F 806 vs IKKΔMye 2325).

























Figure 3.2.1 1 IKKMye macrophages express higher level of CD80, CD86 and MHCII
3x106 tg elicited macrophages/well were plated in 6 well plates and stimulated with or without 100ng/ml LPS.  After 24 h, non-adherent cells were removed and only adherent cells were collected, the expression of CD80, CD86 and MHC II gated on CD11b+ cells were measured by FACS. Data are represented as histogram and MFI is indicated.  Black – isoptype control.  Red - IKKF/F macrophages.  Blue - IKKMye macrophages.  Experiments were repeated at least 3 times and representative data are shown.



According to the previous data, IKKMye macrophages have high MHC II expression and IL-12 production, which are markers of M1 macrophages.  IL-4 is important for M2 macrophages development (Gordon 2003; Herbert, Hˆlscher et al. 2004), so I sought to test for the presence of IL-4 receptor (IL-4R)  on IKKMye macrophages. Thioglycolate elicited macrophages were stimulated with LPS for 24 h and IL-4R was measured by FACS.  As shown in Figure 3.2.1.2A & B, there were 20% of IKKF/F macrophages expressed IL-4R, by comparison, only 2% of IKKMye macrophages were IL-4R positive.











Figure 3.2.1 2 Thioglycolate elicited peritoneal IKKMye macrophages express reduced IL-4R
3x106 tg elicited macrophages/well were plated in 6 well plates and stimulated with 100ng/ml LPS.  After 24 h, non-adherent cells were removed and only adherent cells were collected, the expression of CD11b and IL-4R by FACS. CD11b and IL-4R double positive cells are illustrated by (A) dot plot and (B) histogram.  Experiments were repeated at least 3 times and representative data are shown.

3.2.2 Bacteria elicited peritoneal macrophages from IKKMye mice express high levels of CD80, CD86, MHC II and low IL-4R

To confirm the previous data obtained from LPS stimulated tg elicited macrophages, IKKF/F and IKKΔMye mice were injected i.p with heat killed Group B Streptococcus (GBS - Gram positive bacteria), costimulatory molecules, MHC II and IL-4R expression levels were measured by FACS.  Consistent with Tg elicited IKKΔMye macrophages, GBS elicited macrophages from IKKΔMye mice expressed higher levels of CD80, CD86, MHC II and lower IL-4R.  Compared to IKKF/F macrophages, 3 fold of CD80 (MFI; IKKF/F 179 vs IKKΔMye 512) and 2 fold of CD86 (MFI; IKKF/F 140 vs IKKΔMye 277) were detected on IKKΔMye macrophages (Figures 3.2.2.1A & B). Both IKKF/F and IKKΔMye macrophages express high levels of MHC II, but 30% higher MHC II expression (MFI; IKKF/F 1046 vs IKKΔMye 1478) was detected on IKKΔMye macrophages (Figure 3.2.2.1C). IL-4R was present on GBS elicited IKKΔMye macrophages, however the expression level was 70% lower compared to the IKKF/F macrophages (MFI; IKKF/F 56.5 vs IKKΔMye 15.6) (Figure 3.2.2.1D).

























Figure 3.2.2 1 Bacteria elicited peritoneal macrophages from IKKMye mice express high costimulatory molecules, MHC II and low IL-4R
1x108 heat killed GBS were injected i.p into IKKF/F and IKKMye mice and peritoneal macrophages were harvested after 3 days.  3x106 peritoneal macrophages/well were plated with 6 well plates.  After 24 h, non-adherent cells were removed and IL-4R, CD80, CD86 and MHC II expression were measured on adherent cells by FACS.  The expression of IL-4R, CD80, CD86 and MHC II were gated on CD11b positive cells and the expression levels are indicated with the mean fluoresce intensity.  Black – isotype control. Red - IKKF/F macrophages.  Blue - IKKMye macrophages.  Experiments were repeated 3 times and representative data are shown.








3.2.3 Allogenic mix lymphocyte reaction
In an allogenic mix lymphocyte reaction (MLR), the proliferation of T cells is dependent on the recognition of mismatched human leukocyte antigen (HLA class II antigen). This assay is routinely used to measure the stimulatory activity of antigen presenting cells in T cell activation.  As shown in earlier data, MHC II and costimulatory molecules expression were increased in IKKΔMye macrophages, thus I hypothesised that IKKΔMye macrophages could enhance allogenic T cell proliferation.  

3.2.3.1 CD4+ T cell isolation
CD4+ T cells were collected from lymph nodes of Balb/c mice (H-2d haplotype) and cultured with allogenic macrophages of C57BL/6 mice (H-2b haplotype).  CD4+ T cells were purified by negative immunogenic cell separation using CD4+ T cell isolation kit.  To confirm the efficiency of the isolation, CD4, CD8, B220, CD11b and CD11c were stained on purified cells by FACS.  As shown from Figure 3.2.3.1.1, the purity of the isolated CD4+ T cell population was approximately 90%, and there were 8% of CD8+ T cells.  No contaminating antigen presenting cells were found as indicated by CD11b, CD11c, B220 negative staining.















Figure 3.2.3.1 1 Isolation of CD4+ T cells with magnetic bead separation
Inguinal, brachial, superficial cervical, and mesenteric lymph nodes were collected from Balb/c mice.  CD4+ T cells were isolated by negative selection with MACS separation kit (Miltenyi Biotec).  Selected cells were collected and stained with CD11b-PE, CD11c-PE, CD4-FITC, CD8-PE, B220-FITC and analysed by FACS.  Blue – isotype control.  Red – different surface markers as indicated.  Experiments were performed twice and representative data are shown.







3.2.3.2 Optimisation of allogenic MLR
To determine the optimal ratio of T cells: macrophages for allogenic MLR, a dose response assay with different numbers of macrophages was performed.  2x104, 4x104 and 6x104 tg elicited peritoneal macrophages were cultured with 3x105 CFSE labelled T cells.  T cell proliferation was measured with FACS by dilution of CFSE.  As shown in Figure 3.2.3.2.1, ratio of 1:5 and 1:7 provided the greatest percentage of T cell proliferation and the allogenic response was further increased with macrophages stimulated with LPS alone or in combination with IFN.



















Figure 3.2.3.2 1 Optimization of the ratio of T cells and macrophages in allogenic MLR
2x104, 4x104 and 6x104 tg elicited macrophages/well (C57BL/6) were plated in 96 well plates and stimulated 100ng/ml LPS or in combination with 100U/ml IFN.  After 24 h, 3x105 CFSE labelled CD4+ T cells purified from lymph nodes of Balb/c mice were added. Non-adherent T cells were collected after 4 days and T cell proliferation was measured by FACS. Only viable cells were gated and dead cells were excluded by staining with 7-Amino-actinomycin D.  Percentage of proliferating cells is indicated.  Experiments were performed twice and representative data are shown.

3.2.3.3 Capacity of different macrophages in promoting T cell proliferation 
Different sources of macrophages have different activation states and therefore may induce different levels of T cell activation. I tested three different types of macrophages; tg elicited, Biogel elicited peritoneal macrophages and BMDM. tg elicited peritoneal macrophages had the greatest capacity in the induction of T cell proliferation compared to Biogel elicited cells and BMDM (Figures 3.2.3.3.1A, B & C).  Between the 3 timepoints tested, highest allogenic T cell proliferation was detected on day 5 with 30% proliferation detected from T cells co-cultured with tg elicited macrophages stimulated with LPS and IFN (Figure 3.2.3.3.1C).  In comparison, 15% T cell proliferation was induced by BMDM and even less (5%) was detected from macrophages elicited by Biogel (Figure 3.2.3.3.1A & B).  Taken together, these experiments establish that ratio of 1:5 tg elicited macrophages: T cells was optimal for allogenic T cell proliferation.


























Figure 3.2.3.3 1 Activity of different macrophages in allogenic MLR 
1.5ml of 3% Biogel or tg was injected i.p to C57BL/6 mice, after 3 days, peritoneal macrophages were harvested.  6x104 macrophages/well were plated in 96 well plates and stimulated with 100ng/ml LPS or in combination with 100U/ml IFN.  BMDM were tested in parallel.  After 24 h of stimulation, 3x105 CFSE labelled CD4+ T cells purified from lymph nodes of Balb/c mice were added to the macrophages and T cell proliferation was measured at indicated timepoints by FACS. Only viable cells were gated and dead cells were excluded by staining with 7-Amino-actinomycin D.  Data represents mean+sem of triplicates. Experiments were performed twice and representative data are shown.


3.2.3.4 IKKMye macrophages increase allogenic T cell proliferation
I next investigated the ability of IKKF/F and IKKMye macrophages to induce allogenic T cell proliferation. As shown in Figure 3.2.3.4.1, allogenic T cell proliferation was more than 50% higher from T cells co-cultured with IKK∆Mye macrophages compared to IKKF/F macrophages.














Figure 3.2.3.4 1 IKKMye macrophages induced enhanced allogenic T cell proliferation
6x104 tg elicited macrophages/well were plated in a 96 well plate and stimulated with 100ng/ml LPS for 24 h.  3x105 CFSE labelled CD4+ T cells purified from lymph nodes of Balb/c mice were added and T cell proliferation was measured by FACS on day 4. Only viable cells were gated and dead cells were excluded by staining with 7-Amino-actinomycin D.  Data represents mean+sem of triplicates. Experiments were repeated 3 times and representative data are shown. Student’s T test was used to test statistical significance; *** P<0.001




3.2.4 Delayed type hypersensitivity 
Delayed type hypersensitivity (DTH) is an in vivo model to measure cell-mediated immune responses.  I used this model as an in vivo system to study the roles of IKK in T cell activation. In DTH, mice are immunised to a specific antigen and then subsequently challenged with the same antigen to measure antigen-specific T cell activation. This model tests the ability to ‘prime’ T cell responses and the activation of secondary responses by APCs.  By using this model, the capacity of IKKβ∆Mye macrophages to generate antigen specific T cells in vivo was tested.  

3.2.4.1 Immunisation
C57BL/6 mice were immunised with mBSA and complete Freund adjuvant (CFA).  On day 14, mice were boosted with mBSA and incomplete Freund adjuvant (IFA).  To determine the efficiency of immunisation, a recall assay was preformed.  Spleens were collected on day 21 from the mBSA immunised mice and splenocytes were stimulated with mBSA in vitro.  Tissue culture supernatant was collected on day 4, IFN and IL-10 were measured by ELISA. Both IFN and IL-10 production were dose dependently induced with mBSA up to 50g/ml (Figures 3.2.4.1.1A & B). A positive control was performed in parallel with an antigen independent T cell activator concanavalin A (ConA) and both IFN and IL-10 were induced upon stimulation (Figures 3.2.4.1.1C & D).










Figure 3.2.4.1 1 Splenocytes from mBSA immunised mice elicited antigen dependent cytokine production ex-vivo
C57BL/6 mice were immunised with mBSA and CFA.  After 21 days, spleens were collected and splenocytes were cultured with 0-100g/ml mBSA in vitro.  Supernatant was collected on day 4, IFN and IL-10 production was tested by ELISA. Data represents mean+sem of triplicates. Experiments were repeated 3 times and representative data are shown.









3.2.4.2 Dose response assay for mBSA induced T cell proliferation
To determine the optimal loading dose of mBSA for macrophages, a dose response assay was preformed. Macrophages pre-loaded with different doses of mBSA were cultured with CFSE labelled CD4+ T cells and T cell proliferation was measured by FACS. As shown in Figure 3.2.4.2.1, 30% of T cell proliferation was induced with 10μg/ml of mBSA and proliferation was further increased with increased antigen dose. 





Figure 3.2.4.2 1 Optimisation of the dose of mBSA for T cell proliferation assay
6x104 tg elicited macrophages/well were plated in 96 well plates and macrophages were loaded with different concentration of mBSA as indicated and stimulated with or without 100ng/ml LPS.  After 24 h, 3x105 CFSE labelled CD4+ T cells from mBSA immunised C57BL/6 mice were added and T cell proliferation was measured by FACS on day 4. Only viable cells were gated and dead cells were excluded by staining with 7-Amino-actinomycin D.  Data represents mean+sem of triplicates. Experiment was repeated 3 times and representative data are shown.




3.2.4.3 IKKβ∆Mye splenocytes increase mBSA specific IFNγ production ex-vivo
Earlier data showed increased IL-12 production in IKKΔMye macrophages, thus I predicted that knocking out IKK in macrophages could promote the development of TH1 responses. To study the development of mBSA specific T cell responses elicited by IKKβ∆Mye macrophages in vivo, splenocytes were prepared from IKKβF/F and IKKβ∆Mye mBSA immunised mice and re-stimulated with mBSA in vitro. In response to mBSA, IFNγ production was significantly increased from splenocytes of IKKβ∆Mye mice when compared to IKKβF/F splenocytes (Figure 3.2.4.3.1).













Figure 3.2.4.3 1 IKKβ∆Mye splenocytes increased mBSA specific IFNγ production ex-vivo
IKKβF/F and IKKβ∆Mye mice were immunised with mBSA and CFA.  After 21 days, spleens were collected and splenocytes were cultured in vitro with 0-100g/ml mBSA.  Supernatant was collected on day 4 and IFN was measured by ELISA. Data represents mean+sem of triplicates. Experiments were repeated 3 times and representative data are shown. Two way ANOVA and post-hoc Bonferroni tests were used for statistical analysis; *** P<0.001
IL-10 is a well known anti-inflammatory cytokine that can be produced by TH2 cells and antagonises TH1 responses (Abbas, Murphy et al. 1996).  I therefore measured IL-10 in parallel.  In contrast to IFN, IL-10 production was reduced from IKKβ∆Mye splenocytes in response to mBSA (Figure 3.2.4.3.2).  Taken together, these data indicate IKKβ∆Mye mice are more prone to develop TH1 responses.  













Figure 3.2.4.3 2 IKKβ∆Mye splenocytes decreased mBSA specific IL-10 production ex-vivo 
IKKβF/F and IKKβ∆Mye mice were immunised with mBSA and CFA.  After 21 days, spleens were collected and splenocytes were cultured with 0-100g/ml mBSA in vitro.  Supernatant was collected on day 4 and IL-10 was measured by ELISA. Data represents mean+sem of triplicates. Experiments were repeated 3 times and representative data are shown. Two way ANOVA and post-hoc Bonferroni tests were used for statistical analysis;  *P<0.05






3.2.4.4 Priming mBSA specific T cell responses in IKK∆Mye mice
B cells, DCs and macrophages are antigen-presenting cells in the immune system that can activate T cells and develop antigen specific T cell responses.   It is generally considered DCs are responsible for priming naïve T cells although macrophages have also been reported to have this ability (Moser.M 2001; T. Rothoeft 2003).  To study the ability of IKKMye macrophages to prime T cells and develop antigen specific responses in vivo, IKKF/F and IKKMye mice were immunised with mBSA in the combination with CFA and lymph nodes were collected on day 21.  CD4+ T cells were purified from lymph nodes by negative selection and cultured with mBSA loaded wild type BMDM.  Tissue culture supernatant was collected on day 4 and IFN production was measured by ELISA (Figure 3.2.4.4.1).  In this experiment, a high basal level of IFN production was detected in the absence of mBSA.  Although mBSA only slightly increased IFN production from lymph node T cells, by comparison IFN production was much greater in T cells from IKKMye lymph nodes (IKKF/F – 12,000pg/ml vs IKKMye – 25,000pg/ml)























Figure 3.2.4.4 1 Increased TH1 cell development in IKKMye mice
6x104 BMDM/well were plated in 96 well plates and stimulated with 100ng/ml LPS with or without 20g/ml mBSA for 24 h.  Inguinal, brachial, superficial cervical, and mesenteric lymph nodes were collected from IKKF/F and IKKMye mBSA immunised mice.  CD4+ T cells were isolated by negative selection with MACS separation kit (Miltenyi Biotec) and 3x105 CD4+ T cells were added to the mBSA loaded BMDM.  Tissue culture supernatant was collected on day 4 and IFN was measured by ELISA.  Data represents mean+sem of triplicates.  Experiments were repeated 3 times and representative data are shown. One way ANOVA and post-hoc bonferroni tests were used for statistic analysis; ** P<0.01








3.2.4.5 Secondary mBSA specific response elicited by IKKMye macrophages in vitro
I next tested the APC activity of IKKMye macrophages in activating mBSA specific T cells.  mBSA loaded tg elicited macrophages from IKKF/F and IKKMye mice were co-cultured with CD4+ T cells from mBSA immunised C57BL/6 mice.  Tissue culture supernatant was collected on day 4 and IFN was measured by ELISA (Figure 3.2.4.5.1).  Similar to earlier data, basal level of IFN was detected from CD4+ T cells co-cultured with IKKF/F and IKKMye macrophages in the absent of antigen.  However, higher IFN production was detected from T cells cultured with IKKMye macrophages.


























Figure 3.2.4.5 1 IKK∆Mye macrophages increase mBSA specific IFN production in vitro
IKKF/F and IKKMye mice were injected with 1.5ml of 3% tg and peritoneal macrophages were harvested after 3 days.  6x104 tg elicited macrophages/well were plated in 96 well plates with or without 20g/ml mBSA for 24 h.  Inguinal, brachial, superficial cervical, and mesenteric lymph nodes were collected from mBSA immunised C57BL/6 mice.  CD4+ T cells were isolated by negative selection with MACS separation kit (Miltenyi Biotec) and 3x105 T cells were added to the macrophages.  Tissue culture supernatant was collected on day 4 and IFN was analysed by ELISA.   NS – not significant.  Data represents mean+sem of triplicates.  Experiments were repeated 3 times and representative data are shown. One way ANOVA and post-hoc bonferroni tests were used for statistic analysis; ** P<0.01, *** P<0.001






3.2.4.6 IKKMye macrophages increase antigen specific IFN production by OTII T cells
Previous experiments suggested IKKMye macrophages increased priming of antigen-specific T cells as well as activation of effector T cells upon secondary stimulation.  To further confirm the ability of IKKMye macrophages in activating naïve T cells, I used CD4+ T cells from OTII T cell receptor (TCR) transgenic mice (H-2b) that have been genetically engineered to express ovalbumin peptide (OVA323-339)-specific TCR.  Co-culture of CD4+ OTII T cells with antigen (OVA323-339) loaded IKKMye macrophages in vitro showed 7 fold higher antigen dependent IFN production than T cells co-cultured with IKKF/F cells (Figure 3.2.4.6.1). In the absence of antigen, no IFN production was detected from the OTII T cells co-cultured with IKKMye or IKKF/F macrophages, which confirms IFN production was antigen-dependent.  This data is consistent with the previous results and confirms the capacity of IKKMye macrophages to activate naïve T cells and the development of TH1 responses. 




















Figure 3.2.4.6 1 IKK∆Mye macrophages enhance OVA323-339 specific T cell activation in vitro   
6x104 tg elicited macrophages/well were plated in 96 well plates with or without 20nM OVA323-339.  After 24 h, inguinal, brachial, superficial cervical, and mesenteric lymph nodes were collected from OTII TCR transgenic mice (H-2b).  3x105 CD4+ T cells were isolated by negative selection with MACS separation kit (Miltenyi Biotec) and added to the macrophages.  Tissue culture supernatant was collected on day 4 and IFN was measured by ELISA.  Data represents mean+sem of triplicates.  Experiments were performed twice and representative data are shown. One way ANOVA and post-hoc bonferroni tests were used for statistic analysis; *** P<0.001








3.2.4.7 IKKMye macrophages increase TH1 specific gene expression in OTII cells
To confirm the CD4+ OTII T cell phenotype, RNA was isolated from T cells co-cultured with IKKF/F or IKKMye macrophages and analysed by qRT-PCR.  As shown in Figure 3.2.4.7.1, the expression of IFN mRNA was antigen dependent.  Compared to the control, the mRNA level of IFN was increased by almost 20 fold from the T cells co-cultured with IKKMye macrophages (Figure 3.2.4.7.1A).  In addition to IFN, the transcription factors T-bet and IRF1 have been shown to participate in the development of TH1 responses  ADDIN EN.CITE (Taki, Sato et al. 1997; Szabo, Kim et al. 2000), I therefore tested the influence of IKKMye macrophages on the expression of these transcription factors.  In the presence of OVA peptide, IRF1 expression was elevated by 4 fold from OTII T cells co-cultured with IKKMye macrophages whereas the levels of IRF1 mRNA was only increased by 2 fold from OTII T cells cultured with IKKF/F macrophages (Figure 3.2.4.7.1B).    However, T bet mRNA was slightly reduced in the presence of OVA peptide and no significant differences were observed in the mRNA level of T-bet between T cells co-cultured with IKKF/F or IKKMye macrophages (Figure 3.2.4.7.1C).  In parallel, the mRNA of IL-12 receptor subunits IL-12R1 and IL-12R2 require for TH1 cell development (Szabo, Dighe et al. 1997) were measured on OTII cells from co-culture experiments.  As shown in Figures 3.2.4.7.1 D & E, the mRNA levels of IL-12R1 and IL-12R2 were higher in OTII cells co-cultured with IKKMye macrophages in the presence of OVA peptide.  In response to antigen, IL-12R1 mRNA expression increased by 2 fold in OTII cells cultured with IKKF/F macrophages and there were 3 fold from the knockout group. IL-12R2, another subunit of IL-12R was more than 2 fold higher in OTII cells cultured with IKKMye macrophages compared to IKKF/F macrophages.  TH1 cell commitment can antagonise development of TH2 cells by inhibiting IL-4 expression (Szabo, Kim et al. 2000).  Earlier data showed IKKMye macrophages promote TH1 cell responses, so I predicted that TH2 specific genes would be inhibited by IKKMye macrophages.  In response to OVA peptide, the mRNA expression of IL-4 was increased by 3 fold in OTII cells co-cultured with IKKF/F macrophages while IL-4 mRNA was reduced in OTII T cells cultured with IKKMye macrophages (Figure 3.2.4.7.1F).  The mRNA of GATA3 was induced by 2 fold in response to OVA peptide in OTII cells co-cultured with IKKF/F macrophages whereas slightly less GATA3 mRNA was induced by IKKMye macrophages (Figure 3.2.4.7.1G).

























 








Figure 3.2.4.7 1 IKK∆Mye macrophages increase expression of TH1 specific genes in OTII cells 
IKKF/F and IKKMye mice were injected with 1.5ml of 3% tg and peritoneal macrophages were harvested after 3 days, 1.6x106 tg elicited macrophages/well were plated in 6 well plates together with or without 20nM OVA peptide for 24 h. Inguinal, brachial, superficial cervical, and mesenteric lymph nodes were collected from OTII TCR transgenic mice (H-2b) and CD4+ T cells were isolated by negative selection with MACS separation kit (Miltenyi Biotec).   8x106 OTII T cells were added to macrophages, non-adherent T cells were collected on day 4 and total RNA was isolated and analysed by qRT-PCR. 


































3.2.5 Inhibitory roles of TNF on macrophage APC activity
3.2.5.1 TNF inhibits MHC II and CD80 expression on BMDM
Data from the previous sections suggest TNFα inhibits ‘classical’ macrophage activation through IKKβ activation.   I therefore predicted that TNFα would have an inhibitory effect on promoting TH1 cell responses.  I first studied the effect of TNFα on MHC II and costimulatory molecule expression.  BMDM were pre-treated with recombinant TNFα prior stimulation with LPS/IFNγ and CD80, CD86 and MHC II were measured by FACS.  Upon LPS/IFNγ stimulation, CD80 expression (MFI; 45) was 40% lower on TNFα pre-treated BMDM as compared with the untreated group (MFI; 74.4) (Figure 3.2.5.1.1A).  Similarly, 35% reduction of MHC II was detected on BMDM pre-treated with TNFα (MFI; BMDM 97.8 vs TNFα treated BMDM 62.3) (Figure 3.2.5.1.1B).  However, the inhibitory effect did not apply to CD86 and compared to the untreated BMDM (MFI; 14), TNFα treatment actually increased CD86 expression (MFI; 35.8) (Figure 3.2.5.1.1C).



















  


 


 

Figure 3.2.5.1 1 Inhibition of CD80 and MHC II by TNFα in BMDM
Bone marrow cells were cultured with 10ng/ml MCSF, on day 4, 20ng/ml TNF was added to the culture.  On day 7, 3x106 BMDM/well were plated in a 6 well plate and stimulated with 100ng/ml LPS and 100U/ml IFN for 24 h.  BMDM were stained with CD80-PE, CD86-APC, MHC II-FITC and the expression levels were measured by FACS and MFI is indicated. Blue – BMDM.  Red – BMDM treated with TNF.  Black – isotype controls. Experiments were repeated 3 times and representative data are shown. 







3.2.5.2 TNF inhibits allogenic T cell proliferation
I next investigated the affect of TNFα on allogenic T cell proliferation.  BMDM of C57BL/6 mice were pre-treated with or without TNFα and stimulated with LPS, after 24 h BMDM were co-cultured with CFSE labelled CD4+ T cells of Balb/c mice, allogenic T cell proliferation was measured by FACS.  As shown in Figure 3.2.5.2.1, allogenic T cell proliferation was reduced by 50% when BMDM were pre-treated with TNFα.













Figure 3.2.5.2 1 TNFα treatment of BMDM reduced allogenic T cell proliferation
Bone marrow cells were cultured with 10ng/ml MCSF, on day 4, 20ng/ml TNF was added to the culture.  On day 7, 6x104 BMDM/well were plated in a 96 well plate and stimulated with 100ng/ml LPS. After 24 h, 3x105 cells/well of CD4+ T cells purified from Balb/c mice were stained with CFSE and added to the macrophages.   After 4 days, non-adherent T cells were collected and the dilution of CFSE was measured by FACS. Only viable cells were gated and dead cells were excluded by staining with 7-Amino-actinomycin D.  Data represents mean+sem of triplicates.   Experiments were repeated 3 times and representative data are shown. Student T test was used to test statistical significance; ** P<0.01


3.2.5.3 TNFα treatment inhibits BMDM induced IFN production by OTII cells
From the previous data, knocking out IKK in macrophages increased classical macrophage activation and TH1 responses, further experiments show TNF inhibits the ability of macrophages to activate T cells.  So I next tested if TNF treated BMDM could inhibit IFN production, a characteristic cytokine produce by TH1 cells.  BMDM with or without TNF pre-treatment were cultured with CD4+ T cells from OTII transgenic mice in the presence of OVA peptide.  Tissue culture supernatant was collected on day 4 and IFN was measured by ELISA. As shown in Figure 3.2.5.3.1, antigen induced IFN production was completely inhibited from OTII cells co-cultured with TNF pre-treated BMDM. 
























 
Figure 3.2.5.3 1 TNFα treatment inhibits BMDM induced IFN production by OTII cells  
Bone marrow cells were cultured with 10ng/ml MCSF, and 20ng/ml TNF was added on day 4.  On day 7, 6x104 BMDM/well were plated in a 96 well plate and stimulated with 100ng/ml LPS with or without 20nM OVA peptide. After 24 h, 3x105cells/well CD4+ T cells from OTII TCR transgenic mice were added to the BMDM.   Tissue culture supernatant was collected on day 4 and IFN was measured by ELISA.  ND – not detected.  Data represents mean+sem of triplicates. One way ANOVA and post-hoc bonferroni tests were used for statistic analysis; *** P<0.001







3.2.5.4 TNFα inhibits TH1 specific gene expression
To further study the inhibitory role of TNF on TH1 cell development, BMDM with or without TNF pre-treatment were cultured with OTII T cells and TH1 characteristic genes were analysed by qRT-PCR.  From untreated BMDM, the mRNA levels of IFN were increased by 40 fold in response to OVA peptide and only basal level of IFN mRNA was detected in OTII cells co-cultured with TNF pre-treated BMDM (Figure 3.2.5.4.1A).  This data correlates with ELISA data (Figure 3.2.5.3.1) and showed TNF inhibits IFN at the transcription level.  In the case of IRF1, 2 fold induction in mRNA was seen in OTII cells cultured with OVA peptide loaded BMDM and 1.5 fold from OTII cells with TNF treated BMDM (Figure 3.2.5.4.1B). In the presence of OVA peptide, IL12-R2 mRNA was induced by more than 2 fold in OTII cells cultured with BMDM, but with TNF treated BMDM the mRNA levels of IL-12R2 was almost remained at the basal levels (Figure 3.2.5.4.1D).  By comparison, less profound induction of IL-12R1 mRNA was detected from both groups (Figure 3.2.5.4.1C). In response to OVA peptide, the mRNA levels of IL-12R1 were increased by 50% from OTII cells co-cultured with untreated BMDM whereas there was 30% IL-12R1 mRNA induction detected from OTII cells cultured with TNF treated BMDM.






















Figure 3.2.5.4 1 TNF treatment of BMDM inhibits characteristic TH1 gene expression in OTII cells  
Bone marrow cells were cultured with 10ng/ml MCSF, on day 4, 20ng/ml TNF was added to the culture.  On day 7, 1.6x106 BMDM/well were plated in 6 well plates and stimulated with 100ng/ml LPS with or without 20nM OVA peptide for 24 h.  Lymph nodes were collected from OTII TCR transgenic mice and 8x106 OTII cells were added to the BMDM.  Total RNA was isolated on day 4 from non-adherent OTII T cells and analysed by qRT-PCR.  
3.2.6 Summary
In this section, I have shown the role of IKK in macrophages in inhibiting TH1 cell development and activation.  Upon LPS stimulation, Tg elicited IKKMye macrophages increased expression of MHC II, CD80 and CD86 but reduced IL-4R levels.  Consistent results were obtained from bacteria elicited peritoneal macrophages from IKKMye mice.  In addition, IKKMye macrophages showed an increased ability to drive T cell proliferation in MLR, indicating the APC function of IKKMye macrophages.  To further investigate the inhibitory role of IKK in T cell mediated responses, a model of DTH was used. From a recall assay with splenocytes from mBSA immunised mice, IKKMye mice showed increased antigen specific IFN production ex-vivo, but antigen induced IL-10 production was reduced.  The inhibitory effects of IKK in priming naïve T cells and TH1 responses were further confirmed using OTII TCR transgenic mice.  OVA peptide dependent IFN production was greatly enhanced by CD4+ OTII T cells co-cultured with IKKMye macrophages, indicating the inhibitory role of IKK in priming naïve CD4+ T cells and promoting TH1 responses. Furthermore, qRT-PCR analysis showed expression of characteristic TH1 genes such as; IRF1, IFN, IL-12R1 and IL-12R2, were increased in OTII cells co-cultured with IKKMye macrophages, but the TH2 marker IL-4 was reduced.  These genes are important for the development of TH1 responses and the commitment of TH1 cell lineage.  From sections 3.1.5-3.1.7, I have shown the inhibitory role of TNF mediated IKK activation in IL-12 production by macrophages, so I sought to further characterise the regulatory role of TNF in TH1 responses.  TNF inhibited TH1 cell development in vitro; BMDM treated with TNF had reduced MHC II and CD80 but not CD86 expression, TNF treatment of BMDM also reduced allogenic T cell proliferation.  These data indicate the inhibitory effect of TNF on APC function.  Further experiments showed TNF treatment of BMDM inhibits priming CD4+ T cells; this was illustrated by the marked reduction on IFN production from OTII T cells co-cultured with TNF treated BMDM loaded with antigen peptide.  Furthermore, the expression of characteristic TH1 genes; IFN, IRF1 and IL-122 were reduced during T cell priming by TNF treatment of BMDM.



















3.2.7 Discussion
3.2.7.1 NF-B and APC function of macrophages
NF-B has been shown to have an important role in adaptive immunity, for example, mutation of IB in T cells leads to a reduction of T cell proliferation and IL-4, IL-10 and IFN production (Ferreira, Sidenius et al. 1999). Mora et al. 2001 also showed that T cells expressing mutated IB failed to activate STAT5a, a transcription factor required for IL-2 production (Mora, Youn et al. 2001). These studies demonstrated an intrinsic role for NF-B signalling in T cell activation.  My studies have shown NF-B can regulate T cell activation indirectly through modulation of macrophage APC activity.  For naïve T cell activation, two signals are required from the APC; signal 1 is engagement of MHC II-peptide complex and the second signal is activation of costimulatory molecules, e.g. CD80 and CD86. Failure to provide signal 2 often leads to T cell apoptosis or anergy (Jenkins, Chen et al. 1990). In my experiments, FACS analysis demonstrated increased expression of MHC II, CD80 and CD86 on LPS stimulated IKKβ∆Mye macrophages when compared to control cells (Figure 3.2.1.1). Consistent with the enhanced MHC II expression, increased allogenic T cell proliferation was obtained with IKKβ∆Mye macrophages (Figure 3.2.3.4.1). These data suggest a role of IKKβ in suppressing the APC activity of macrophages. This is in contrast to studies with DCs that suggest APC activity is positively regulated by NF-B signalling  ADDIN EN.CITE (Rescigno, Martino et al. 1998; Yoshimura, Bondeson et al. 2001; Yoshimura, Bondeson et al. 2003).  These studies showed inhibiting NF-B activation with protease inhibitor or adenovirus expressing IB in DCs impaired MHC II and B7 costimulatory molecule expression  ADDIN EN.CITE (Rescigno, Martino et al. 1998; Yoshimura, Bondeson et al. 2001). Furthermore, blocking IKK in DCs with Ad-IKK dominant negative inhibited T cell proliferation in an allogenic MLR assay  ADDIN EN.CITE (Yoshimura, Bondeson et al. 2001; Yoshimura, Bondeson et al. 2003). This is the exact opposite to what I have observed in macrophage that lack IKK expression.  The discrepancy between these observations may be due to different roles for NF-B in DCs and macrophages.  Alternatively, these differences may due to the use of different experimental systems.  Over expression of IB has been reported to affect the activity of several proteins including p53 (Chang 2002; Dreyfus, Nagasawa et al. 2005), cyclin-dependent kinase 4 (Li, Joo et al. 2003) and histone acetyltransferases and deacetylases (HDACs)  ADDIN EN.CITE (Viatour, Legrand-Poels et al. 2003; Aguilera, Hoya-Arias et al. 2004).  These off target effects may have an influence on the experimental outcome.  Other studies have used the serine protease inhibitor N--tosyl-L-phenylalanine chloromethyl ketone (TPCK) that blocks nuclear translocation of NF-B by stabilising IB and preventing its degradation (Finco TS 1994). It has been shown that TPCK blocked NF-B dependent nitric oxide synthase in murine macrophages (Kang BY 1999) and consistent with experiments using adenovirus expressing IB  ADDIN EN.CITE (Yoshimura, Bondeson et al. 2001; Yoshimura, Bondeson et al. 2003), DCs treated with TPCK showed reduction of CD86 and MHC II (Rescigno, Martino et al. 1998).  Furthermore, TPCK inhibit IL-12 production in LPS stimulated macrophages (Kang BY 1999).   This is again in contrast to my data using IKK deficient macrophages or adeno-IKKdn.  Although NF-B activation can be blocked by TPCK, this inhibitor was also shown to affect other pathways, including proteolytic loss of STAT6 (Perez-G, Cortes et al. 2008) and disrupting of 3-phosphoinositide-dependent kinase 1 (PDKI) signalling (Ballif, Shimamura et al. 2001). The NF-B-independent effects may also impact this data.  However, studies from Ouaaz et al. that show no impairment of MHC II and CD86 expression and allogenic T cell proliferation with DCs isolated from RelA-/-, p50-/-, c-Rel-/- and p50-/-c-Rel-/- chimeric mice (Ouaaz, Arron et al. 2002), also suggest over expression of IB and use of protease inhibitors have resulted in NF-B independent effects on DCs function.

A cell-specific role of NF-B could be another explanation for the contradictory observations between my studies and those of Yoshimura et al.   ADDIN EN.CITE (Yoshimura, Bondeson et al. 2001; Yoshimura, Bondeson et al. 2003).  Earlier studies from our group showed enhanced bacterial clearance when IKKβ was ablated in macrophages but not in epithelial cells (Fong, Bebien et al. 2008), illustrating a cell specific role in inflammation.  Other studies have shown NF-B from different cells, NF-B may also have a differential function within the same cell lineage, for example Lin et al 1999 have shown the involvement of NF-ĸB in both pro- and anti-apoptotic function in T cells. Inhibition of NF-ĸB reduced PMA/ionomycin mediated induction of FasL and apoptosis but increased glucocorticoid-mediated apoptosis.  Glucocorticoids are produced in the thymus and function to induce thymocyte apoptosis during positive selection (Vacchio MS 1997) whereas Fas and FasL interaction is important in AICD and peripheral T cell deletion (Lin B 1999). These data suggest NF-ĸB inhibits glucocorticoid-mediated apoptosis and survival during positive selection. On the other hand, NF-ĸB has the opposite role in mature peripheral T cells, promoting apoptosis by increasing FasL expression. Collectively, these studies suggest NF-ĸB activation can have distinct roles in different cell lineages, physiological contexts or even throughout cell differentiation. 

3.2.7.2 IKK activation in macrophages and generation of antigen-specific T cell responses
In cell-mediated immunity, antigen presentation by APC is critical for T cell priming and subsequent antigen-specific T cell activation. Using a model of DTH, I tested the role of IKK activation in macrophages in generation of antigen-specific T cell responses in vivo. Splenocytes isolated from mBSA immunised IKKΔMye mice showed increased antigen-specific IFNγ production when restimulated with mBSA in vitro (Figure 3.2.4.3.1), suggesting IKK in macrophages inhibits the development of TH1 responses in vivo.  However, splenocytes are a mixed cell population, to specifically measure CD4+ T cell responses, CD4+ T cells were purified from mBSA immunised IKKΔMye mice and co-cultured with mBSA pre-loaded BMDM.  Increased IFN production was detected from T cells isolated from IKKΔMye mice, although high basal IFN production made it difficult to conclude the effect of IKK on antigen-specific IFNγ production (Figure 3.2.4.4.1). These data provide an indication that IKK in macrophages modulates development of TH1 responses, however, the limitations of the experimental system leave some unanswered questions. 




I have used CD4+ T cells isolated from immunised mice, purified CD4+ T cells can be heterogenous and consist of naïve cells, effector cells, memory and regulatory T cells.  Although my studies show IKK inhibits ability of macrophage to activate TH1 cells in vitro, it isn’t clear what affect IKK on T cell responses in vivo.  Mice were immunised with mBSA/CFA and CD4+ T cells were collected on day 21.  Naïve T cells are ‘primed’ during immunisation with mBSA/CFA.  In this model, mBSA specific T cells develop a TH1 phenotype dependent on production of IL-12 by APC.  Once naïve T cells develop into TH1 lineage, IL-12 receptor (IL-12R) expression is increased and consequently creates a positive feedback loop to reinforce the responsiveness to IL-12  ADDIN EN.CITE (Rogge, Barberis-Maino et al. 1997; Szabo, Dighe et al. 1997). In addition to IL-12R, IL-18 receptor is also selectively induced on TH1 cells after activation (Xu, Chan et al. 1998). Cooperation between IL-12 and IL-18 has been reported as an antigen-independent means of inducing IFN production by T cells (Jianfei Yang 1999). This provides a boost for persistent IFN production for and complete clearance of infection.  The background of antigen-independent IFNγ production observed in some of my experiments may be due to increased IL-12 and IL-18 produced by macrophages in co-culture.  Differentiated TH1 cells isolated from mBSA immunised mice express both IL-12 receptor and IL-18 receptor (Xu, Chan et al. 1998) (Szabo, Dighe et al. 1997) and responded to these cytokines to produce IFNγ without the requirement of antigen. 





It is difficult to conclude from my experiments if IKK in macrophages inhibits T cell priming or maintenance of the TH1 response in vivo.  Immunisation was performed intradermally, although macrophages have been demonstrated as a major cell population in the mouse dermis (Dupasquier, Stoitzner et al. 2004), other cells such as Langerhans cells and dermal dendritic cells are also abundant.  It is possible that Langerhan cells and dermis DCs are responsible for CD4+ T cell priming and macrophages trigger activation of primed CD4+ T cell as APC.  To address this question, I have taken advantage of OTII transgenic mice with TCR specific for ovalbumin peptide (OVA323-339), T cells from OTII mice have not encountered antigen (OVA323-339) previously and therefore display a naïve phenotype, thus OTII mice provide an ideal source of naïve T cells with defined antigen-specificity.  Using OTII mice, the inhibitory role of IKKβ in the development of TH1 responses was confirmed; IKK∆Mye macrophages were able to activate naïve OTII T cells and enhance antigen specific IFN production (Figure 3.2.4.6.1).  This data suggests IKK activation in macrophages could inhibit T cell priming at least in vitro and confirms an inhibitory role for IKK in the development of TH1 cells and subsequent TH1 responses.  However, to further confirm the capacity of macrophage on priming naïve CD4+ T cells, further experiments will be required; naïve T cells (CD4+CD62L+CD44-CD25-) can be selected from OTII cells by cell sorting and co-cultured with IKK∆Mye and IKKF/F macrophages with or without antigen and IFN production can be measured by ELISA as described.


In normal circumstances, TH1 and TH2 cells produce specific cytokines to promote and maintain the cell lineage (Abbas, Murphy et al. 1996) (O'Garra 1998).  At the same time, cytokines produce by TH1 or TH2 cells inhibit the development of the opposing subset (Abbas, Murphy et al. 1996).  Quantitative RT-PCR analysis of the OTII T cells co-cultured with IKK∆Mye macrophages showed increased expression of TH1 characteristic genes; IFN, IRF1, IL-12R1 and IL-12R2 but reduced expression of the TH2 gene, IL-4. IRF1 has been identified as a transcription factor involved in TH1 cell development  ADDIN EN.CITE (Lohoff, Ferrick et al. 1997; Kano, Sato et al. 2008) (Taki, Sato et al. 1997), CD4+ T cells from IRF-/- DO11.10 TCR transgenic mice fail to differentiate into IFNγ producing TH1 cells when stimulated with OVA in the presence of APC. IL-12R1 and IL-12R2 are subunits of IL-12 receptor that are selectively induced by TH1 cells  ADDIN EN.CITE (Rogge, Barberis-Maino et al. 1997; Szabo, Dighe et al. 1997).  These data support the conclusion that IKKβ activation in macrophages negatively regulates TH1 cell development.  The experiments described above with OTII T cells suggest IKKMye macrophages can increase priming of naïve T cells.  The role of macrophages in priming naïve T cells is controversial and is in conflict with the general belief that DCs are unique in this capacity (Banchereau and Steinman 1998).  However, accumulating evidence has revealed this may not always be the case and macrophages can also prime naïve T cells.  Direct comparison of naïve T cell activation by DCs and macrophages was performed by Rothoeft et al. 2003 who showed that both cell populations are able to activate naïve T cells (T. Rothoeft 2003). DCs were shown to be more efficient in inducing TH1 responses, as demonstrated by the enhanced IL-2 and IFNγ production, while the macrophages selectively induced IL-4 production (T. Rothoeft 2003). Similarly, Moser et al reported that adoptive transfer of antigen pulsed macrophages could prime T cells in vivo and TH2 cell development was selectively elicited by macrophages when compared to DCs that have skewed cells to TH1 differentiation (Moser.M 2001).  These data are consistent with the idea macrophages can prime naïve T cells and favour TH2 responses in normal circumstances.  Deleting IKK in macrophages not only increases T cell activation but favours TH1 responses rather than TH2, it may be possible that IKKMye macrophages are unable to promote TH2 responses and therefore favour TH1 cell activation.

3.2.7.3 The role of TNF in TH1 responses 
Despite the fact TNF is a major pro-inflammatory cytokine, increasing evidence suggests a negative regulatory role of TNF in TH1 responses.  For example, TNF was shown to limit T cell activation by promoting apoptosis (Kanaly, Nashleanas et al. 1999) and TNF can dampen TH1 cell activation by inhibiting IL-12 production by APC  ADDIN EN.CITE (Hodge-Dufour, Marino et al. 1998; Notley, Inglis et al. 2008). Previous studies have also shown increased lethality of TNFR1-/- mice after infection with Mycobacterium avium, associated with elevated systemic IL-12 levels and increased CD4 and CD8 T cell accumulation (Ehlers, Kutsch et al. 2000). Similar observations were made in a lung infection model; TNF-/- mice succumbed to lung failure after infection with M.bovis BCG.  These mice suffered a severe type I immune response, illustrated by elevated IL-12 and uncontrolled CD4 and CD8 T cell expansion. Recently, the inhibitory effect of TNF on TH1 cells was further demonstrated in an autoimmune disease (collagen induced arthritis - CIA) by Notley et al 2008. Expanded TH1 cells were found in the lymph nodes of TNFR1 deficient mice, further analysis with TNFR1 deficient mice showed increased IL-12p40 expression.  Collectively, these studies suggest a negative regulatory role for TNF in the type I inflammatory responses. Although it has been shown IL-12 expression was inhibited by TNF in macrophages and dendritic cells  ADDIN EN.CITE (Ma, Sun et al. 2000; Zakharova and Ziegler 2005; Notley, Inglis et al. 2008), the inhibitory effect of TNF on APC activity and the influence of T cell activation have not previously been studied. My studies have shown TNF treatment suppresses MHC II and CD80 expression on BMDM (Figure 3.2.5.1.1), furthermore decreased allogenic T cell proliferation (Figure 3.2.5.2.1) and antigen-specific IFN production by OTII T cells (Figure 3.2.5.3.1) were obtained from BMDM pre-treated with TNF. Quantitative RT-PCR analysis of OTII T cells showed a reduction of TH1 genes including IFN, IRF1, and IL-122 when compared with T cells co-cultured with BMDM without TNF pre-treatment.  Taken together, these results clearly demonstrate the inhibitory effect of TNF on APC function and the subsequent influence on T cell activity.  However, these data appear to be in contradiction with the success of anti-TNF therapy in patients with autoimmune diseases (Feldmann and Maini 2003). But recent study of collagen induced arthritis by Notley et al 2008 has shown TNF inhibition can expand TH1 cells, this was limited to the lymph nodes and not in the joint, which may explain how anti-TNF therapy ameliorates arthritis despite increasing numbers of potentially pathogenic T cells. 

3.3 IKKMye macrophages increase anti-tumour immunity
Chronic inflammation has been shown to be associated with the development of human malignant diseases (H. Kuper 2000; Mantovani, Allavena et al. 2008) (Schottenfeld and Beebe-Dimmer 2006). The immune system is capable to recognise and remove malignant cells (Ostrand-Rosenberg 2008), however, tumours generate a microenvironment that prevents the development of protective anti-tumour immunity (Halak, Maguire et al. 1999; Yang and Lattime 2003).  Tumours frequently have a significant macrophage infiltrate, but TAM acquire a M2 phenotype that promotes immunosupression through increased IL-10 production and reduced IL-12 expression (Yang and Lattime 2003; Hagemann, Lawrence et al. 2008). From the previous data, I have shown that knocking out IKK in macrophages increases iNOS production and TH1 cell development.  TH1 cytokines; IL-12 and IFN are critical cytokines for protective anti-tumour immunity, I therefore predicted that knocking out IKK in TAM would reverse the M2 phenotype and enhance the activity of effector T cells and consequently increase anti-tumour immunity.

3.3.1 Targeting IKK in macrophages inhibits MB49 tumour growth in female mice
MB49 is a bladder carcinoma cell line derived from a male C57BL/6 mouse.  MB49 cells express the male minor histocompatibility antigen H-Y, and therefore when grown in syngenic female mice, H-Y provides a surrogate tumour-specific antigen which can be used to study anti-tumour immune responses.  To investigate the role of IKKβ in TAM, MB49 cells were injected s.c to IKKF/F and IKK∆Mye female mice, and tumour growth was measured every other day for 13 days.  As shown in Figure 3.3.1.1, tumour growth was similar between IKKF/F and IKK∆Mye female mice up to 7 days, however tumour growth completely regressed between 7-12 days in IKK∆Mye female mice.  In contrast, the growth of tumours in IKKF/F female mice continued to progress until experimental limits were reached. 


 










Figure 3.3.1 1 Targeting IKK in macrophages promotes rejection of MB49 tumours in female mice  
0.5x106 MB49 cells were injected s.c to the right flank of IKKF/F and IKKMye female mice.  Tumour size was measured every other day with electronic callipers for 13 days.  Data represents mean+sem of n=10.  Experiments were repeated 3 times and representative data are shown. Two way ANOVA and post-hoc Bonferroni were used for statistical analysis; ** P< 0.01, *** P<0.001









3.3.2 Targeting IKK in macrophages does not inhibit MB49 tumour growth in male mice
The growth of MB49 tumours was completely suppressed in IKK∆Mye female mice.   To determine if the inhibition of tumour growth in IKK∆Mye female mice was due to H-Y specific anti-tumour immunity, MB49 cells were injected s.c to IKK∆Mye and IKKF/F male mice and tumour size was measured every other day for 12 days.  As shown in Figure 3.3.2.1, tumour growth rate was consistent between IKKF/F and IKKMye male mice throughout the period monitored.  Between days 7-12, the size of tumour was slightly smaller in IKK∆Mye mice when compared to the control mice.  However, tumours from both groups continue to progress and no suppression was observed in IKKMye male mice, this data suggested rejection of MB49 tumours in IKKMye female mice is dependent on immune response to H-Y antigen.


























Figure 3.3.2 1 Targeting IKK in macrophages does not affect MB49 tumour growth in male mice
0.5x106 MB49 cells were injected s.c to the right flank of IKKF/F and IKKMye male mice. Tumour size was monitored every other day for 12 days.  Data represents mean+sem of n=10.  Experiments were repeated 3 times and representative data are shown.











3.3.3 IKKMye splenocytes increase H-Y specific IFN production ex-vivo
Previous data shows MB49 tumours were rejected in IKKβ∆Mye female mice but not in IKKβ∆Mye male mice.  These observations suggest that IKKβ in macrophages might play a role in developing antigen (H-Y) specific anti-tumour immunity.  To test for H-Y specific immune responses, splenocytes from tumour bearing IKKβ∆Mye female mice were co-cultured with naïve splenocytes from WT syngeneic female or H-Y bearing male mice, and IFNγ was measured in culture supernatant by ELISA.  As shown in Figure 3.3.3.1, 8 fold of IFNγ production was detected from IKKβ∆Mye splenocytes co-cultured with H-Y bearing male splenocytes compared to female splenocytes.  No IFNγ was detected from IKKβF/F splenocytes co-cultured with either male or female splenocytes.
























Figure 3.3.3 1 H-Y restimulation assay with splenocytes from MB49 tumour-bearing female mice
0.5x106 MB49 cells were injected s.c to the right flank of IKKF/F and IKKMye female mice.  Spleens were collected on day 12 and splenocytes were co-cultured with H-Y bearing splenocytes from male mice or H-Y negative female splenocytes.  Tissue culture supernatant was collected after 24 h and IFN production was measured by ELISA. ND – not detected.  Data represents mean+sem of triplicates. Experiments were repeated 3 times and representative data are shown. Two way ANOVA and post-hoc Bonferroni tests were used for statistical analysis; *** P<0.001
















3.3.4 Targeting IKK in macrophages inhibits the immunosuppressive tumour microenvironment
Solid tumours generate a microenvironment to suppress immune responses and promote their growth (Halak, Maguire et al. 1999; Yang and Lattime 2003).  To characterise the MB49 tumour microenvironment in IKKF/F and IKKMye mice, tumours were collected on 7 days from IKKF/F and IKKMye female mice and total RNA was isolated for qRT-PCR analysis.  As shown in Figure 3.3.4.1A, the mRNA levels of IFNγ were 2 fold higher in tumours of IKKβ∆Mye compared to the control group. IP10, a chemokine for TH1 cells and has been shown to have anti-tumour activity (Angiolillo AL 1995; Dufour, Dziejman et al. 2002).  I thus tested if IKK inhibited IP10 expression in MB49 tumours, as shown in Figure 3.3.4.1B, mRNA expression of IP10 was 30% higher in tumours of IKKβ∆Mye mice when compared to the control group.  In contrast, the expression of CD206 (MR) and arginase-1 – both established markers of TAM and M2 macrophages, were reduced in IKK∆Mye tumours. In the case of CD206, 50% reduction of CD206 mRNA expression was detected in tumours of IKKβ∆Mye mice (Figure 3.3.4.1D) and slightly lower arginase-1 mRNA expression was obtained although this was not statistically significant (Figure 3.3.4.1C).
























Figure 3.3.4 1 Gene expression in MB49 tumours from IKKF/F and IKKMye female mice  
0.5x106 MB49 cells were injected s.c to the right flank of IKKF/F and IKKMye female mice.  Tumours were collected on day 7 and total RNA was isolated for qRT-PCR analysis. Data represents mean±SEM of 8 animals. Student T test was used to test statistical significance; * P<0.05





To determine if the enhanced IFN RNA level was related to tumour infiltrating T cells (TIL).  Tumours were collected from IKKβF/F and IKKβ∆Mye female mice after 7 days and intracellular IFNγ was measured from CD3+ T cells by FACS.  In tumours isolated from IKKF/F mice, 9.49% of CD3+ T cells were IFNγ positive (MFI; 12.9).  In comparison, there were 22.3% IFNγ positive CD3+ T cells (MFI; 24.8) detected in tumours isolated from IKKMye mice, suggesting the enhanced IFN mRNA was related to CD3+ T cells (Figure 3.3.4.2). 











Figure 3.3.4 2 CD3+ tumour infiltrating lymphocytes from IKKβ∆Mye mice expressed higher intracellular IFNγ
0.5x106 MB49 cells were injected s.c to the right flank of IKKF/F and IKKMye female mice.  Tumours were collected on day 7 and intracellular IFN was measured on CD3+ T cells by FACS.  MFI is indicated.  Black – isotype control, Red – IKKβF/F mice Blue - IKKβ∆Mye mice. 







TAM express the phenotype of M2 macrophages which are predominantly involved in anti-inflammation and tissue repair (Mantovani, Sozzani et al. 2002).  Previous studies from our group showed that knocking out IKKβ altered the M2 phenotype of TAM into a pro-inflammatory M1 phenotype (Hagemann, Lawrence et al. 2008).   To determine if knocking out IKKβ in macrophages could alter the immunsuppressive phenotype of TAM in MB49 tumours, tumours were collected on day 7 and the TAM phenotype was analysed by FACS.  IL-4R is required for the development of M2 macrophages (Gordon 2003), hence IL-4R expression was studied on tumour associated F4/80+ cells (TAM).  As shown in Figure 3.3.4.3A, the expression of IL-4R (MFI; IKKβF/F 24 vs IKKβ∆Mye 7.5) was 70% lower on F4/80+ cells from IKKβ∆Mye mice while MHC II expression (MFI; IKKβF/F 770.0 vs IKKβ∆Mye 1116) (Figure 3.3.4.3B), a marker of M1 macrophage activation was increased.  These data suggest a role of IKK in skewing the M2 phenotype of TAM and blockade of IKK could restore the proinflammatory M1 phenotype.


















Figure 3.3.4 3 IL-4R and MHC II expression on TAM from MB49 tumour
0.5x106 MB49 cells were injected s.c to the right flank of IKKF/F and IKKMye female mice.  Tumours were collected on day 7 and IL-4R and MHC II were measured on F4/80+ cells by FACS.  Black – isotype control, Red – IKKβF/F mice Blue - IKKβ∆Mye mice. 


3.3.5 MB49 tumour rejection in IKKMye female mice is CD8 dependent
From the previous data, I have shown that IFN expression was increased in the MB49 tumour from IKKMye female mice.  FACS analysis showed increased IFN production by TIL.  CD8+ cytotoxic T lymphocytes (CTL) are critical effector cells in tumour regression, to determine if MB49 tumour rejection observed in IKKMye female mice was mediated by CTL, anti-CD8 antibody was administered to IKKMye female mice before injection of MB49 tumour cells.  Mice were culled when the tumour size reached experimental limits and data are represented as percentage survival. As expected, tumour rejection was observed in untreated IKKMye female mice, however treatment with anti-CD8 antibody resulted in a dramatic reduction in survival (Figure 3.3.5.1), indicating CD8 T cells are required for MB49 tumour rejection.











Figure 3.3.5 1 Tumour rejection in IKKMye female mice was mediated by CD8+ T cells
On day 1 and 3, IKKMye female mice were injected i.p with or without 0.2ml of anti-CD8 antibody or IgG isotype control.  0.5x106 MB49 cells were injected s.c to the right flank on day 4 and tumour size was monitored every other days.  Mice were culled when the tumour size reached the experimental limit and data are representing as survival of mice in each group over time.  n=8.  Log-rank test was used to test statistical significance; ** P<0.01























3.3.6 MB49 tumour rejection in male mice after Dxr treatment is CD8 T cell dependent 
Chemotherapy and radiotherapy are conventional treatments for many cancers, recently it has been shown the response to chemo- and radio-therapies is dependent on adaptive immune responses  ADDIN EN.CITE (Apetoh, Ghiringhelli et al. 2007; Zitvogel, Apetoh et al. 2008).   In response to chemotherapy, it was reported that dying tumour cells release high mobility group box 1 (HMGB1) that can trigger TLR4 on APC and elicit the activation of anti-tumour immunity (Apetoh, Ghiringhelli et al. 2007).  From earlier data, IKKMye macrophages were shown to promote TH1 cell development, furthermore CD8+ T cell-associated tumour rejection was observed in IKKMye female mice and enhanced anti-tumour immunity was associated with increased response to tumour antigen.  To determine if IKKMye macrophages can also enhance immune responses against other tumour antigens revealed during chemotherapy, I administrated doxorubicin (Dxr) to IKKF/F and IKKMye male mice with established tumours.  According to the previous experiment, MB49 tumours reached experimental limits after 14 days from both IKKF/F and IKKMye male mice (Figure 3.3.2.1).  As shown in Figure 3.3.6.1, Dxr treatment significantly prolonged the survival time of IKKF/F mice to 36 days however 80% of mice eventually reached experimental limits.  But 70% of IKKMye mice receiving Dxr remained survived the course of the experiment, showing a significant increase in survival.  To test if the response to Dxr in IKKMye mice requires CD8+ T cells, anti-CD8 antibody was administered to IKKMye male mice twice before MB49 tumour cells injection and Dxr was given every other day as described. 90% of IKKMye male mice reached experimental limits after 23 days when treated with Dxr and anti-CD8 antibody.    Taken together, these data suggest inhibition of IKK in macrophages enhances anti-tumour immunity and increase immune responses to antigens revealed by chemotherapy.



Figure 3.3.6 1 Targeting IKK in TAM increased response to chemotherapy
On day 1 and 3, IKKMye male mice were injected with 0.2ml of IgG or anti-CD8 antibody i.p.  On day 4, 0.5x106 MB49 tumour cells were injected s.c to the right flank of all mice.  When the tumour size reached 0.5cm2, mice were injected with 0.2ml 2mg/kg doxorubicin i.p three times per week. Mice were culled when the tumour size reached the experimental limit and data are indicated as percentage survival.  n=10 Log-rank test was used to test statistical significance; * P<0.05, *** P<0.001









3.3.7 Summary
NF-B is a ubiquitous transcription factor that plays an important role in both immunity and cancer (Karin, Cao et al. 2002; Karin 2006).  Earlier data have shown that knocking out IKKβ in macrophages increases IL-12, MHC II, and costimulatory molecule expression, furthermore, IKKMye macrophages enhanced TH1 cell development and activation.  These factors are critical in the development of protective anti-tumour immunity, therefore the aim of this section was to evaluate the hypothesis that blocking IKKβ in TAM will enhance protective anti-tumour immunity.  MB49 tumour cells were injected s.c to IKKF/F and IKKMye female mice and tumour growth was measured for 2 weeks.  From days 0-7, both animal groups display no difference in tumour growth. However, tumour regression was observed from day 7 in IKKβMye female mice and tumours were completely rejected after day 13.    To investigate if tumour rejection in IKKMye female mice was due to H-Y specific anti-tumour immunity, the experiment was repeated in IKKF/F and IKKMye H-Y bearing male mice.  Both groups had similar rates of tumour growth and reached experimental limits within 14 days.  To test if H-Y specific tumour immunity had developed in IKKβMye female mice, a H-Y re-stimulation assay was preformed.  Splenocytes from tumour bearing IKKF/F and IKKMye female mice were cultured with splenocytes from WT syngeneic female or H-Y bearing male mice.  Splenocytes of IKKMye mice had dramatically increased IFN production when co-cultured with H-Y bearing male splenocytes. These data support the hypothesis that IKKβ activation in TAM is important in the regulation of antigen specific tumour immunity.  

Characterisation of the tumour microenvironment in IKKMye female mice suggested a switch from an immunosuppressive (CD206High Arginase-1High IFNLow IP10Low) phenotype to a more proinflammatory and immuno-stimulatory environment (CD206Low Arginase-1Low IFNHigh IP10High).  Intracellular staining also revealed increased IFN expression by TIL.  Finally, chemotherapy of MB49 tumours was greatly enhanced in IKKMye male mice that were dependent on the presence of CD8+ T cells, despite the absence of anti-H-Y immune responses.  These data suggest inhibition of IKK in macrophages can increase immune responses to tumour antigens revealed by chemotherapy.















3.3.8 Discussion
3.3.8.1 IKK deletion in macrophages enhanced H-Y antigen specific anti-tumour immunity
Previous studies by our group have shown targeting IKK in macrophages increased resistance to infection (Fong, Bebien et al. 2008). In vitro analysis confirmed enhanced iNOS production (Figurer 3.1.2.1) and bacterial killing by IKKMye macrophages.  In addition to anti-bacterial activity, iNOS/NO production also contributes to the tumoricidal activity of macrophages (Chang, Liao et al. 2001). Earlier studies from our lab showed IKKβ deletion in TAM enhanced tumoricidal activity through increased NO production (Hagemann, Lawrence et al. 2008), furthermore these studies also showed targeting IKK in TAM increased IL-12 expression and NK cell mediated cytotoxicity towards tumour cells.  Collectively, these data suggest targeting IKKβ in TAM increased innate immunity to cancer cells. Adaptive immunity is also important for tumour suppression, I have shown IKK activation in macrophages inhibits cell-mediated immunity in the previous sections, to study the role of IKK in the development of anti-tumour immune responses, I used the MB49 bladder carcinoma cell line; MB49 tumour cells express the male H-Y antigen, therefore when grown in syngeneic female mice, H-Y antigen provides a surrogate tumour-specific Ag to track anti-tumour immune responses. MB49 tumours were completely rejected by IKKMye female mice after 13 days (Figure 3.3.1.1).  On the other hand, no tumour rejection was observed from IKKMye male mice (Figure 3.3.2.1). MB49 tumour rejection in IKKMye female mice and not male mice indicates tumour rejection is H-Y dependent and suggest the development of anti-tumour immunity to H-Y antigen.  Increased H-Y specific immune responses was confirmed by further analysis with antigen-recall assay; splenocytes from MB49 tumour bearing IKK∆Mye female mice showed significantly enhanced IFNγ production when co-cultured with H-Y positive male splenocytes (Figure 3.3.3.1).  This is consistent with the conclusion MB49 rejection in IKK∆Mye female mice is due to increased anti-H-Y immune responses. Intracellular cytokine staining of MB49 tumour cell suspensions showed increased IFN expression in CD3+ tumour infiltrating lymphocytes from IKKβ∆Mye female mice (Figure 3.3.4.2).  This also suggests tumour rejection might be dependent or partially dependent on enhanced cytotoxic T lymphocyte activity. CD8+ T cell depletion in IKKβ∆Mye female mice prior to MB49 tumour growth confirmed a role for CD8+ T cells in tumour rejection; no tumour rejection was observed in IKKβ∆Mye female mice receiving anti-CD8 depleting antibody (Figure 3.3.5.1). These data indicate IKKβ activation in TAM inhibits the activation of tumour-specific immune responses.  

3.3.8.2 Mechanisms for tumour rejection in IKKβ∆Mye mice
Several mechanisms might be lead to enhanced CTL activity in IKKβ∆Mye mice.  First, knocking out IKK in macrophages could enhance CTL activity directly, as observed in CD4+ T cells in previous sections, the capacity of macrophages to increase CTL activity has previously been demonstrated (Pozzi, Maciaszek et al. 2005). Pozzi et al compared the ability of Ag-pulsed BMDM and DCs to trigger CTL activation in vivo and macrophages were comparable with DCs in their ability to stimulate CTL proliferation, express effector functions and mature into memory cells (Pozzi, Maciaszek et al. 2005). Accumulating evidence has also shown the importance of CD4+ T cell in CTL-mediated anti-tumour immunity  ADDIN EN.CITE (Marzo, Kinnear et al. 2000; Gao, Khammanivong et al. 2002; Wang and Livingstone 2003).  Marzo et al 2000 have shown that CD4+ T cells are not only required for the infiltration of CTL into tumours, but also the induction of CTL effector function (Marzo, Kinnear et al. 2000).  Furthermore, a study from Gao et al 2002 has shown the requirement of CD4+ T cells in activating memory CD8+ T cells to facilitate tumour killing (Gao, Khammanivong et al. 2002).  CD4+ T cell help for CTL activity is also dependent on interactions with APC  ADDIN EN.CITE (Bennett, Carbone et al. 1998; Ridge, Di Rosa et al. 1998; Schoenberger SP 1998).  Thus, CD4+ T cells may contribute to tumour rejection in the IKKMye female mice by enhancing CTL activation. Another possibility is elevated IFN produced by CD4+ T cells or CTLs may increase cytotoxic activity of NK cells and TAM.  Further experiments are required to elucidate the exact mechanism for increased CD8+ dependent tumour regression in IKKMye mice.

3.3.8.3 IKK deletion in macrophages response to chemotherapy
In response to chemotherapy tumour cells undergo apoptosis and necrosis, apoptosis is silent cell death that is characterised by chromatin condensation (pyknosis) and nuclear fragmentation (karyorhexis) occurring within an intact plasma membrane (Zamzami and Kroemer 1999), in contrast necrotic cells release damage associated molecular patterns (DAMPs) including; hyaluronans, heat shock proteins (HSPs), fibronectin and high mobility group box 1 (HMGB1) (Marshak-Rothstein 2006). DAMPs have been suggested to activate TLRs and trigger immune responses (Marshak-Rothstein 2006) (Apetoh, Ghiringhelli et al. 2007).  Apetoh et al. have shown that HMGB1 released by dying tumour cells activates DCs via TLR4 to elicit activation of antigen specific T cell immunity.  To test the role of IKK in this context I used chemotherapy treatment of MB49 tumours.  IKKMye male mice treated with doxorubicin showed significantly prolonged survival and tumours were rejected in 70% of the mice compared to control mice that all eventually reached experimental limits (Figure 3.3.6.1).  Depleting CD8+ T cells in these mice reversed this effect as demonstrated by reduced survival and tumour rejection was decreased to just 10%.  These experiments suggest targeting IKK in TAM not only increases immune responses specific to H-Y in female mice as shown previously, but also increased the immune response to other antigen revealed upon chemotherapy treatment.

3.3.8.4 IKK maintains tumour-induced tolerance
From the previous studies, Halak et al. have shown MB49 tumour cells inhibit priming of H-Y specific type I responses in female mice (Halak, Maguire et al. 1999). However, in my experiments MB49 tumours were rejected in female mice when IKK is deleted in macrophages (Figure 3.3.1.1) and H-Y specific type I responses developed as illustrated from the antigen-recall assay (Figure 3.3.3.1).  These studies suggest a role for IKK in tumour-induced immune tolerance.  It was reported that increased production of anti-inflammatory cytokines such as IL-10 are found in the tumour microenvironment that suppress anti-tumour immunity (Halak, Maguire et al. 1999; Jarnicki, Lysaght et al. 2006).   Halak and colleagues have shown that MB49 failed to prime an HY specific type I (IFN) responses in WT female mice while HY specific type I (IFN) responses were able to induce from IL-10-/- mice.  Furthermore, IL-10-/- mice show prolonged survival and increased capacity to reject MB49 tumours.

Because IL-10 production was measured in MB49 tumours in WT mice but not IL-10-/- mice, whose infiltrating cells are unable to produce IL-10 (Halak, Maguire et al. 1999), authors suggested that MB49 tumour induces infiltrating cells to produce IL-10, which consequently suppress the development of anti-tumour immunity.  Elevated IL-10 has been found in cancer patients and IL-10 production is often correlated with the induction of T cell anergy (De Vita, Orditura et al. 2000) (Ferdinando De Vita 1999).  It has also been shown that DCs cultured with IL-10 have reduced capacity to stimulate T cells and instead promote anergy (Steinbrink, Wolfl et al. 1997). IL-10 can also promote the development of regulatory T cells that actively suppress immune responses (Groux, O'Garra et al. 1997) (Asseman C 1998).  TAMs are potential sources for the IL-10 production in MB49 tumours (Hagemann, Lawrence et al. 2008), previous studies from our group showed deleting IKK in TAM could switch the TAM phenotype (IL-10 high, IL-12 low) to a M1 phenotype (IL-10 low, IL-12 high) (Hagemann, Lawrence et al. 2008).  These studies suggest IKK activation in TAM may promote tumour-induced tolerance, possibly mediated by IL-10 production, blocking IKK activity can reverse tolerance by switching off IL-10 production.  Further experiments targeting IL-10 in IKKMye mice are required to confirm this hypothesis.



4. General discussion
4.1 IKK/NF-B inhibits classical macrophage activation
NF-B transcription factors regulate expression of many genes important in the inflammatory response (Li and Verma 2002), the NF-B signalling pathway is thus considered a potential target for new anti-inflammatory drugs (Li and Verma 2002; Karin, Yamamoto et al. 2004). However, recent research has revealed roles for NF-B in the resolution of inflammation.  Lawrence et al. 2001 reported that NF-B activity is required for leukocyte apoptosis during the resolving phase of inflammation (Lawrence, Gilroy et al. 2001).  More recently, mice with IKK deletion in myeloid cells were shown to have elevated plasma IL-1 and increased sensitivity to endotoxin-induced shock (Greten, Arkan et al. 2007).  Moreover, recent studies published by our group have shown enhanced bacterial clearance in mice with a myeloid-specific deletion of IKK, but the opposite was observed in mice with IKK deletion in lung epithelial cells, suggesting this anti-inflammatory role for IKK is tissue specific (Fong, Bebien et al. 2008).   







4.2 NF-B-STAT signalling and regulation of macrophage activation
NF-B mediated inflammatory responses are crucial during infection, however fine-tuning the amplitude of the response to balance effective pathogen clearance and avoiding excessive inflammation are equally important. Effective pathogen clearance requires cooperation between innate and acquired immune responses.  For example, LPS, a component of gram-negative bacteria and the TH1-cytokine IFN elicit M1 macrophage activation.  M1 macrophages are important effector cells that are characterised by increased production of NO, reactive oxygen intermediates and inflammatory cytokines such as IL-12 that promote TH1 responses.  On the other hand, IL-4 promotes the development of M2 macrophages, characterised by production of anti-inflammatory cytokines such as TGF and IL-10.  Moreover, arginase 1 (Arg1) expression is also considered a typical marker for M2 macrophages, which not only counteracts NO production by iNOS but also inhibits T cell activation. In general, M1 macrophages are potent effector cells that kill microorganisms, tumour cells, produce proinflammatory cytokines and promote the development of adaptive immune responses.  In contrast, macrophages with M2 phenotype are more prone to produce anti-inflammatory cytokines, suppress adaptive TH1 immunity and promote angiogenesis  ADDIN EN.CITE (Mantovani, Sozzani et al. 2002; Gordon 2003; Gordon and Taylor 2005). 

Macrophages are able to switch their phenotype in response to changes in the environment (Stout and Suttles 2004), a recent study showed M2 macrophages elicited by helminth infection can be reprogrammed to an M1 phenotype by LPS and IFNγ stimulation (Mylonas, Nair et al. 2009).   These studies demonstrate the plasticity of macrophage phenotype, however the molecular mechanisms involved are still unknown. A role for NF-B signalling in the M2-like TAM phenotype was indicated in a study by Biswas et al. 2006. Microarray analysis showed several NF-B regulated genes including IL-6, TNF-alpha and CCL3 were reduced in LPS stimulated TAMs compared to peritoneal macrophages (Biswas SK 2006). In a mouse ovarian cancer model, Hagemann and colleagues have also shown a role for IKK in maintenance of the IL-10High/IL-12Low TAM phenotype (Hagemann, Lawrence et al. 2008). Furthermore, enhanced tumoricidal activity was observed associated by increased iNOS expression and IL-12 dependent activation of NK cells. Previous studies from our group have shown increased activation of M1 macrophages in IKKMye mice infected with Cryptococcus neoformans (Cn), a pathogen that promotes an M2-phenotype (Fong, Bebien et al. 2008). These studies indicate a role for IKK/NF-B activation in M2/TAM phenotype and activity. 

I have shown that knocking out IKK in macrophages promotes a M1 phenotype based on the following observations;

4.2.1 Cytokine production
Specific cytokine production is a key feature of different macrophage subtypes; M1 macrophage activation is characterized by proinflammatory cytokine production, such as IL-12, IL-6 and TNF whereas M2 macrophages favour the synthesis of anti-inflammatory cytokines IL-10 and TGF  ADDIN EN.CITE (Fenton, Buras et al. 1992; Schebesch, Kodelja et al. 1997). I have shown that blocking IKK with adenovirus expressing dominant negative inhibitor in macrophages increased IL-12 production and conditional deletion of IKK in macrophages increased IL-12, iNOS and MHC II expression.  Consistent with the current study, conditional knock down IKK in TAM also showed elevated IL-12 production and reduction in IL-10 (Hagemann, Lawrence et al. 2008). These studies suggest a role of IKK in suppressing the proinflammatory phenotype of M1 macrophages.

4.2.2 iNOS-Arginase balance
From an earlier in vivo study (Fong, Bebien et al. 2008), immunohistochemical analysis showed increase iNOS expression in alveolar macrophages from IKKMye mice.  Increased iNOS expression by IKKMye macrophages was further confirmed in vitro (Figure 3.1.2.1).  The iNOS-arginase balance represents one of the features to distinguish M1 and M2 macrophages (Munder, Eichmann et al. 1998). M1 macrophages produce elevated NO by upregulating iNOS, which uses L-arginine as a substrate for NO production.  In M2 macrophages, arginase is upregulated instead of iNOS (Hesse, Modolell et al. 2001), arginase hydrolyses L-arginine into L-ornithine and urea, therefore depleting the substrate for iNOS-mediated NO production.  L-ornithine is also a metabolite for polyamine and proline production.  The upregulation of NO production contributes to microbicidal and tumoricidal activity of M1 macrophages  ADDIN EN.CITE (Fong, Bebien et al. 2008; Hagemann, Lawrence et al. 2008), whereas prolines and polyamines produced by M2 macrophages and TAM are important for wound healing and promotion of tumour growth respectively  ADDIN EN.CITE (Song, Ouyang et al. 2000; Chang, Liao et al. 2001).  Over-expression of arginase in macrophages can directly enhance tumour cell proliferation (Chang, Liao et al. 2001). Furthermore, increased arginase activity can attenuate NO production by LPS activated macrophages and reduce its cytotoxic activity towards co-cultured tumour cells (Chang, Liao et al. 2001). These studies suggest an important role of iNOS-Arginase balance in the effector functions of M1 and M2 macrophages. My data shows a role for IKK in skewing the iNOS-Arginase balance by inhibiting iNOS expression that may have important implications for macrophage effector function in infection and cancer.

4.2.3 APC activity
Induction of TH1 responses and CTL activation are other important roles of M1 macrophages in combating infection and tumour development.  In contrast, TAMs or M2 macrophages have poor APC function and in fact express several mechanisms to suppress T cell responses that may contribute to evasion of protective immune responses.  For example; TGF-, an immunosuppressive cytokine produced by TAMs, has been shown to interfere with the development of anti-tumour immune responses (Mantovani, Sozzani et al. 2002). Microarray analysis has shown TGF- suppresses genes encoding key effector proteins of CTLs; perforin, granzymes A and B, Fas ligand, and IFN (Trapani 2005). TAM can also suppress T cell responses through induction of Treg cells.  Neutralizing IL-10 in vivo indicates the association of IL-10 production by TAM and Treg cell development.   ADDIN EN.CITE (Kusmartsev, Nagaraj et al. 2005; Huang, Pan et al. 2006). In a murine lung carcinoma model, arginase production by M2-like TAMs was shown to decrease expression of T cell receptor CD3 chain and impair T cell function (Rodriguez, Quiceno et al. 2004).  My data demonstrate that knocking out IKK in macrophages enhances the development of TH1 responses and anti-tumour immunity. Similar studies have shown conditional knock down IKK or inhibition of IKK with adenovirus expressing dominant negative inhibitor in TAMs increased the innate anti-tumour immune responses through increased NO-mediated tumouricidal activity and IL-12 dependent NK cell recruitment (Hagemann, Lawrence et al. 2008).  These data suggest IKK inhibits innate and adaptive protective immunity through blocking M1 macrophage activation.

4.3 Molecular mechanisms of macrophage regulation by IKK
Here I have further explored the inhibitory role of IKK in macrophage activation and revealed negative cross-talk between IKK and STAT1 signalling.  Negative cross-talk between STAT1 and NF-B pathways was also indicated by other studies of LPS tolerance. Pre-treatment with LPS results in a dramatic reduction of IFN-induced DNA binding of STAT1 (Crespo, Filla et al. 2000).  Further experiments suggested accumulation of SOCS1 in response to LPS contributed to STAT1 inhibition. LPS does not induce SOCS1 expression directly, this was dependent on autocrine or paracrine IFN production (Crespo, Filla et al. 2000).  In addition to the indirect SOCS1 production, LPS can also directly induce expression of SOCS3  ADDIN EN.CITE (Bode, Nimmesgern et al. 1999; Stoiber, Kovarik et al. 1999), another SOCS family member that can suppress IFN responses. The inhibitory effects of SOCS1 and SOCS3 has been reported on iNOS (Ana Crespo 2002), IL-12 (Eyles, Metcalf et al. 2002) and MHC II expression (Stoiber, Kovarik et al. 1999).  The current study has shown that IKK deficient (IKKMye) macrophages have increased STAT1 tyrosine phosphorylation, MHC II expression, iNOS and IL-12 production in response to bacteria, LPS alone or LPS plus IFN.    Quantitative RT-PCR has shown that the mRNA of IFN was reduced in IKKMye macrophages and there were no differences in expression of SOCS1/SOCS3 (Fong, Bebien et al. 2008), this suggests IKK may inhibit STAT1 signalling by regulating the activity of SOCS proteins rather than their expression. There are three ways that SOCS proteins inhibit JAK-STAT signalling; SOCS1 and SOCS 3 directly inhibit JAK kinase activity through their kinase inhibitory region (KIR) (Yasukawa H 1999). SOCSs proteins also inhibit STAT signalling by competing with STATs for common phosphotyrosine-binding (PTB) sites within the cytoplasmic domains of cytokine receptors.  The third mechanism of SOCS action is by promoting the degradation of target signalling proteins through ubiquitin ligase activity (Krebs and Hilton 2001). IKK/NF-B could inhibit STAT1 activation by affecting one of these mechanisms.  For example; the stability of SOCS proteins is regulated by phosphorylation (Chen XP 2002; Haan, Ferguson et al. 2003) and degradation through the 26S proteasome and this involves the interaction between SOCS box and Elongin B and C (Zhang, Farley et al. 1999), IKK could modulate phosphorylation of SOCS1 or its interaction to the regulatory proteins Elongin B and C.  Further experiments are required to determine the affects of IKK on SOCS1 activity and interaction with other regulatory proteins.  






4.4 IL-4 signalling and STAT6 

4.4.1 STAT1 and STAT6 
IFN and IL-4 are the master regulators of TH1 and TH2 differentiation and their distinctive roles in driving cellular and humoral immune responses. In addition to driving TH1 and TH2 cell differentiation, IFN and IL-4 also antagonize each other to ensure continuous development of the signature lineage (Abbas, Murphy et al. 1996). Apart from T cells, IFN and IL-4 also regulate macrophage phenotype; IFN signalling is required for M1 macrophage activation, suggesting STAT1 is important for the M1 phenotype.  On the other hand, IL-4 is critical for M2 differentiation and thus STAT6 is likely the transcription factor required for M2 activation. Several studies have demonstrated a suppressive role of IL-4 on IFN/STAT1 regulated gene expression in mouse macrophages  ADDIN EN.CITE (Gautam, Tebo et al. 1992; Deng, Ohmori et al. 1994; Ohmori and Hamilton 1997; Paludan, Lovmand et al. 1997). However, the exact molecular mechanisms still remain unclear. Ohmori and Hamilton have suggested a possible inhibitory mechanism for IL-4 on STAT-mediated IRF1 expression (Ohmori and Hamilton 1997).  They showed IL-4 treatment inhibited IRF1 induction when the IFN concentration was low, this was suggest to be mediated by competition between STAT6 and STAT1 for the binding of STAT binding element (SBE).  STAT6 does not have trans-activation activity at the IRF1 promoter thus inhibits gene transcription.  However, this mechanism did not apply when the concentration of IFN was high. From my studies, increased STAT1 phosphorylation was observed in IKK deficient macrophages, it is possible the elevated level of activated STAT1 might overcome STAT6 activity and promote M1 macrophage phenotype (Figure 4.4.1.1).


Figure 4.4.1 1 Competition between STAT1 and STAT6 for SBE
Blocking IKK increased STAT1 phosphorylation which competes with STAT6 for IRF1 SBE binding.









4.4.2 STAT6 and NF-B 
Interaction between STAT6 and NF-B could be another molecular mechanism regulating macrophage phenotype.  It has been shown that STAT6 and NF-B cooperate and synergistically activate IgE promoter in B cells (Messner, Stutz et al. 1997; Shen and Stavnezer 1998).   Shen and Stavnezer 1998 provided evidence that STAT6 and NF-B interact directly and cooperatively bind their cognate DNA binding sites (Shen and Stavnezer 1998).  Ablating IKK in macrophages might limit the interaction between STAT6 and NF-B and subsequently impair the expression of IL-4 responsive genes and consequently suppress the M2 phenotype of macrophages.

4.4.3 IKK/NF-B and IL-4R expression
Two types of IL-4 receptors have been reported; type 1 IL-4 receptor consists of IL-4 chain and c chain whereas type 2 receptor is composed of IL-4R and IL-13R (Nelms, Keegan et al. 1999).  The critical role of IL-4 on TH2 cell development has resulted in much attention on IL-4R regulation on T cells, but its regulation in macrophages is not well understood.  In T cells, several intracellular signalling pathways have been reported to control IL-4R expression.  Human T cells stimulated with phorbol myristate acetate (PMA), the protein kinase C (PKC) activator or the calcium ionophore A23187, increased IL-4R expression at mRNA and protein level (Dokter, Borger et al. 1992).  In addition, IL-4 stimulated T cells show increased in IL-4R expression (Renz, Domenico et al. 1991) and later studies have shown the role of STAT6 for IL-4R induction in response to IL-4 (Kotanides and Reich 1996).  In 1994, De Wit and colleagues investigated the regulation of IL-4R in human monocytic cells and showed PKC and c-AMP dependent pathways are involved in IL-4R gene expression while calcium ionophore and IL-4 had no effect (de Wit, Hendriks et al. 1994).  These studies indicate IL-4R expression is differentially regulated between cells. In the current study I have shown that IL-4R is absent on LPS stimulated IKKMye macrophages, indicating the involvement of IKK/NF-B in the regulation of IL-4R expression in macrophages. In the absence of IL-4R macrophages may fail to respond to IL-4 and develop into M2 macrophages (Figure 4.4.3.1), indicating IKK could promote M2 macrophage development by inducing IL-4R expression.
Figure 4.4.1 2 IKK activation promotes IL-4R expression
IL-4/IL-13 mediated STAT6 activation antagonists STAT1 induced by IFN and therefore inhibits M1 associated gene expression.  Deleting IKK in macrophages suppress the expression of IL-4R that may limit their response to IL-4 or IL-13 and the development of a M2 phenotype. 
4.5 Inhibition of classical macrophage activation by TNF 
Synergistic action between proinflammatory cytokines is an important facet of the immune system.  Both synergistic and antagonistic activities between IFN (STAT1) and TNF signalling pathways have been documented. The coordinated binding of TNF activated NF-B and IFN activated STAT1 or IRF1, to specific promoters is a typical example for the enhancement of gene transcription (Ohmori and Hamilton 1995; Ohmori, Schreiber et al. 1997).  Cross-talk between IFN and TNF also occurs at the receptor level of the signalling pathways, an antibody screen for STAT1 binding protein found TRADD to interact with STAT1 in a TNF dependent way in Hela cells (Wang, Wu et al. 2000).  Further experiments showed binding of STAT1 to the TNFR1-TRADD signalling complex promoted TNF-induced apoptosis while preventing NF-B activation (Wang, Wu et al. 2000). TNFR1 and STAT1 interaction was also shown by others as a negative regulator of TNF mediated NF-B activation (Wesemann and Benveniste 2003).  In STAT1 deficient cells, TNF treatment leads to a more robust NF-B activation while restoration of STAT1 inhibits TNF dependent NF-B activation.  Although these studies clearly demonstrated physical interaction between TNFR1/TRADD and STAT1 and their influence on NF-B activation, no experiments were performed to investigate the effect of TRADD/STAT1 complex on IFN signalling.  In 2004, Wesemann et al. demonstrated that IFN induces the formation of a TRADD/STAT1 complex.  In TRADD-/- macrophages, IFN induced a stronger and prolonged STAT1 activation.  Furthermore, nuclear translocation, STAT1 DNA binding activity and transcription were enhanced in the TRADD-/- cells (Wesemann, Qin et al. 2004).  These data clearly indicate the formation of TRADD/STAT1 complex negatively regulates IFN mediated STAT1 activation. From the current study, I have shown that TNF inhibits STAT1 phosphorylation in BMDM.  According to the study by Wesemann et al. 2004, one possible mechanism may be the formation of a TRADD-STAT1 complex that restricts the amount of STAT1 available for phosphorylation by JAK signalling (Figure 4.5.1).  Furthermore, STAT1 phosphorylation was only increased from TNFR1-/- (p55-/-) peritoneal macrophages and not TNFR2-/- (p75-/-) macrophages (Figure 3.1.7.1).  Upon TNF binding, the first protein recruited to TNFR1 is TNFR1-associated death domain protein (TRADD), which serves a platform to recruit FADD, RIP1, TRAF2 and subsequently initiate the signalling cascade.  On the other hand, TNF binding to TNFR2 results in direct recruitment of TRAF2, which in turn recruits TRAF1 (Rothe, Wong et al. 1994).  The absence of TRADD downstream of TNFR2 signalling pathway failed to increase STAT1 activation from p75-/- macrophages as obtained from p55-/- macrophages, hence suggesting this is a mechanism for TNFR1-specific inhibition of STAT1 activation.










Figure 4.5 1 Possible mechanisms of the inhibitory effect of IKK/TNF on STAT1 signalling
1) IKK regulates the induction or the activity STAT inhibitors, such as SOCS1 and/or SOCS3 that can inhibit STAT1 signalling. 2) IKK inhibits STAT1 activity directly. 3) TNF induces TRADD-STAT1 complex formation and subsequently reduced free STAT1 for phosphorylation that are available for JAK signalling.














5. Future work
5.1 Regulation of SOCS by IKK 
The stability of SOCS proteins is regulated by phosphorylation (Chen XP 2002; Haan, Ferguson et al. 2003) and degradation through the 26S proteasome and this involves the interaction between SOCS box and Elongin B and C (Zhang, Farley et al. 1999).  To investigate the possibility that IKK mediates the interaction of SOCS1 with regulatory proteins such as Elongin B and C, I plan to infect IKKF/F and IKKMye macrophages with adenovirus expressing SOCS1-Flag and co-immunoprecipitate (co-IP) with anti-Flag antibody to detect IKK-dependent interactions between SOCS1 and elongin B/C.

To test the hypothesis that SOCS1 is a target for IKK-mediated phosphorylation, I will elicit peritoneal macrophages from IKKF/F and IKKMye macrophages and stimulated with LPS in vitro, following IP with anti-SOCS3 and anti-SOCS1 antibody.  Phosphorylation will be detected with anti-phosphotyrosine immunoblotting.







5.2 Antigen processing and presentation 
I have shown IKKMye macrophages increased antigen specific IFN production by OTII T cells.  In these experiments, OVA323-339 peptide was used and therefore measures the antigen presentation and co-stimulation capacity of macrophages but effects on antigen processing were not measured. To test the role of IKK in antigen processing, I will load whole OVA protein on IKKF/F and IKKMye Tg elicited macrophages and co-culture with OTII T cells and measure T cell proliferation and cytokine production. 

5.3 T cell priming in vivo
To measure the role of IKK activation in T cell priming in vivo, I will pulse IKKF/F and IKKMye Tg elicited macrophages with OVA peptide in vitro.   Antigen loaded macrophages will be injected i.v into syngeneic naive mice and un-treated macrophages will be used as a negative control. Mice will then be injected with CFSE-labelled OTII cells intravenously.  Lymph nodes and spleen will be collected after 1-2 days to measure OVA specific T cell expansion.  These experiments will be done with and without LPS injection as an adjuvant.

5.4 Humoral immune responses 
Type I immune responses are not limited to the production of TH1 cytokines by CD4+ T cells but also characterised by specific antibodies secreted by B cells.   Immune responses dominated by TH1 cells produce IFN and trigger B cells secreting IgG2a antibody whereas TH2 cells are excellent helpers for B cells, and stimulate the production of IgM and IgG1 (Abbas, Murphy et al. 1996). I have shown that deleting IKK in macrophages promotes the development of TH1 responses, thus I would predict high titres IgG2a, but low IgM and IgG1 antibodies will be detected in IKKMye mice after OVA immunisation.  To test this I will immunise IKKF/F and IKKMye mice with OVA protein in CFA. After 14 days, mice will be bled to measure the titre of OVA specific antibodies in the serum.

5.5 STAT6 signalling
I have shown knocking out IKK suppress IL4R expression (Figure 3.2.1.2).  To test the role of IKK in IL-4/STAT6 signalling, macrophages elicited from IKKF/F and IKKMye mice will be stimulated with IL-4 in vitro and STAT6 phosphorylation will be studied by IB.  Arginase, FIZZ1 and YM1 are IL-4 regulated genes in macrophages (Gordon 2003), therefore I will measure their expression by qRTPCR from RNA isolated from IL-4 stimulated IKKF/F and IKKMye macrophages.  Previous studies have shown that STAT6 and NF-B cooperate and synergistically activate gene transcription in B cells (Messner, Stutz et al. 1997; Shen and Stavnezer 1998).  I will also test the influence of IKK in STAT6-NF-B interactions by co-IP and IB with protein lysate collected from IL-4 stimulated IKKF/F and IKKMye macrophages.





5.6 Tumour-induced tolerance
As I have discussed, in addition to CD8 T cells, CD4 T cells are also important in anti-tumour immunity.  To investigate their possible role in rejection of MB49 tumours in IKKMye female mice, depleting antibodies to CD4 T cells will be injected 3 days prior to s.c. injection of MB49 cells. I will also confirm the dependency of tumour rejection on IFN with neutralising IFN antibodies.

To investigate the role of IKKβ in the development of antigen (HY)-specific T cells, tetramers will be used to track for the presence of HY specific CD4+ and CD8+ T cells in vivo. Spleen, lymph nodes T cells and TIL will be collected and stained with anti-Uty - PE (CD4) and anti-Dby - APC (CD8) the proportion of antigen specific cells will be determined with FACS. 

To assess the role of IKKβ in TAM on HY-specific T cell proliferation, I will isolate TAM from MB49 tumours of IKKβ∆Mye and IKKβF/F mice and co-culture with CD4 and/or CD8 T cells from Marylin (CD8) and MataHari (CD4) HY TCR transgenic mice in the presence of Uty or Dby peptide.  I will extend the study in vivo by performing competitive in vivo killing assays with a mixture of male and female splenocytes labelled with 0.2 and 2μM CFSE respectively.  After injected into MB49 tumour bearing IKKMye and IKKF/F mice.  Spleen and the tumour draining lymph nodes (inguinal and axillary) will be collected and killing of CFSE+ cells will be detected by FACS. 
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